



Department of Dermatology

Biennial Report 2023/2024

Imprint

Project lead

Prof. Dr. med. Thomas Kündig
Catherine Frey-Blanc

Contact

c.frey-blanc@usz.ch

Layout

KlauserDesign, info@klauserdesign.ch

Print

Vogt Print AG, Siebnen

Circulation

300 copies

Copyright

Department of Dermatology,
University Hospital Zurich

Table of Contents

| | |
|---|-----------|
| Editorial | 4 |
| 1 Assignment | 6 |
| 2 Mission statement | 7 |
| 3 Team | 9 |
| 4 Patient care and laboratories & financial key figures | 10 |
| 5 Digitization/Online Consultations | 16 |
| 6 Research | 17 |
| 6a Clinical Trial Unit | 18 |
| 6b Selected Clinical Research Projects | 19 |
| 6c Research groups | 22 |
| 7 Quality Management | 42 |
| 8 Medical education and training | 44 |
| 9 Research collaborations – Foundations and associates | 54 |
| SKINTEGRITY.CH, URPP, Bruno Bloch Foundation, Association for Research on Cancer of the Skin, Christine Kühne Center for Allergy Research and Education (CK-CARE), Riemsdijk Foundation | |
| 10 Collaborations with other dermatology centers | 59 |
| Zuger Kantonsspital, Hochgebirgsklinik Davos, Kantonsspital Frauenfeld/Thurgau | |
| 11 Congresses/scientific meetings | 60 |
| 12 Public relations | 64 |
| 13 Museum of Wax Moulages | 68 |
| 14 Promotions, grants, honors and awards | 70 |
| 15 Partners, sponsors, collaboration with industry, fundraising | 73 |
| 16 Publications in 2023 and 2024 | 74 |
| 17 Key Figures Department of Dermatology, University Hospital Zurich | 90 |

Editorial

Dear Reader, Friends, and Colleagues,

With pleasure, we present our new Biennial Report 2023/2024. Taking an external perspective on the breadth and depth of services our clinic has delivered over the past two years, we are truly filled with pride. Our continued development, even in the face of logistical and organizational challenges due to our four locations, speaks to the dedication and adaptability of our entire team.

One of our ongoing challenges remains the physical separation of our clinic's locations. While the split between sites presents a daily hurdle – especially in terms of patient flow and leadership coordination – our teams have shown remarkable ability to adapt and make the best of this complex arrangement.

In terms of **patient care**, we have continued to optimize processes and enhance quality through unified leadership structures.

A major milestone in this regard were the **reorganization of the outpatient clinics and physical therapy units in early 2024**. Under the leadership of Dr. med. Dr. sc. nat. Barbara Meier-Schiesser, all specialized outpatient consultations – including light therapy – will be brought under one umbrella. Furthermore, radiotherapy will be integrated into dermatology, and laser medicine will be repositioned within our surgical services. These changes are designed to streamline pathways and further improve the patient journey.

Another significant transition involved a **generational shift in the leadership of the allergy department**. As of March – and officially from July 2024 – Prof. Dr. Peter Schmid-Grendelmeier, known nationwide as “Mr. Allergy Switzerland,” will hand over the reins after more than 20 years of exceptional service. His successor, Prof. Dr. med. PhD Marie-Charlotte Brüggli, has been preparing for this responsibility for several years. This careful and structured transition ensures seamless continuity in both patient care and academic leadership. We express our heartfelt gratitude to both for their outstanding contributions during this handover.

In **research**, we are once again pleasantly surprised by the continued rise of our cumulative impact factor, which has reached 1700 in 2024. The research department of our dermatology clinic is the largest within the University Hospital Zurich, and our international reputation continues to grow. Notably, Prof. Dr. Reinhard Dummer ranks as one of the most highly cited cancer researchers. This success is made possible not only through a strong international network but also through indispensable local research partnerships, especially with the University of Zurich and ETH. We would like to highlight the excellence of the Skintegrit.ch platform and our close collaboration with Prof. Dr. Sabine Werner.

In terms of **quality management and certifications**, we once again achieved excellent audit results in 2023/24, including ISO, TÜV, DKG/OnkoZert, laboratory accreditation, GA²LEN, and recognition by Self-Help Switzerland/Zurich. These results underscore the vital role of quality management in our daily operations – not as a burdensome bureaucracy, but as a truly valuable and facilitating tool for clinical excellence. We thank Catherine Frey-Blanc and PD Dr. Philipp Bosshard for their outstanding coordination and leadership in this area.

Digital innovation continues to transform the way we deliver care. Our digital consultations have become a highly appreciated part of our patient services. They allow for smart triage, reduce long waiting times, and offer a highly efficient, individualized platform for care. Special thanks go to the dedicated team led by Dr. Christian Greis for their ongoing efforts in developing this service further, and for expanding it also into allergy care.

Last but not least, we celebrate several **personal achievements** within our team, reflecting the academic and clinical excellence of our staff:

- **Prof. Dr. Julia-Tatjana Maul** received her titular professorship in December 2024.
- **PD Dr. Lara V. Maul-Duwendag** was awarded the Venia Legendi in 2024.

We thank everyone in our team for their continued commitment, innovation, and teamwork, which make these accomplishments possible. With such a strong foundation, we look forward with confidence to the future.

Enjoy!



Prof. Dr. med. Thomas Kündig
Director
Department of Dermatology
University Hospital Zurich



Prof. Dr. med. Reinhard Dummer
Vice-Chairman
Department of Dermatology
University Hospital Zurich

1 Assignment

The Department of Dermatology at University Hospital Zurich (UHZ) is committed to providing sustained leadership in research, patient care, and education in the fields of dermatology, venereology, and allergology.

Our nationally and internationally acclaimed department features centers of excellence for skin cancer, inflammatory and allergic skin diseases, and dermatological surgery. Our team of 47 specialist physicians delivers high-quality patient care across all areas of dermatology, venereology, and allergology through our extensive outpatient clinic (Dermatologische Poliklinik), inpatient dermatology service, daycare unit, and a network of tertiary care referral clinics. These clinics cover a wide range of specialty areas, including melanoma and challenging pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin diseases, medical dermatology, psoriasis, hair and scalp disorders, occupational and contact dermatitis, dermatologic surgery, dermatopathology, and physical therapies (phototherapy, radiotherapy, and laser therapy).

Our research activities focus on basic and translational research related to skin diseases, primarily skin cancer and inflammatory skin diseases. The efforts of our research groups are reflected in regular publications in high-impact journals and a significant cumulative annual impact factor. Collaboration and networking with talented scientists and research groups at the University of Zurich, ETH, collaborative networks such as the Cancer Network Zurich, and other leading European dermatology centers significantly enhance our research activities. Education is the third main area of focus for our department. In recent years, we have concentrated our resources on pre-graduate and post-graduate training, as well as the development and maintenance of DOIT (Dermatology Online with Interactive Technology), our innovative internet-based pre-graduate learning tool, in collaboration with the European Dermatology Forum.



2 Mission statement



Working in close collaboration with other departments and institutes at UHZ, the top priorities of the Department of Dermatology are to:

Offer high-quality individual diagnosis and therapy for various skin diseases, while educating patients on skincare and the prevention of skin diseases.

Provide a high level of teaching and training in dermatology at both pre- and post-graduate levels.

Conduct innovative basic and clinical research with the ultimate aim of improving patient care.

Foster constructive collaboration and networks with private practitioners and primary and secondary institutional care providers.

Our aim is to strengthen our position as one of the leading dermatology departments in Europe, while fulfilling our mission.



3 Team (as per 31.12.2024)

Klinikleitung



Klinikdirektor
Prof. Dr. med.
Thomas Kündig



**Stv. Klinikdirektor Leiter
Hautkrebszentrum**
Prof. Dr. med.
Reinhard Dummer



**Abteilungsleiterin
Ambulante Pflege**
Dina Zlatic



Chirurgie/Angiologie
Prof. Dr. med.
Jürg Hafner



**Abteilungsleiter
Stationäre Pflege**
Moritz La Roche



Dermatopathologie
PD Dr. med.
Jivko Kamarachev



Dermatopathologie
* PD Dr. med.
Katrin Kerl French



Klinikmanager
David Herzig



**Allergiestation/
Lehrbeauftragte**
* Prof. Dr. med. Ph.D.
Marie-Charlotte Brüggem

Leitende/r Oberärztin/arzt



Konsiliendienst ECP/ISS
* Dr. med.
Mirjam Nägeli



Dermatochirurgie
* Dr. med.
Stephan Nobbe



Poliklinik
* Dr. med. Dr. sc. nat.
Barbara Meier-Schiesser



**Dermatoonkologie
Tagesklinik**
* PD Dr. med.
Joanna Mangana



**Qualitätsmanagement/
Projektleitung**
* Catherine Frey-Blanc

Oberärzt*innen



Bettenstation
* Dr. med.
Andrea Boesch



Dermatoonkologie
* Dr. med.
Omar Hasan Ali



Moulagenmuseum
* Dr. med.
Michael Geiges



Dermatochirurgie
* Dr. med.
Christian Greis



**Allergiestation
Berufsdermatologie**
* Dr. med.
Claudia Lang



**Entzündliche Dermatosen
(Pso/HS) / Studententeam**
* Prof. Dr. med.
Julia-Tatjana Maul



Dermatoonkologie
* PD Dr. med. Lara Valeska
Maul-Duwendag



Allergiestation
* Dr. med.
Sara Micaletto



Dermatochirurgie
* Dr. med.
David Muggli



Allergiestation
* Dr. med.
Larissa Meier



**Studententeam/
Lymphom**
Dr. med. Dr. sc. med.
Egle Ramelyte



Oberarzt
* Dr. med.
Fabio Bertoldo



Oberärztin
* Dr. med.
Diana Lazarevic

Oberärzt*innen i.V.



Oberärztin i.V.
Dr. med.
Fabienne Huber



Oberärztin i.V.
* Dr. med.
Zara Liniger



Oberärztin i.V.
* Dr. med.
Marina Schneider



Oberärztin i.V.
Dr. med.
Fabienne Fröhlich



Oberärztin i.V.
Dr. med.
Madeina Senn



Oberärztin i.V.
Dr. med.
Johanna Ziegler

* Teilzeitpensum

4 Patient care and laboratories & key financial figures



In the Swiss healthcare system, the five university hospitals are responsible for providing the country's inpatient dermatology services. In contrast, outpatient care is available in both the private sector and public institutions, including university and cantonal hospitals. The USZ Department of Dermatology is the largest academic dermatology center in Switzerland, offering state-of-the-art inpatient medical care for complex and rare skin conditions. The department's skilled surgeons perform intricate surgical procedures and histologically controlled interventions, while the team is equipped to administer complex chemotherapeutic regimens and intravenous immunotherapy, including antibodies and fusion molecules. Additionally, we provide a comprehensive range of outpatient services, including highly specialized consultations. Our department benefits from a robust referral base for these specialized activities, as well as its own on-site histopathology laboratory.

Outpatient unit ("Poliklinik") and specialist care clinics

Our Dermatological Outpatient Clinic ("Poliklinik") provides expert care for patients with a wide range of general skin conditions, while also offering specialized consultations for complex dermatologic disorders. These include autoimmune skin diseases, psoriasis, atopic dermatitis, hidradenitis suppurativa, skin cancer, acne and other severe dermatoses, hair and scalp disorders, hyperhidrosis, urticaria, and pediatric dermatology, among others. The clinic is led by Dr. med. Dr. sc. nat. Meier-Schiesser, supported by a dedicated team of specialists: Dr. med. Fabio Bertoldo, Dr. med. Madleina Senn, Dr. med. Fabienne Fröhlich and Prof. Dr. med. Julia-Tatjana Maul. Together, they ensure comprehensive and individualized care in a welcoming and professional environment. Since February 2024, our outpatient unit has been enhanced by the integration of the Light and Photodynamic Therapy Division. This addition offers valuable treatment options, particularly for patients with inflammatory skin diseases, which often benefit from light therapy. Furthermore, photodynamic therapy plays a key role in treating sun-induced skin damage, such as actinic keratosis, providing an effective and evidence-based therapeutic approach.

Dermatooncology clinic

The dermatoncology clinic is one of the largest in Switzerland, with over 11,000 consultations per year concerning all types of skin cancer. Most of our patients suffer from metastatic melanoma and are primarily treated with recently developed immunotherapies, which are highly effective treatment modalities. We also have a large unit dedicated to Non-Melanoma Skin Cancer (NMSC) and serve as a referral center for lymphomas and Merkel cell carcinomas.

The dermatoncology clinic comprises a large team of cancer specialists, including Prof. Dr. med. Reinhard Dummer, PD Dr. med. Joanna Mangana, PD Dr. med. Lara Maul-Duwendag, Dr. med. Mirjam Nægeli, Dr. med. Omar Hasan Ali, Dr. med. Dr. sc. med. Egle Ramelyte, and Dr. med. Lukas Krähenbühl. In our daycare immunotherapy unit, we primarily treat skin cancer patients, administering over 2,800 infusions annually in both inpatient and outpatient settings.

The center includes the following clinics:

- The Pigmented Lesion & Skin Cancer Prevention Clinic, previously led by Prof. R. Braun (until January 2024) and now headed by PD Dr. Lara V. Maul-Duwendag, utilizes modern high-tech equipment such as confocal microscopy, skin surface video microscopy, dermatoscopy, and full-body imaging for the early detection of melanoma.
- The Radiotherapy Sector, formerly headed by PD Dr. Laurence Imhof until January 2024 and now led by Dr. Dr. Egle Ramelyte, features advanced X-ray devices for superficial radiotherapy of skin cancer and selected refractory inflammatory diseases. Over 3,000 treatments are performed each year.



- The Skin Cancer Clinic, led by Prof. Dr. R. Dummer and PD Dr. J. Mangana, provides highly professional treatment and follow-up services for patients with various types of skin cancer. Outpatient infusion therapies are managed by PD Dr. J. Mangana, while Dr. M. Nægeli oversees a specialized non-melanoma skin cancer clinic. Access to the most innovative clinical trials is available through the clinical trial unit, headed by Dr. Dr. E. Ramelyte and Prof. Dr. J.-T. Maul.

With the incidence of melanoma and other skin cancers rising worldwide, and new therapies extending the survival of patients with advanced stages of these diseases, complex medical care has become essential. The most effective treatment for complicated melanoma and skin cancer is provided at specialized referral centers, such as the Skin Cancer Center, which is part of USZ's Comprehensive Cancer Center Zurich. Our goals are to deliver optimized melanoma therapy, document the best patient-reported treatment outcomes, and conduct successful clinical and translational research, all of which require a dedicated interdisciplinary team.

In today's rapidly evolving scientific landscape, modern skin cancer management exemplifies precision medicine. Networking and collaborative projects involving basic research at local, national, and international levels are crucial. We particularly seek to include well-established local basic research groups and cooperative projects, including the investigation of patient samples collected in the biobank.

Clinical research, including clinical trials sponsored by pharmaceutical companies and initiated by investigators, is vital

for developing a comprehensive understanding of clinical science. Patients are regularly informed about these projects and actively support these efforts when possible.

Dermatologic surgery and Mohs micrographic surgery

Our dermatosurgery unit is dedicated to skin cancer surgery, primarily by peripheral and deep en face margin assessment (PDEMA), i.e., Mohs micrographic surgery and the Tübinger Torte technique. Surgical repair is one of the many special focuses of our team. An excellent interdisciplinary cooperation with plastic surgery, ENT-, maxillofacial and oculoplastic surgery is available to treat patients with complex surgical defects. The staff consists of PD Dr. med. Marjam Barysch-Bonderer, Dr. med. Fabio Bertoldo, Dr. med. Christian Greis, Prof. Dr. med. Jürg Hafner, PD Dr. med. Severin Läuchli, PD Dr. med. David Muggli, Dr. med. Valerio Del Prete, Dr. med. Carla Murer, Dr. med. Stephan Nobbe, and the team of specialized nurses (Dina Zlatic and team). Together, they treat over 4,000 skin cancer lesions annually. The vast majority can be operated on under local an-

esthesia. Elderly and frail persons can stay as inpatients for brief periods of hospitalization, making this center particularly suitable for geriatric dermatologic surgery. Phlebology and chronic wounds, as well as keloids and scars are further fields of activity, where our team can provide a large variety of modern treatments, based on long and profound clinical experience.

Laser Division: One important area of dermatology concerns laser skin treatments. We have a small but excellent division here, which, in addition to the frequent laser applications in aesthetic dermatology, is also dedicated to the treatment of rare skin diseases. Teaching residents is of course also a central concern here.

Clinic for immunocompromised patients

The clinic for immunocompromised patients, led by Dr. Mirjam Nägeli, primarily serves individuals who are on immunosuppressive medication following organ or stem cell transplants, as well as those undergoing long-term immu-



nosuppressive treatment for inflammatory diseases. The primary goal is to prevent skin cancer, as the risk for these patients to develop non-melanoma skin cancer (NMSC) is at least 65 times higher than that of immunocompetent individuals. Additionally, we offer guidance on preventive measures such as protective clothing, sunscreen, and other strategies. The clinic benefits from close collaboration with the USZ Transplantation Center, whose coordinators regularly refer patients to us. As organ transplant recipients are now living longer, the number of patients seeking our services continues to rise.

We are also affiliated with international organizations such as SCOPE (Skin Care in Organ Transplant Patients Europe; scopenetwork.org) and ITSCC (International Transplant Skin Cancer Collaborative).

Allergy unit

Diagnosis and management of the full range of allergic diseases

Allergic conditions are becoming increasingly prevalent. We diagnose and treat a comprehensive spectrum of allergies, including skin disorders related to allergies such as atopic dermatitis, urticarial contact dermatitis, and mastocytosis. Additionally, we address inhalant allergies like rhinoconjunctivitis and allergic asthma caused by pollen, dust mites, or pet allergens, as well as the rising incidence of food allergies and intolerances. We also manage reactions to honey-bee and wasp stings, with severe cases benefiting from highly effective ultra-rush immunotherapy regimens. For drug allergies, we offer a full range of skin tests, state-of-the-art in vitro diagnostics such as the Basophil Activation Test (BAT) and modified Lymphocyte Transformation Test (LLT), provocation tests, and various drug deactivation protocols. We maintain close interdisciplinary ties with many other specialties, sharing outpatient clinics and boards.

For many years, our department was led with great dedication by Prof. Dr. med. Peter Schmid-Grendelmeier, who played a pivotal role in shaping modern allergology at the University Hospital Zurich. In spring 2024, he took his well-deserved retirement after an impressive career. His expertise, tireless commitment to patient care, and contributions to research and education have left a lasting impact on the department.

Since April 2024, Prof. Dr. med. Marie-Charlotte Brüggemann has taken over as head of the department. With her extensive experience in allergology and immunology, she continues the work with renewed dynamism, introducing innovative diagnostic and therapeutic approaches while strengthening interdisciplinary collaboration and translational research. Under her leadership, the team remains dedicated to providing cutting-edge allergy management,

combining state-of-the-art diagnostics and therapies with a strong patient-centered approach. By effectively managing allergies and emphasizing education on preventive measures, her focus is on further enhancing high-quality patient care and establishing the department as a leading center for allergic diseases and translational research.

Education of Patients and Health Professionals

Patient education is one of our top priorities. In addition to individual education for anaphylaxis, asthma, and atopic dermatitis, we work closely with organizations like aha! and CK CARE to promote patient education for allergic diseases. We offer highly sought-after training opportunities for individuals to become board-certified specialists in allergies and immunology, as well as training courses for allied health professionals. Thanks to the support of CK CARE, we have re-initiated a patient-care consultation where patients can meet face-to-face with an experienced nurse to discuss how to manage atopic dermatitis care. We regularly organize educational events for health professionals, including our annual Allergy Symposium and contributions to the ZDFT, as well as national and international educational events for healthcare providers.

Our inpatient clinic

The inpatient ward consists of 18 beds for dermatologic patients, as well as 6 flexible beds that can be shared with other departments based on current demand. These beds are dedicated to the treatment of particularly severe and extensive forms of skin diseases. The ward is especially suited for patients with refractory atopic dermatitis, psoriasis, complex autoimmune diseases, as well as those with skin cancer, including metastatic melanoma, cutaneous lymphoma, or elderly and frail patients undergoing major skin cancer surgery for non-melanoma skin cancer. As part of dermatological complex therapy, we offer bath therapy, light therapy, and cloth therapy.

The medical team, including Prof. Dr. Thomas Kündig, Prof. Dr. Reinhard Dummer, Prof. Dr. Jürg Hafner, Dr. Mirjam Nägeli, Dr. Andrea Boesch, Dr. Marina Schneider, and Dr. Fabienne Huber, along with a team of staff physicians and residents, bring extensive clinical experience to benefit our patients suffering from severe skin conditions. The dedication, professionalism, and friendly atmosphere are highly appreciated by our patients.

Photopheresis

The extracorporeal photopheresis has established itself as a cross-disciplinary therapy derived from dermatology. At the USZ, it is performed on a short-stay basis in the derma-

tology ward with 4 machines (a total of 703 treatments in 2024). In Switzerland, this therapy is approved for cutaneous T-cell lymphoma of the Sézary type, chronic lung rejection after lung transplantation, and chronic graft-versus-host disease after stem cell transplantation. The therapy is applied monthly after an induction phase, is safe, effective, and has few side effects. Leukocytes are obtained from peripheral blood through centrifugation, which are then irradiated with ultraviolet A (UVA) light after the addition of the photosensitizer 8-methoxypsoralen and reinfused into the patient on two consecutive days once a month. It has immunomodulatory effects. Chair Dr. Mirjam Nägeli

Consultative Service

At the USZ, we offer a consultative service for all inpatients in other departments who suffer from skin disorders. Additionally, we provide care for patients in the Burn Intensive Care Unit with toxic epidermal necrolysis (TEN), the most severe form of drug allergy. We also actively participate in various interdisciplinary boards.

Nursing care

The ward is managed by Moritz La Roche, the department head. The nursing staff consists of qualified nurses and healthcare professionals who work in shifts on the ward. Heiko Müller (Nursing Expert Dermatology, MScN) is responsible for professional development and nursing quality. Inpatient dermatology is located on the top floor of the NORD 2 building, sharing the floor with Rheumatology. The new

inpatient dermatology rooms include single, double, and four-bed rooms, a shared medication and supplies room, various utility rooms, and a spacious ward room. Patients are welcomed at the information desk on the ward, and an attractive waiting area is provided for them.

All rooms are designed with wooden panels and are equipped with a bathroom, including a WC and shower. Automatic air conditioning ensures a comfortable temperature throughout the year, both in winter and summer. With the relocation, the extracorporeal photopheresis service has also been moved to the ward. This consists of four machines with four bed spaces, divided into two rooms.



“As health economists, we focus on efficient resource use, sustainable healthcare, and evidence-based medicine to ensure cost-effective, high-quality care and long-term benefits.”

David Herzig



“Our aim is to contribute to a better understanding of allergic diseases, and, through this, improve diagnostic and therapeutic approaches.”

Brügggen Charlotte, Prof. Dr. med. PhD

Laboratory facilities

The laboratories of the Department of Dermatology, led by Prof. Dr. Thomas Kündig, are dedicated to both routine diagnostics and research.

Routine Diagnostic Laboratories

The state-of-the-art diagnostic laboratories (deputy: PD Dr. Philipp Bosshard) are accredited according to ISO 15189:2022. These laboratories consist of two main units:

Dermatopathology

The dermatopathology lab is managed by PD Dr. Jivko Kamarachev and PD Dr. Katrin Kerl French, and it processes over 35,000 internal and external samples per year. Formalin-fixed or frozen (cryo-) tissues are analyzed using conventional histological staining or more specific immunopathological tests, such as immunohistochemistry and immunofluorescence. The lab also conducts pathogen or oncogene screening tests in collaboration with the molecular diagnostics lab and the USZ Institute of Pathology. Additionally, the dermatopathology lab is a certified teaching center, organizing regular dermatology courses for residents in collaboration with the European Academy of Dermatology and Venereology (EADV).

Allergology, Molecular Diagnostics, Mycology and Syphilis Serology

These four labs together analyze more than 15,000 patient samples annually. The allergology lab offers, among other tests, microarray-based IgE testing (ALEX/ISAC) and the ba-

sophil activation test (BAT) for drug allergies. In molecular diagnostics, pathogen detection tests for infections like HSV-VZV or genital ulcer disease are performed. The mycology lab is a renowned reference laboratory for dermatophyte infections, offering both culture and dermato-mycoses PCR testing. Notably, the syphilis serology lab detects approximately one-tenth of all new syphilis cases in Switzerland.

Research Laboratories

The research unit of the Department of Dermatology (deputy: Prof. Pål Johansen, PhD) has been continuously expanding over the past 13 years (see separate article in this issue). Currently, about 60 researchers and 15 students are working in the laboratories, which were relocated in February 2021 to new research facilities at Wagistrasse 18 in Schlieren. These labs are equipped with state-of-the-art settings and technology to facilitate competitive pre-clinical and basic research in cell and tumor biology, skin inflammation and infections, immunology, and allergy.

The research labs are TÜV SÜD certified according to ISO standards and adhere to GCP and GLP guidelines for research involving patient materials. The Schlieren campus also houses numerous other research departments and units from USZ and UZH. The new site provides access to many shared research facilities, including flow cytometry, genomics, microscopy and imaging, as well as modern animal labs for pre-clinical research and development with rodents. The Dermatology research labs are TÜV SÜD certified according to ISO standards and comply with GCP and GLP guidelines for research with patient materials.

Quantitative and Financial Key Facts

| | 2020 | 2021 | 2022 | 2023 | 2024 |
|--|--------|--------|--------|--------|--------|
| Number of Leaves in Inpatient Clinic | 1'648 | 1'654 | 1'531 | 1'599 | 1'523 |
| Duration of stay of Inpatients (average) | 4.8 | 4.2 | 3.9 | 3.4 | 3.4 |
| Casemix-Index | 0.893 | 0.885 | 0.841 | 0.773 | 0.795 |
| Number of Outpatients | 22'309 | 24'829 | 26'271 | 28'790 | 31'596 |
| Consultations outpatient setting | 67'577 | 79'131 | 80'363 | 81'645 | 82'951 |
| Taxpoints (outpatient setting in thousand) | 19'815 | 21'598 | 21'354 | 22'566 | 24'259 |
| Biopsies Dermatopathology | 32'133 | 33'816 | 34'229 | 35'028 | 37'340 |

5 Digitization/ Online consultations

Hybrid Care: A Combination of Online and In-Person Consultations to Optimize Patient Flow in Our Clinic

Our digital consultation service has been widely embraced by patients, reflecting the growing demand for digital medical care. To enhance patient care, we introduced a hybrid consultation model that combines online and in-person visits. Patients often begin with an online consultation (triage) before transitioning to an in-person consultation if further examination or treatment is needed. Follow-up consultations can then be conducted online, ensuring personalized care and a seamless healthcare experience while optimizing resources.

New Features: Online Booking of Appointments, Insurance Coverage & ePrescription

Patients can now book their in-clinic consultations directly through our tele dermatology portal, making access to medical care even easier. Since last year, online consultations have been covered by Swiss health insurance, increasing accessibility and affordability for more patients. Additionally, patients can now order medication via ePrescription, allowing them to receive prescriptions digitally and pick up their medication directly from local pharmacies.




Positive Patient Feedback

Patients appreciate the convenience and quality of our hybrid services. One patient shared: "I received a quick diagnosis and treatment without leaving home. The process was smooth, and I felt well cared for." Another noted: "The hybrid model made my treatment seamless, and I valued the flexibility."

Commitment to Innovation

The University Hospital Zurich remains dedicated to modern, patient-centered care. By integrating hybrid consultations covered by insurance, we continue to set new standards in dermatology and telemedicine.

Top 10 online diagnoses



6 Research

In addition to the primary goal of providing the best possible treatment options for current patients, the Department of Dermatology is strongly committed to research and development that may lead to a better understanding of diseases and improved therapies for future dermatology patients. Leading projects in this regard focus on patient-oriented translational and clinical research across various fields of dermatology, generating important knowledge related to the pathogenesis, diagnosis, and treatment of skin cancer (e.g., melanoma, cutaneous lymphoma, and non-melanoma skin cancers), inflammatory skin diseases (e.g., psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and skin infections), as well as allergies (e.g., atopic dermatitis and food allergies).

In recent years, the department has played a crucial role in establishing novel immunotherapies by testing new biologics, such as anti-cytokine antibodies for allergies and inflammatory skin diseases, as well as checkpoint and targeted therapies for melanoma. This work has garnered significant international recognition, and our clinic is considered a world leader, particularly in the field of melanoma research. Our achievements in this area – reflected in the cumulative impact factors for 2023 and 2024 (1.667 and 1.771) – position us among the world's leading departments. The experimental research focuses on the same areas as

the clinical research, namely skin cancer, inflammatory skin diseases, and allergies. It comprises eight research groups, each led by scientists and medical doctors. Additionally, some research activities are directed toward inflammatory skin conditions and allergies in veterinary medicine.

Beyond the targeted research projects, the overarching goals of our research are to:

1. promote high-quality, clinically relevant research,
2. foster networking and collaboration with other institutions,
3. support fellowships for our researchers abroad,
4. maximize competitive research funding, and
5. establish endowed professorships to recruit and retain leading experts in the field

Annual Internal Research Retreat of the Department of Dermatology USZ, March 2023 and 2024

Our 26th and 27th Annual Internal Research Retreat took place in March 2023 and 2024. Approximately 50 researchers participated in this event. Over the course of one and a half days, our young researchers presented their work and updated the attendees on their progress, which also led to intense discussions.



Research Retreat March 2024

Publication and Impact Factor – A Measure of Success

One of the most commonly used quality measures for research is the number of publications and the corresponding impact factors, which reflect the quality of the journal based on how frequently a publication is cited or shared. Our excellent achievements in dermatology research, both clinical and experimental, are evident from the growth of our cumulative impact factor. Researchers in the Department of Dermatology have published more than 300 original articles in the past two years. These publications have achieved a cumulative impact factor of 1700–1800 each year, positioning us not only at the top of USZ departments but also among the world’s leading departments of dermatology.

6a Clinical Trial Unit

Dr. sc. med. Egle Ramelyte / Prof. Dr. med. Julia-Tatjana Maul

Prof. Dr. med. Julia-Tatjana Maul has been leading the clinical study team since 2019 and has been researching in the field of dermatological oncology and inflammatory dermatoses at the University Hospital Zurich (USZ) since 2011. After completing two years of specialist training in oncology at the University Hospital Zurich, she finished her specialist training in dermatology in 2018 and has since led her own research group focusing on “Inflammatory Dermatoses.” Since 2021, Julia-Tatjana Maul has been habilitated, and in 2024, she received the title of honorary professor.


Dr. med. Dr. sc. med. Ramelyte has been working in clinical research with a focus on dermatological oncology since 2015. She earned a PhD in Clinical Research from the University of Zurich (UZH) in 2018 and has completed specialist training in Pharmaceutical Medicine in addition to dermatology. This comprehensive training served as an excellent foundation for her position in the leadership team of the clinical research department.

Overview of Studies in Dermatological Oncology and Inflammatory Skin Diseases

In 2024, patients were enrolled in 16 dermatological oncology studies, three of which were newly initiated interventional dermatological oncology studies. The range of dermatological oncology and inflammatory studies includes research in early development phases (Phase I) as well as later phases (Phase III).

The oncology studies cover treatment applications in the adjuvant, neoadjuvant, as well as first, second, and last-line treatments. The studies target patients with melanoma, squamous cell carcinoma, and other solid tumors. In 2024, 59 new patients were enrolled and treated in the dermatological oncology studies. With these numbers, the clinical study team ranks among the top recruiting study centers nationwide in Switzerland.

Publication and impact factor



“We combine medical excellence with research to sustainably improve skin health and quality of life.”

Kündig Thomas, Prof. Dr. med.



Six new studies in the research area of inflammatory skin diseases – including psoriasis, hidradenitis suppurativa, vitiligo and prurigo nodularis – were initiated, and 93 new patients were enrolled in the ongoing studies.

The clinical research in dermatology underwent several audits in 2024: a DKG audit, a GCP center inspection (Swiss-medic), and a sponsor audit. No critical deficiencies were found, and the feedback received was largely very positive. We are committed to continuously improving ourselves.

6b Selected Clinical Research Projects

Principal Investigator of the Global Healthcare Study on Psoriasis (GHSP) and Global Healthcare Registry on Skin Disease: Prof. Dr. Julia-Tatjana Maul

Since 2020, we have been collecting data worldwide on the care and treatment options for psoriasis as part of the Global Healthcare Study on Psoriasis (GHSP). To expand this successful model to other chronic inflammatory skin diseases, the initiative has now been developed into the



Global Healthcare Registry on Skin Diseases. The registry provides a structured, standardized data collection for inflammatory skin diseases and creates an international platform for dermatological research and scientific collaboration. The further development was approved by the Ethics Committee of Zurich in early 2025 and made possible through close collaboration with the University of Zurich (UZH) and the University Hospital Zurich (USZ).

At this time, we have included more than 4,200 psoriasis patients in the GHSP across 6 continents and 22 countries.

Prof. Julia-Tatjana Maul:

"I am very happy and proud to work together with specialists from around the world to better research chronic inflammatory skin diseases, improve access to treatment options, and better understand patient needs."



For more information, visit www.dermastudy.org

Prof. Dr. Charlotte Brügggen: Atopic Dermatitis in Africa

For a long time, it was widely believed that atopic dermatitis was primarily a health issue affecting Western countries. In recent years, however, it has become clear that many people in Africa are also affected and experience a significant reduction in their quality of life.

In a large-scale project, we have started about 4 years ago to investigate atopic dermatitis in Africa. One key question is whether environmental factors—such as pollen allergens—are different in Africa, and how these differences affect atopic dermatitis.

We are collaborating with two African hospitals: in Moshi (Tanzania) and Antananarivo (Madagascar). We are comparing data from patients with atopic dermatitis and healthy individuals from each region and so far have more than 200 participants. We have collected stool, blood, and skin samples from the participants. These are being analyzed using cutting-edge experimental methods like multiplex cellular imaging or microbiome analyses.

Our initiative has gained attention not only in the scientific international community, but also in African countries, where more centers want to join us. On a global level, we have been involved in a World Health Organization (WHO) initiative recognizing AD as a major non-communicable disease and topical treatments.

www.bruggenlab.com



"It is a privilege to collaborate with our partners in this project and work together towards a better understanding of the many open issues related to AD in Africa."

Brügggen Charlotte, Prof. Dr. med. PhD





6c Research groups



Prof. Barbara Ballmer-Weber, MD

Group Members and Associates

Prof. Barbara Ballmer-Weber, MD (group leader)
Claudia Lang, MD
Muriel Trächslar

Main Fields of Research

Our research activities are focused on food allergy, in particular pollen-related food allergy. We are especially involved in the identification and molecular characterization of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Allergen-based or component resolved diagnosis in food allergy is a major topic of our research group. Another important aspect of our research activity is risk assessment in food allergy with regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and animal food allergens.

Selected References

Ballmer-Weber BK, Wangorsch A, Bures P, Hanschmann KM, Gadermaier G, Mattson L, Mills CEN, van Ree R, Lidholm J, Vieths S. New light on an old syndrome: role of Api g 7 in mugwort pollen-related celery allergy. *J Allergy Clin Immunol* 2024;154:679-689.

Wangorsch A, Lidholm J, Mattsson LA, Larsson H, Reuter A, Gubesch M, Gadermaier G, Bures P, Scheurer S, Ballmer-Weber B, Vieths S (shared last authorship). Identification of a defensin as novel allergen in celery root: Api g 7 as a missing link in the diagnosis of celery allergy? *Allergy* 2022; 77:1294-1296.

Ballmer-Weber BK, Lidholm J, Lange L, Pascal M, Lang C, Gernert S, Lozano-Blasco J, Gräni N, Guillod C, Wangorsch A, Hanschmann KM, Pontoppidan B, Tjäder L, Bartra J, Vieths S. Allergen Recognition Patterns in Walnut Allergy Are Age Dependent and Correlate with the Severity of Allergic Reactions. *J Allergy Clin Immunol Pract.* 2019;7(5):1560-1567.

Datema MR, van Ree R, Asero R, Barreales L, Belohlavkova S, de Blay F, Clausen M, Dubakiene R, Fernández-Perez C, Fritsche P, Gislason D, Hoffmann-Sommergruber K, Jedrzejczak-Czechowicz M, Jongejan L, Knulst AC, Kowalski M, Kralimarkova TZ, Le TM, Lidholm J, Papadopoulos NG, Popov TA, Del Prado N, Purohit A, Reig I, Seneviratne SL, Sinanotis A, Versteeg SA, Vieths S, Zwinderman AH, Mills ENC, Fernández-Rivas M, Ballmer-Weber B. Component resolved diagnosis and beyond: multivariable regression models to predict severity of hazelnut allergy. *Allergy* 2018;73:549-559.

Ballmer-Weber BK, Beyer K. Food challenges. *J Allergy Clin Immunol.* 2018;141:69-71.



Hans-Dietmar Beer, PD PhD

Group Members and Associates

Hans-Dietmar Beer, PD PhD

Paulina Hennig (Postdoc)

Michela Di Filippo (Postdoc)

Tugay Karakaya (PhD student)

Marta Slafova (PhD student)

Main Fields of Research

The group aims to characterize the molecular mechanisms underlying the regulation of inflammation in human skin. This is relevant for inflammatory skin diseases, such as psoriasis or atopic dermatitis, and the development of skin cancer (squamous cell carcinoma). The focus in these studies is on the roles of the NLRP1 inflammasome expressed by epidermal keratinocytes. Experiments are based on patient-derived primary cells, such as keratinocytes, but also on skin cancer cells and (cancer-associated) fibroblasts and patient-derived biopsies. The dermal-epidermal crosstalk of wild type and genetically modified cells (by the CRISPR/Cas9 technique) is analyzed in three-dimensional organotypic skin models. State-of-the-art transcriptomics approaches are used to identify novel regulatory pathways underlying skin inflammation and cancer development.

Selected References

Slafova M, Karakaya T, Di Filippo M, Hennig P, Beer HD (2023)

The gasdermins: A pore-forming protein family expressed in the epidermis. *Frontiers in Immunology*, 14:1254150

Karakaya T, Slafova M, Di Filippo M, Hennig P, Kündig T, Beer HD (2024)

CARD8: A Novel Inflammasome Sensor with Well-Known Anti-Inflammatory and Anti-Apoptotic Activity Cells, 13:1032

Karakaya T, Slafova M, Di Filippo M, Hennig P, Fenini G, Kündig T, Beer HD (2024)

Efficient Generation of CRISPR/Cas9-Mediated Knockout Human Primary Keratinocytes by Electroporation Methods *Mol Biol.*, doi: 10.1007/7651_2024_518.

6c Research groups



PD Philipp P. Bosshard, PhD
Prof. Yvonne Achermann, MD

Group Members and Associates

Tiziano Schweizer, PhD
Melike Ak, MD
Annabel Lechner, MD candidate
Deborah M. Rebmann, MD candidate
Judith Demeter, Msc student
Julia S. Würmli, Msc student
Anja L. Honegger, Msc student

Main Fields of Research

Research Group Philipp Bosshard: The research group studies skin infections and pathogen–host interactions to improve diagnostics and advance insights into syphilis, dermatomycosis, and other skin diseases.

Research Group Yvonne Achermann: The research group innovates in preventing and treating postoperative orthopedic infections, pioneering photodynamic therapy and advanced diagnostics to combat implant–associated infections through humanized preclinical models and clinical research.

Selected References

Schweizer TA, Würmli JS, Prinz J, Wölfle M, Marti R, Koliwer–Brandl H, Rooney AM, Benvenga V, Egli A, Imhof L, Bosshard PP, Achermann Y. Photodynamic therapy with protoporphyrin IX precursors using artificial daylight improves skin antisepsis for orthopedic surgeries. *Microorganisms*. 2025; 13(1):204. doi: 10.3390/microorganisms13010204.

Honegger AL, Schweizer TA, Achermann Y, Bosshard PP. Antimicrobial efficacy of five wound irrigation solutions in the periprosthetic joint infection microenvironment in vitro and ex vivo. *Antibiotics*. 2025; 14(1):25. doi: 10.3390/antibiotics14010025.

Theiler M, Luchsinger I, Rast AC, Schwieger–Briel A, Weibel L, Bosshard PP. Precision diagnostics in paediatric dermatology: Advancing management of tinea capitis through dermatophyte PCR. *J Eur Acad Dermatol Venereol*. 2024. doi: 10.1111/jdv.20147.

Rodríguez I, Noda AA, Bosshard PP, Lienhard R. Anti-Treponema pallidum IgA response as a potential diagnostic marker of syphilis. *Clin Microbiol Infect*. 2023; 29(12):1603.e1-1603. doi: 10.1016/j.cmi.2023.08.015.

Prinz J, Wink M, Neuhaus S, Grob MC, Walt H, Bosshard PP, Achermann Y. Effective biofilm eradication on orthopedic implants with methylene blue based antimicrobial photodynamic therapy in vitro. *Antibiotics*. 2023;12(1):118. doi: 10.3390/antibiotics12010118.



Marie-Charlotte Brüggén, Prof. MD, PhD

Group Members and Associates

Nick Li, Lab manager; Anna White, PostDoc; Danielle Fehr, MD PhD candidate; Milad Ameri, PhD candidate; Camilla von Wachter, MD candidate; Clara Clemens, MD candidate; Selina Steiger, MD candidate; Franziska Meyer, MD candidate; Michaela Mokra, MD candidate; Tamara el Sadaany; Marine Casanova, MD candidate/research resident; Annika Wilder-Smith, MD candidate/research resident; Patrick Schmitthausen, Research resident; Stefanie Bösch, Study nurse; Lisa Lehmann, Master Student; Daniela Zumkehr, Study coordinator; Meike Distler, Clinical trial manager

Main Fields of Research

Our research group specializes in the immunological mechanisms underlying allergic diseases, with a particular emphasis on allergic skin conditions. We conduct innovative translational projects aimed at improving the diagnosis and treatment of allergies and are actively engaged in clinical trials.

Key areas of focus include atopic dermatitis, metal allergies in prosthesis patients, and severe drug hypersensitivity reactions. In particular, we investigate the role of eosinophils as central drivers and potential therapeutic targets.

Selected References

Brüggén MC, Traidl S, Mitamura Y, Walsh S, French LE, Gulati N, Phillips E, Maverakis E, Ingen-Housz-Oro S. Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients. *Allergy*. 2024 Oct;79(10):2876-2880. doi: 10.1111/all.16122.

Brüggén MC, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S; DRESS Delphi consensus group; Abe R, Ardern-Jones M, Assier H, Barbaud A, Bensaid B, Bernal W, Bernier C, Brassard A, Brezinová E, Cabañas R, Cardones A, Chu CY, Chua SL, Descamps V, Didona B, Divito SJ, Dodiuk-Gad R, Elman S, Gaspar K, Mortz CG, Hama N, Lee HY, Horváth B, Jörg L, Kaffenberger BH, Kucinskiene V, Lebrun-Vignes B, Lehloeny R, Meyersburg D, Micheletti R, Milpied B, Miyagawa F, Mostaghimi A, Nägeli M, Naldi L, Opiel E, Phillips EJ, Pirani T, Ranki A, Mälkönen T, Rosenbach M, Salavastru C, Staumont-Salle D, Sandberg H, Setterfield J, Shinkai K, Shiohara T, Soria A, Tartar D, Tiplica GS, Traidl S, Vorobyev A, von Wachter C, Worswick S, Cho YT. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. *JAMA Dermatol*. 2024 Jan 1;160(1):37-44. doi: 10.1001/jamadermatol.2023.4450.

Schmidt V, Lalevée S, Traidl S, Ameri M, Ziadlou R, Ingen-Housz-Oro S, Barau C, de Prost N, Nägeli M, Mitamura Y, Meier-Schiesser B, Navarini AA, French LE, Contassot E, Brüggén MC. Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: Diverse effects on systemic inflammation. *Allergy*. 2023 May;78(5):1280-1291. doi: 10.1111/all.15608.

Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Bärenfaller K, Behrendt H, Bieber T, Bigliardi P, Bigliardi-Qi M, Bonefeld CM, Bösch S, Brüggén MC, Diemert S, Duchna HW, Fähndrich M, Fehr D, Fellmann M, Frei R, Garvey LH, Gharbo R, Gökkaya M, Grando K, Guillet C, Guler E, Gutermuth J, Herrmann N, Hijnen DJ, Hülpüsch C, Irvine AD, Jensen-Jarolim E, Kong HH, Koren H, Lang CCV, Lauener R, Mantel PY, Maverakis E, Möhrenschrager M, Müller S, Nadeau K, Neumann AU, O'Mahony L, Rabenja FR, Renz H, Rhyner C, Rietschel E, Ring J, Roduit C, Sasaki M, Schenk M, Schröder J, Simon D, Simon HU, Sokolowska M, Ständer S, Steinhoff M, Piccirillo DS, Taieb A, Takaoka R, Tapparo M, Teixeira H, Thyssen JP, Traidl S, Uhlmann M, van de Veen W, van Hage M, Virchow C, Wollenberg A, Yasutaka M, Zink A, Schmid-Grendelmeier P. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. *Allergy*. 2024 Oct;79(10):2605-2624. doi: 10.1111/all.16247.

6c Research groups



Prof. Reinhard Dummer, MD

Group Members and Associates

Joanna Mangana, MD, Egle Ramelyte, MD PhD

Ramon Stäger, Andrea Roggo, Lukas Krähenbühl, Laura Pawlik, Natalia Roshardt, Elias Burri, Isabella Dommann, Lara Grossmann, Sarah Morgenroth, Melike Ak, Isabella Dommann, Aurelio Börlin, Amelie Cerniec, Mario Teufer, Michele Welti

Main Fields of Research

The team has established a world-class skin cancer center providing the best clinical care connected to translational and clinical research. We intensively investigate the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with the best quality of life.

In cutaneous lymphomas, we investigate the origin of disease associated itch by analyzing and overlapping the findings from the malignant and non-malignant cells from different affected tissues. Assessing the samples on genetic, transcriptomic and translational level enables identification of pathways affected. Given this knowledge, we can translate this knowledge and initiate investigator clinical trials. Recently, one of the investigator-initiated clinical trials demonstrated unprecedented results by combining sophisticated next generation high throughput technologies such as single cell analysis with minimally invasive technique for sample collection and response assessment.

Along the bench and bedside research, we also focus on high quality clinical data management that allows to integrate translational data with clinical findings and generate further hypotheses for clinical research. In this context we have contributed to long term (10years) survival data in the adjuvant or metastatic setting.

Selected References

Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerding V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Matter CM, Michielin O, Gutzmer R, Long GV, Becher B, Levesque MP, Dummer R. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma. *Nat Cancer*. 2024;5(9):1390-1408.

Vasilevska J, Cheng PF, Lehmann J, Ramelyte E, Gómez JM, Dimitriou F, Sella F; TuPro Consortium; Ferretti D, Salas-Bastos A, Jordaán WS, Levesque MP, Dummer R, Sommer L. Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance. *Cell Rep Med*. 2024;16;5(7):101611.

Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, Merelli B, Sileni VC, Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnaik SB, Burgess P, Jandoo T, Dummer R. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *N Engl J Med*. 2024;7;391(18):1709-1720.

Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. *N Engl J Med*. 2023;14;389(24):2256-2266.



Antonia Gabriel (Fettelschoss-Gabriel), PhD

Group Members and Associates

Fabia Canonica, PhD; Fadi Jebbawi, PhD; Katharina Birkmann DVM ECEIM; Juwela Lam, Master; Jefferson Brito de Souza, Bachelor; Tanya Rhiner, DVM; Nina Waldern, DVM PhD; Giulia Keller, Master; Virginie de Woelmont, Master

Main Fields of Research

Our main research area is translating immunology of chronic diseases or hyperreactivities such as allergies into new cutting-edge therapeutic vaccines. Our virus-like particle (VLP)-based therapeutic vaccines target key molecules involved in disease pathology and, in contrast to other biologicals, are an inexpensive and effective way of treating chronic disorders. Thus, advanced technology can become available even to our companion animals. One of our main interests are skin-related and hypereosinophilic diseases in horses. The most common chronic allergic dermatitis in horses is caused by insect bites. Insect-bite hypersensitivity (IBH)-affected horses suffer from pruritic skin lesions, caused by type-I/type-IVb allergic reactions accompanied by prominent eosinophilic infiltration into the skin. We study the interplay of underlying allergic reactions in early and chronic stages of disease. IBH in horses shares common features with human eosinophilic asthma. Thus, we believe understanding the molecular mechanisms in such allergic reactions can be translated to other species including humans allowing to improving treatment modalities in the future.

Selected References

Schwarz E, Jebbawi F, Keller G, Rhiner T, Fricker A, Waldern N, Canonica F, Schoster A, Fettelschoss-Gabriel A. (2024) Phenotypic shift of inflammatory eosinophil subset into 2 steady-state resident phenotype after 2 years of vaccination against IL-5 in equine insect bite hypersensitivity. *Veterinary Science*.

Birkmann K, Jebbawi F, Waldern N, Hug S, Inversini V, Keller G, Holm A, Grest P, Canonica F, Schmid-Grendelmeier P, Fettelschoss-Gabriel A. (2024) Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses. *Vaccines*.

Pantelyushin S, Rhiner T, Jebbawi F, Sella F, Waldern N, Lam J, Chemnitz A, Fricker A, Schoster A, Birkmann K, Widmer D, Canonica F, Fettelschoss-Gabriel A. (2023) Interleukin 5-dependent inflammatory eosinophil subtype involved in allergic insect bite hypersensitivity of horses. *Allergy*.

Jonsdottir S, Fettelschoss V, Olomski F, Talker S C, Birkmann K, Thoms F, Wagner B, Bachmann M F, Kündig T M, Marti E, Fettelschoss-Gabriel A (2020) Safety profile of a virus-like particle-based vaccine targeting self-protein Interleukin-5 in horses. *Vaccines*.

6c Research groups



Christian Greis, MD, MBA, FEBDV

Prof. Ralph Braun, MD

Group Members and Associates

Dr. med. Christian Greis; Prof. Dr. med. Ralph Braun; Alexander Braun, Masterstudent (UZH); Andrin Crittin, Masterstudent (UZH); Andrina von Stokar Sielentz, Masterstudent (UZH); Ann-Christin Cirkel, Doktorandin (LMU); Isabelle Burri, Masterstudentin (UZH); Javier Barranco-Garcia PHD (USZ); Julia Beck, Masterstudentin (UZH); Marianna Guerrero Corrales, Masterstudentin (UZH); Mathias Gassner, Masterstudent (ETH); Sara Hofer, Masterstudentin (UZH); Thaadsajini Manivannan, Masterstudentin (UZH); Vullnet Usemi, Masterstudent (ETH)

Main Fields of Research

Our main research activities are centered on advancing telemedicine and artificial intelligence in dermatology to enhance diagnostic accuracy and treatment personalization. We evaluate both the economic impacts of telemedicine and its tangible benefits for patients, such as increased accessibility and efficiency in care delivery. Recent publications have highlighted the evaluation of teledermatological services at Swiss university hospitals, showcasing their role in optimizing healthcare delivery while reducing costs. Furthermore, our group has explored innovative telemedicine approaches to managing common skin conditions, including scaling digital platforms for real-world clinical applications. In addition, we focus on the potential of telemedicine in allergy care, where our research has examined pilot projects and novel patient questionnaires to improve care pathways and assess interim outcomes. These efforts contribute to shape the future of dermatological care through technology-driven solutions.

Selected References

Beck J., De Lira R., Maul L., Anzengruber F., Brockes C., Meier-Schiesser C., Braun R., Greis C. (2024) Teledermatological services at a Swiss university hospital - Evaluation of patient benefits and economic impact (submitted)

Otten M, Greis C, Reinders P, Fleyder A, Reich K, Augustin M. Patient and physician outcomes of a store-and-forward teledermatology application in Germany. *J Eur Acad Dermatol Venereol.* 2024 Feb;38(2):e148-e151. doi: 10.1111/jdv.19501. Epub 2023 Sep 26. PMID: 37669866.

Useini V, Tanadini-Lang S, Lohmeyer Q, Meboldt M, Andratschke N, Braun RP, Barranco Garcia J. Automatized self-supervised learning for skin lesion screening. *Sci Rep.* 2024 Jun 3;14(1):12697. doi: 10.1038/s41598-024-61681-4. PMID: 38830890; PMCID: PMC11148053.

Greis C. (2021) AIM in Dermatology. In: Lidströmer N., Ashrafian H. (eds) *Artificial Intelligence in Medicine*. Springer, Cham. https://doi.org/10.1007/978-3-030-58080-3_188-1

Greis C, Maul LV, Hsu C, Djamei V, Schmid-Grendelmeier P, Navarini AA. Artificial intelligence to support telemedicine in Africa. *Hautarzt.* 2020 Sep;71(9):686-690. German. doi: 10.1007/s00105-020-04664-6. PMID: 32761386; PMCID: PMC7407433.

Greis C, Meier Zürcher C, Djamei V, Moser A, Lautenschlager S, Navarini AA. Unmet digital health service needs in dermatology patients. *J Dermatolog Treat.* 2018 Nov;29(7):643-647. doi: 10.1080/09546634.2018.1441488. Epub 2018 Mar 14. PMID: 29455570.



Prof. Jürg Hafner, MD

Group Members and Associates

Natalie Anasiewicz, Dr. med.; Marjam Barysch, PD Dr. med.; Fabio Bertoldo, Dr. med.; Fabienne Fröhlich, Dr. med.; Christian Greis, Dr. med.; Fabienne Huber, Dr. med.; Diana Lazarevic, Dr. med.; Dieter Mayer, PD Dr. med.; David Muggli, Dr. med.; Carla Murer, Dr. med.; Mirjam Nägeli, Dr. med.; Stephan Nobbe, Dr. med.; Johanna Ziegler, Dr. med.

Main Fields of Research

Principle Investigator of SKINTEGRITY/Local anaesthesia/Geriatric dermatologic surgery/Medical compression of lower leg/Severe skin diseases: Chronic prurigo, Hidradenitis suppurativa, Hypertensive ischemic leg ulcer

Summary Report

The Department of Dermatologic Surgery, Mohs Micrographic Surgery, Phlebology, Wounds and Lasers invests a great deal in medical education and surgical skills training for registrars/residents and young staff. In recent years, more and more trainees from Europe have also been coming. Our department, together with the City Hospital/Europaallee, runs a Mohs Fellowship Programme of the ESMS/EADV (coordinated by PD Dr. S. Lächli). As a result, we have an increasing number of proficient dermatologic skin cancer surgeons in Switzerland who are ready to effectively help the Swiss population, which is particularly affected by skin cancer.

For several years, our research has focused on the topics of local anaesthesia, skin cancer surgery in old age (geriatric dermatologic surgery) and compression treatment of the legs. Here, some larger studies are in the making that will certainly be well suited for publication in the coming years. Of great importance is the cooperation with the large ETH-UZH-USZ research platform SKINTEGRITY, through which a large number of excellent research projects have already been carried out (see also list of publications).

Selected References

Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics.

Doerfler P, Schoemann N, Cabral G, Bauer W, Berli MC, Binder B, Borst C, Botter S, French LE, Goerge T, Hafner J, Hartmann D, Høgh A, Hoetzenecker W, Holzer-Geissler JCJ, Kamolz LP, Kofler K, Luger T, Nischwitz SP, Popovits M, Rappersberger K, Restivo G, Schlager JG, Schmutz M, Stingl G, Stockinger T, Stroelin A, Stuetz A, Umlauf J, Weninger WP, Wolff-Winiski B. *J Invest Dermatol* 2024;DOI10.1016/j.jid.2024.05.029.

Identifying Key Drivers in the Pathogenesis of Martorell Hypertensive Ischaemic Leg Ulcers: A Comparative Analysis with Chronic Venous Leg Ulcer.

Hess J, Barysch-Bonderer M, Seeli C, Laube J, Ghosh A, Deinsberger J, Weber B, Hafner J, Meier-Schiesser B. *Acta Derm Venereol* 2024;104: DOI 10.2340/actadv.v104.40090.

Zinc oxide patches are a highly effective treatment for chronic prurigo: a randomized split-body study.

Schuermann ML, Richter C, Tanadini M, Steigmiller K, Burri E, Guillet C, Luchsinger I, Meier-Schiesser B, Boesch A, Nägeli M, Hafner J. *Dermatology* 2023;239:996-1006.

6c Research groups



Omar Hasan Ali, MD

Group Members and Associates

Yadusha Mahenthiran (Doctoral candidate)

Cheyenne Collins (Doctoral candidate)

Nicola Davaz (Doctoral candidate)

Former Group Members: Elena DeLorenzi

Main Fields of Research

While immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment many patients do not respond to treatment. Dr. Hasan Ali's new research group at our center investigates the immune responses underlying ICI therapies, focusing on how various modulators can either enhance or undermine their efficacy. A proper immune response is essential for successful ICI treatment, yet it can be shaped by numerous factors—understanding these factors is key to improving patient outcomes.

The group builds on his prior work on uncovering potential predictors of ICI outcomes—such as IgG responses to BP180 and certain HLA variations—and exploring how they correlate with both clinical success and immune-related side effects. The understanding of immunological responses is further aided by research on COVID-19, which demonstrated that autoimmune IgA is elevated in severe disease and can drive surfactant dysfunction.

Understanding the mechanisms of immune modulation, such as protein glycosylation, may inform future immunomodulatory strategies to enhance therapeutic efficacy. The group's efforts are supported by active collaborations within Switzerland and with leading centers in Austria and Canada.

Selected References

Sinnberg T*, Lichtensteiger C*, Hasan Ali O*, Pop OT, Jochum AK, Risch L, Brugger SD, Velic A, Bomze D, Kohler P, Vernazza P, Albrich WC, Kahlert CR, Abdou MT, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Rocken M, Dulovic A, Shambat SM, Ruetalo N, Buehler PK, Scheier TC, Jochum W, Kern L, Henz S, Schneider T, Kuster GM, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy KD, Spengler W, Brutsche MH, Macek B, Twerenbold R, Penninger JM, Matter MS, Flatz L. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. *Am J Respir Crit Care Med.* 2023;207:38-49

Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M, Thiel S, Kern L, Albrich WC, Kohler P, Kahlert CR, Vernazza P, Buehler PK, Schupbach RA, Gomez-Mejia A, Popa AM, Bergthaler A, Penninger JM, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis.* 2021;73:e2869-e2874

Hasan Ali O, Berner F, Bomze D, Fassler M, Diem S, Cozzio A, Jorger M, Fruh M, Driessen C, Lenz TL, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. *Eur J Cancer.* 2019;107:8-14

Bomze D*, Hasan Ali O*, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol.* 2019;5:1633-1635

Hasan Ali O*, Diem S*, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Fruh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology.* 2016;5:e1231292.



Lukas Krähenbühl, MD, FEBDV

Group Members and Associates

Dr. med. Lukas Krähenbühl (principal investigator)
pract.med. Tanja Patricia Eicher (doctoral candidate)
cand.med. Thilo Gwerder (medical student, doctoral candidate)

Main Fields of Research

Our research focuses on cancer patients. In particular, we aim at improving cancer patient's quality of life and reducing interruptions or dose-reductions of potentially life-saving cancer treatments. Our special interest is on dermatologic adverse events of any cancer treatment as well as tumor immunology and immune-related adverse events occurring during cancer treatment with immune checkpoint blockade. Our experimental work is conducted in collaboration and at the Merghoub/Wolchok lab at Weill Cornell Medicine, New York, NY. For our clinical work, we closely collaborate within the EADV taskforce "dermatology for cancer patients" and with colleagues at USZ and KSA.

Selected References

- Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schröder D, Chow A, Ricca JM, Gasmi B, De Henau O, Mangarin LMB, Li Y, Hamadene L, Flamar AL, Choi H, Cortez CA, Liu C, Holland A, Schad S, Schulze I, Betof Warner A, Hollmann TJ, Arora A, Panageas KS, Rizzuto GA, Duhon R, Weinberg AD, Spencer CN, Ng D, He XY, Albregues J, Redmond D, Egeblad M, Wolchok JD, Merghoub T. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. *Cell*. 2023 Mar 30;186(7):1432-1447.e17. doi: 10.1016/j.cell.2023.03.007. PMID: 37001503; PMCID: PMC10994488.
- Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. *Nat Rev Clin Oncol*. 2022 Jan;19(1):37-50. doi: 10.1038/s41571-021-00552-7. Epub 2021 Sep 27. PMID: 34580473.
- Kuo AM, Gu S, Stoll J, Moy AP, Dusza SW, Gordon A, Haliasos EC, Janjigian Y, Kraehenbuehl L, Quigley EA, Chapman P, Lacouture ME, Markova A. Management of immune-related cutaneous adverse events with dupilumab. *J Immunother Cancer*. 2023 Jun;11(6):e007324. doi: 10.1136/jitc-2023-007324. PMID: 37270183; PMCID: PMC10255229.
- Kraehenbuehl L, Schneider S, Pawlik L, Mangana J, Cheng P, Dummer R, Meier-Schiesser B. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. *Pharmaceuticals (Basel)*. 2023 Jun 27;16(7):935. doi: 10.3390/ph16070935. PMID: 37513847; PMCID: PMC10383648.
- Sahu A, Kose K, Kraehenbuehl L, Byers C, Holland A, Tembo T, Santella A, Alfonso A, Li M, Cordova M, Gill M, Fox C, Gonzalez S, Kumar P, Wang AW, Kurtansky N, Chandrani P, Yin S, Mehta P, Navarrete-Dechent C, Peterson G, King K, Dusza S, Yang N, Liu S, Phillips W, Guitera P, Rossi A, Halpern A, Deng L, Pulitzer M, Marghoob A, Chen CJ, Merghoub T, Rajadhyaksha M. In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response. *Nat Commun*. 2022 Sep 9;13(1):5312. doi: 10.1038/s41467-022-32738-7. PMID: 36085288; PMCID: PMC9463451.

6c Research groups



Prof. Thomas Kündig, MD

Group Members and Associates

Pål Johansen, Prof. PhD; Gary Jennings, PhD; Senta Walton, PhD; Antonia Fettelschoss-Gabriel, PhD; Steve Pascolo, Prof. Dr., PhD; Lara Susic, MD-PhD student; Stephan Flory, doctoral candidate (MD); Yasmin Adlany, doctoral candidate (MD); Emma Widmer, doctoral candidate (MD); Alexandra Chabot, doctoral candidate (MD)

Main Fields of Research

New therapeutic approaches for the treatment of allergies and skin diseases in animals are being researched. These new approaches include the direct injection of allergens and modified recombinant allergens into the lymph nodes, known as intralymphatic allergen immunotherapy, as well as the epicutaneous administration of high allergen doses in epicutaneous immunotherapy. Another approach involves giving allergens the immunological properties of viruses by recombinantly producing virus-like particles. With these new therapeutic approaches, the number of allergen administrations required for desensitization can be reduced from the current 30-60 injections to just 3.

These technologies are also being used to develop new therapeutic approaches for allergic diseases in animals, such as canine atopic dermatitis or equine summer eczema. Active anti-cytokine vaccines have been developed, allowing horses to be immunized against Interleukin-5 and dogs against Interleukin-31. These studies are a collaboration with various veterinarians and animal hospitals.

Prof. Pascolo is a pioneer in using RNA molecules to treat various diseases. He was the first to propose using RNA as a vaccine. At the time, the idea was considered exotic, but during the COVID-19 pandemic, it demonstrated its strengths.

Selected References

Paolucci M, Antz N, Homère V, Kolm I, Kündig TM, Johansen P. A murine model of peanut-allergic asthma. *Front Allergy*. 2024 Apr 25;5:1378877.

Hjálmsdóttir Á, Hasler F, Waeckerle-Men Y, Duda A, López-Deber MP, Pihlgren M, Vukicevic M, Kündig TM, Johansen P. T cell independent antibody responses with class switch and memory using peptides anchored on liposomes. *NPJ Vaccines*. 2024 Jun 22;9(1):115.

Paolucci, M; Wullemin, N; Homère, V; Bieli, D; Köhli, A; Ballmer-Weber, B; Waeckerle-Men, Y; Pengo, N; Kündig, TM; Sonati, T; Johansen, P Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. doi.org/10.1111/all.15659 Feb 2023 ALLERGY.



Claudia Lang, MD

Group Members and Associates

Anna White, postdoc

Fiona Schmid, MD candidate

Maurice Mattenberger, Masterstudent

Main Fields of Research

Our group is investigating mast cell pathologies and allergic diseases conducting a registry for patients with hypertryptasemia and mastocytosis. Within the registry we focus on translational research and patient-oriented outcomes. Additionally, we investigate correlations in allegro-oncology through biomarkers and perform epidemiology studies in contact dermatitis. We are also involved in clinical trials treating atopic dermatitis, urticaria and intralymphatic immunotherapy.

Selected References

Darbellay B, Huber M, Bisschoff IJ, Guillod C, Hügel R, Pirkhammer D, Sator PG, Taskesen T, Lang CCV. Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study. *J Dermatolog Treat.* 2024 Dec;35(1):2415407. doi: 10.1080/09546634.2024.2415407. Epub 2024 Oct 17. PMID: 39419511.

Fehr, D., Rentschler, M., Sendrasoa, F., Lang, C. et al. Sensitizations to pollen differ between Central European and Sub-Saharan African atopic dermatitis patients. *Allergo J Int* (2024). <https://doi.org/10.1007/s40629-024-00313-9>

Piontek K, Radonjic-Hoesli S, Grabbe J, Drewitz KP, Apfelbacher C, Wöhrl S, Simon D, Lang C, Schubert S. Comparison of patch testing Brazilian (Green) propolis and Chinese (poplar-type) propolis: Clinical epidemiological study using data from the Information Network of Departments of Dermatology (IVDK). *Contact Dermatitis.* 2024 Oct 5. doi: 10.1111/cod.14701. Epub ahead of print. PMID: 39367763.

Flory S, Hviid-Vyff B, Šošić L, Schmid JM, Ahlbeck L, Widmer ECJ, Lang CCV, Ikenberg K, Kündig TM, Hoffmann HJ, Johansen P. How to hit the allergy target: A critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound-guided injections. *Allergy.* 2024 Aug;79(8):2222-2234. doi: 10.1111/all.16138. Epub 2024 May 7. PMID: 38712754.

Storz L, Schmid B, Bosshard PP, Schmid-Grendelmeier P, Brügggen MC, Lang C. Decreased skin colonization with *Malassezia* spp. and increased skin colonization with *Candida* spp. in patients with severe atopic dermatitis. *Front Med (Lausanne).* 2024 Feb 20;11:1353784. doi: 10.3389/fmed.2024.1353784. PMID: 38444416; PMCID: PMC10912638.

6c Research groups



Prof. Mitchell Levesque, PhD

Group Members and Associates

Ossia Eichhoff, Senior Scientist; Aizhan Tastanova, Senior Scientist; Andreas Dzung, Post-doc; Corinne Stoffel, Post-doc; Veronika Hauerdinger, Post-doc; Evelyn Lattmann, Post-doc; Annalisa Saltari, Post-doc; Corinne Stoffel, Post-doc; Gaetana Restivo, Project Manager; Julia Martinez-Gomez, Project Manager; Patrick Turko, Bioinformatician; Mauro Esposito, PhD Student; Prachi Shukla, PhD Student; Jan Käsler, Lab Manager; Victoria Hermes, technician

Especially concerning group of Prof. Reinhard Dummer:

Mirka Schmid, technician; Federica Sella, technician; Dani Hug, technician

Main Fields of Research

Our group applies the latest omics tools to translational research questions in order to identify better predictive biomarkers for precision medicine as well as novel targets in late stage melanoma. We are particularly interested in understanding the complexity of the tumor microenvironment and how it leads to skin cancer progression. We do this through sequencing and imaging approaches and the application of computational models. With access to one of the largest live-cell melanoma collections in the world, we have a unique resource in which to study the functional mechanisms of cellular heterogeneity and how these respond to various therapeutic regimens.

Selected References

Dimitriou, F., Cheng, P.F., Saltari, A. et al. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma. *Nat Cancer* 5, 1390–1408 (2024). <https://doi.org/10.1038/s43018-024-00810-4>

Nordmann, T.M., Anderton, H., Hasegawa, A. et al. Spatial proteomics identifies JAKi as treatment for a lethal skin disease. *Nature* 635, 1001–1009 (2024). <https://doi.org/10.1038/s41586-024-08061-0>

Elbatsh, A.M.O., Amin-Mansour, A., Haberkorn, A. et al. INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas. *Nat Cancer* 5, 481–499 (2024). <https://doi.org/10.1038/s43018-023-00710-z>



PD Dr. med. Joanna Mangana

Group Members and Associates

Ramon Stäger (doctoral candidate)
Alexander Braun (master candidate)
M: Welti (resident dermatology)
Isabel Pieper Scholz (Data manager)

Main Fields of Research

Our research focuses on systemic treatment and identification of response patterns in advanced melanoma patients receiving immune checkpoint inhibitors, as well as cutaneous toxicity of anticancer drugs. Since 2016, we have established a high-quality clinical database of advanced melanoma patients, which is currently being expanded to other melanoma centres in Switzerland. Our goal is to integrate translational data with clinical findings and generate further hypotheses for clinical research.

Selected References

Staeger R, Martínez-Gómez JM, Turko P, Ramelyte E, Kraehenbuehl L, Del Prete V, Hasan Ali O, Levesque MP, Dummer R, Nägeli MC, Mangana J Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. *Cancers (Basel)*. 2024 Feb 20;16(5):854

Burri E, Mangana J, Cheng PF, Schneider A, Weber A, Dummer R, Ramelyte E. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids. *J Immunother Cancer*. 2024 Jul 5;

Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. *Eur J Cancer*. 2024 Mar;199:113563.

Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJ, Bhave P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA, McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, Blank CU, Lo SN, Long GV, Menzies AM. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma *Eur J Cancer*. 2024.

6c Research groups



Prof. Julia-Tatjana Maul, MD

Group Members and Associates

Ion Birkenmaier (PHD candidate); Ramtin Lichtenberger, MD (doctoral candidate); Vivienn Kaiser, MD (doctoral candidate); Michael Wedel, MD (doctoral candidate); Ana Zimmermann, MD (doctoral candidate); Viola Schön, MD (doctoral candidate); Rahel Looser, MD (resident physician); Laura Pawlik, MD (resident physician); Isabella Dommann (resident physician); Stefanie Sand (resident physician); Melike AK, MD (resident physician); Mia Nielsen, PhD (Associate)

Main Fields of Research

Our main research activities are focused on inflammatory skin diseases, with a particular emphasis on psoriasis, a highly stigmatizing disease that affects patients both physically and mentally, leading in most cases to poor quality of life and increased risk of severe comorbidities. Despite the highly efficacious treatment options since the introduction of specific therapies targeting key cytokines involved in pathogenesis such as TNF α , IL-17 and IL-23, many clinical and immunological questions remain. Our goal is to investigate the drug survival of biologics and conventional systemics, sex and gender differences in treatment response and access to treatment, as well as the underlying immunological mechanisms involved.

Selected References

Maul JT, Lara V. Maul, Johannes A. Didaskalu, Fernando Valenzuela, Ricardo Romiti, Hannah Peterson, Edwin Korouri, Farah Novoa, Hazel H. Oon, Min Zheng, Jashin J. Wu, Jacob P. Thyssen, Alexander Egeberg, April W. Armstrong, Mia-Louise Nielsen. Correlation between DLQI and PASI in patients with psoriasis – a cross-sectional Global Healthcare Study on Psoriasis (GHSP). *Acta Derm Venereol.* 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.

Verardi F, Maul LV, Borsky K, Steinmann S, Rosset N, Pons HO, Sorbe C, Yawalkar N, Micheroli R, Egeberg A, Thyssen JP, Heidemeyer K, Boehncke WH, Conrad C, Cozzio A, Pinter A, Kündig T, Navarini AA, Maul JT. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). *J Eur Acad Dermatol Venereol.* 2023 Dec 12. doi: 10.1111/jdv.19730.

Maul JT, Kolios A, Thomsen SF, Ring H-C. Secukinumab treatment of hidradenitis suppurativa: questions remain. *Lancet.* 2024 Feb 17;403(10427):616–617. doi: 10.1016/S0140–6736(23)01616–1.

Maul JT, Fröhlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. *Br J Dermatol.* 2023 Mar 30;188(4):533–541. doi: 10.1093/bjd/ljac128.

Zwicky P, Ingelfinger F, Silva de Melo BM, Ruchti F, Schärli S, Puertas N, Lutz M, Phan TS, Kündig TM, Levesque MP, Maul JT, Schlapbach C, LeibundGut-Landmann S, Mundt S, Becher B. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasisiform inflammation. *Sci Immunol.* 2021 Oct 22;6(64):eabg9012. doi: 10.1126/sciimmunol.abg9012. Epub 2021 Oct 22. PMID: 3467804.



PD Dr. med. Lara Valeska Maul-Duwendag, MD

Group Members and Associates

Benjamin Nutz, MD (doctoral candidate); Anna Andrea Heinzl (doctoral candidate); Sara Wespi (master and doctoral candidate); Vivienn Kaiser, MD (doctoral candidate); Vincent Müller (master student); Hans-Christian Niederfeilner, MD (doctoral student); Elisabeth Gössinger, MD (doctoral student); Lisa Kostner, MD (doctoral student); Sara Cerminara, MD (doctoral student); Jelissa Peters, MD (doctoral candidate); Anna Sophie Jahn, MD (master and doctoral student); Lorena Gantenbein (doctoral student)

Main Fields of Research

Our research focuses on prevention, early detection and management of melanoma as well as surveillance of high-risk individuals. The increasing global incidence of melanoma and the remaining high mortality emphasizes the urgent need to improve skin cancer awareness and early diagnostic techniques. We investigate innovative non-invasive diagnostic imaging approaches utilizing artificial intelligence (AI) in combination with established methods to enhance skin cancer diagnostics. Also psychological distress in skin cancer patients as well as rare skin tumors, e.g. Kaposi sarcoma and Merkel cell carcinoma, belong to our research field. We aim for future translational research approaches to combine novel AI-driven imaging tools with biomarker assessment to identify individuals at highest risk who require enhanced prevention and detection to improve patient care and health outcomes of melanoma.

Selected References

- Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea AM, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvey J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P; Melanoma World Society Study Group (Mangana J, ..., Maul LV, ..., Ramelyte E,...). Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. *Lancet Oncol.* 2025 Jan;26(1):12-14. doi: 10.1016/S1470-2045(24)00627-2.
- Goessinger EV, Dittrich PG, Nöcker P, Notni G, Weber S, Cerminara S, Mühleisen B, Navarini AA, Maul LV. Classification of melanocytic lesions using direct illumination multispectral imaging. *Sci Rep.* 2024 Aug 16;14(1):19036. doi: 10.1038/s41598-024-69773-x.
- Maul LV, Jamiolkowski D, Lapidus RA, Müller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Nemeth IB, Janosi AJ, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roider E. Health Economic Consequences of Delayed Melanoma Diagnosis due to the COVID-19 Pandemic in Europe. *JAMA Netw Open.* 2024 Feb 5;7(2):e2356479. doi: 10.1001/jamanetworkopen.2023.56479.
- Goessinger EV, Niederfeilner JC, Cerminara SE, Maul JT, Kostner L, Kunz M, Huber S, Koral E, Habermacher L, Sabato G, Tadic A, Zimmerman C, Navarini AA, Maul LV. Patient and dermatologists' perspectives on augmented intelligence for melanoma screening: A prospective study. *J Eur Acad Dermatol Venereol.* 2024 Feb 27. doi: 10.1111/jdv.19905. Online ahead of print.
- Cerminara SE, Cheng P, Kostner L, Huber S, Kunz M, Maul JT, Böhm JS, Dettwiler CF, Geser A, Jakopovic CJ, Stoffel LM, Peter JK, Levesque M, Navarini AA, Maul LV. Diagnostic Performance of Augmented Intelligence with 2D and 3D Total Body Photography and Convolutional Neural Networks in a High-risk Population for Melanoma under Real-world Conditions: A New Era of Skin Cancer Screening? *Eur J Cancer.* 2023 Jun 24;190:112954. doi: 10.1016/j.ejca.2023.112954.

6c Research groups



Barbara Meier Schiesser, MD, PhD

Group Members and Associates

Julia Laube, MSc (Research fellow), Vivienn Kaiser (doctoral candidate), Ines Lederbogen (study doctor), Patrick Poffet, MD (doctoral candidate), Cadri Knoch, MD (doctoral candidate), Jamila Hess, MD (doctoral candidate)

Main Fields of Research

Inflammatory skin diseases are frequent in number and often lead to a decreased quality of life in the affected patients. Lichenoid inflammation is one of the most commonly encountered inflammation patterns of the skin. The prototypical lichenoid mucocutaneous disease is Lichen planus (LP) with its several subtype. Besides, lichenoid inflammation can also be caused by several drugs, in particular cancer drugs such as checkpoint inhibitors, leading to artificial lichenoid skin reactions (ALSR). The exact pathophysiology of both LP and ALSR remains poorly understood.

Our laboratory has identified distinct gene expression patterns between different forms of LP and ALSR, emphasizing the need for a comprehensive investigation into their molecular pathways. We aim to thoroughly characterize the various forms of LP and ALSR and uncover the underlying molecular mechanisms. Ultimately, our goal is to identify key molecules that can serve as targets for developing effective therapies for these challenging skin conditions.

Selected References

Knoch C, Baghin V, Winkelbeiner N, Turko P, Stäger R, Wei K, Banzola I, Mellett M, Levesque MP, Kündig T, French LE, Heinzerling L, Meier-Schiesser B (2024). Distinct variations in gene expression and cell composition across Lichen Planus subtypes. *Int J Mol Sci*, 25(17), 9720.

Hess J, Barysch-Bonderer MJ, Seeli C, Laube J, Ghosh A, Deinsberger J, Weber B, Hafner J, Meier-Schiesser B (2024). Identifying key drivers in the pathogenesis of martorell hypertensive ischaemic leg ulcer: a comparative analysis with chronic venous leg ulcer. *Acta Derm Venereol*, 104, adv40090.

Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, Abdullah SE, Orloff M, Nathan P, Piperno-Neumann S, Staeger R, Dummer R, Meier-Schiesser B (2024). Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. *J Invest Dermatol*, S0022-202X(24), 01886-4.

Meier-Schiesser B, Zecha C, S Zierold S, Kolm I, Röckel M, Fröhlich W, Mittag N, Schmitt C, Kumbrink J, Hassel JC, Berking C, Nashan D, French LE, Vera-González J, Dummer R, Kerl-French K, Heinzerling L (2024). Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological and gene expression level. *JAAD Int*, 15, 157-164.

Kraehenbuehl L, Schneider S, Pawlik L, Mangana J, Cheng P, Dummer R, Meier-Schiesser B (2023). Cutaneous adverse events to systemic melanoma treatments: a retrospective single-center analysis. *Pharmaceuticals*, 16(7), 935.

Meier-Schiesser B, Feldmeyer L, Jankovic D, Mellett M, Satoh TK, Yerly D, Navarini AA, Abe R, Yawalkar N, Chung WH, French LE, Contassot E (2019). Culprit drugs induce specific IL-36 overexpression in Acute Generalized Exanthematous Pustulosis. *J Invest Dermatol*, 139(4), 848-858.



Mark Mellet, PhD

Group Members and Associates

Dr. James O' Siorain (Postdoctoral Researcher); Jennifer Keller (PhD student); Laurène Favre (Biomedicine MSc student); Janine Baumann (Immunology MSc student)

Main Fields of Research

Epithelial cells at barrier sites including the skin, gut and mucosal tissue constitute the front line at the host-pathogen interface and mount an immune response to microbial infection that is critical for controlling infection at early stages. Like, innate immune cells, epithelial cells express a panoply of pattern recognition receptors, which distinguish highly conserved biochemical features of microbes to discriminate them from host cells. An uncontrolled or dysregulated innate immune response at the epidermal barrier can lead to sustained activation of pro-inflammatory pathways and the infiltration of lymphocytes and myeloid cells that maintain chronicity in inflammatory skin diseases, especially in genetically susceptible individuals. Rare and common chronic inflammatory skin diseases reduce the quality of life for sufferers and increase in frequency with age.

Our research focuses on elucidating how pattern recognition receptors and cell death pathways are involved in kindling chronic inflammation at the epidermal barrier, and how this drives the pathogenesis of chronic inflammatory dermatological diseases, including psoriasis, pityriasis rubra pilaris and generalized pustular psoriasis. In particular, we investigate how causative mutations associated with these diseases impact the innate immune response, including for example; mutations in the keratinocyte signalling molecule CARD14 and the Interleukin-36 cytokine pathway. Our goal is to better understand underlying disease mechanisms to reveal new therapeutic strategies for exploration, in particular for diseases that have an unmet clinical need.

Selected References

Molecular aspects of IL-36 cytokine activation and regulation at epithelial barriers. Keller J, O' Siorain J, Kündig TM, Mellett M. *Biochem Soc Trans* (2024) BST20230548. doi: 10.1042/BST20230548

Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy. Holzinger T, Frei J, Jarzebska NT, Beer HD, Kündig TM, Pascolo S*, Läubli S*, Mellett M*. *Anti-cancer Drugs* 2024 Nov 1;35(10):912-921. doi: 10.1097/CAD.0000000000001644

Time-of-day control of mitochondria regulates NLRP3 inflammasome activation in macrophages. O'Siorain JR, Cox SL, Payet C, Nally FK, He Y, Drewinski TT, Kennedy OD, Dowling JK, Mellett M, Early JO, Curtis AM. *FASEB J*. 2024 Dec 13;38(24):e70235. doi: 10.1096/fj.202400508RR

Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. Abboud E, Boussetta N, Chrayteh D, Dalle H, Malerba M, Wu T, Le Gall M, Reelfs O, Pourzand C, Mellett M, Assan F, Bachelez H, Poupon J, Aractingi S, Vaulont S, Sohler P, Oules B, Karim Z, Peyssonnaud C. *Nat Commun* 15, 6718 (2024). doi.org/10.1038/s41467-024-50993-8.

The Role of NLRP1 Inflammasome in Skin Cancer and Inflammatory Skin Diseases. Calabrese L, Fiocco Z, Mellett M, Aoki R, Rubegni P, French LE, Satoh TK. *Br J Dermatol*. 2024 Feb 16;190(3):305-315. doi: 10.1093/bjd/ljad421.

6c Research groups



Prof. Steve Pascolo, PhD

Group Members and Associates

Julia Frei; Rocco Penna; Maximilian Feldmann; Jonas Mumenthaler; Thomas Look; Mark Mellett

Main Fields of Research

The main focus of our research is to advance the development and the therapeutic utilization of synthetic RNA. Our approach is two-pronged; firstly, we generate multifunctional anti-cancer drugs based on immunochemo-therapeutic chemically synthesized RNA oligonucleotides that target tumour cells for killing, while also enhancing the immune response. On the other hand, as the mRNA platform of Zürich, we optimize, generate and formulate in vitro transcribed or chemically synthesized mRNA for the expression of therapeutic peptides/proteins that are evaluated in numerous indication-specific models, both within our laboratory and by our extensive collaborative network.

Selected References

Mamaghani S, Penna RR, Frei J, Wyss C, Mellett M, Look T, Weiss T, Guenova E, Kündig TM, Lauchli S, Pascolo S. Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo. *Cells*. 2024 Jul 24;13(15):1242.

Holzinger T, Frei J, Jarzebska NT, Beer HD, Kündig TM, Pascolo S, Läubli S, Mellett M. Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy. *Anticancer Drugs*. 2024 Nov 1;35(10):912-921.

Frei J, Jarzebska NT, Mellett M, Kündig TM, Pascolo S, Reichmuth AM. Design and Synthesis of Circular RNA Expression Vectors. *Methods Mol Biol*. 2024;2786:205-215.

Jarzebska NT, Frei J, Mellett M, Kündig TM, Pascolo S, Reichmuth AM. A Basic Method for Formulating mRNA-Lipid Nanoparticle Vaccines in the Lab. *Methods Mol Biol*. 2024;2786:237-254.

Jarzebska NT, Tusup M, Frei J, Weiss T, Holzinger T, Mellett M, Diken M, Bredl S, Weller M, Speck RF, Kündig TM, Sahin U, Pascolo S. RNA with chemotherapeutic base analogues as a dual-functional anti-cancer drug. *Oncoimmunology*. 2022 Nov 18;11(1):2147665.

Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, Hale BD, Snijder B, Regli L, Ravi VM, Heiland DH, Sentman CL, Weller M, Weiss T. Multifunctional mRNA-Based CAR T Cells Display Promising Antitumor Activity Against Glioblastoma. *Clin Cancer Res*. 2022 Nov 1;28(21):4747-4756.

Tusup M, Läubli S, Jarzebska NT, French LE, Chang YT, Vonow-Eisenring M, Su A, Kündig TM, Guenova E, Pascolo S. mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. *Pharmaceutics*. 2021 Jul 7;13(7):1040.

Jarzebska NT, Frei J, Lauchli S, French LE, Guenova E, Gouttefangeas C, Kündig TM, Mellett M, Pascolo S. Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring. *Viruses*. 2021 Jun 25;13(7):1232.

Pascolo S. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype. *Viruses*. 2021 Feb 9;13(2):270

Tusup M, French LE, De Matos M, Gatfield D, Kundig T, Pascolo S. Design of in vitro Transcribed mRNA Vectors for Research and Therapy. *Chimia (Aarau)*. 2019 May 29;73(6):391-394.



Prof. Peter Schmid-Grendelmeier, MD

In Cooperation with
Marie-Charlotte Brügggen, Prof. MD & Meike Distler, MD

Group Members and Associates

Stefanie Bösch (Study nurse), Miriam Meier, MD, Tamara El Saadany, MD Danielle Fehr, MD PhD Christina Weber, MD Muriel Rentschler

MD Doctorate candidates (together with Danielle Fehr, Charlotte Brügggen and Carole Guillet): Patrick Frey, Noemi Leu, Davina Schretzmann, Thomas Schumacher, Selina Steiger

Main Fields of Research

Our research activities are focused on epidemiology, pathophysiology and treatment of allergic diseases, namely atopic dermatitis, with a special focus on pathophysiology and treatment and innovative methods in the area of allergic diseases, such as new methods of immunotherapy or the observation of the allergy burden by pollens by measuring antihistamines in wastewater.

After the retirement per July 31, 2024, the focus is directed on promotion on research and education in allergy and allergic skin disease in topical areas, facilitating research and exchange in mutual way among young clinicians and researchers between areas with limited resources in the tropics and Switzerland, considering also "One Health aspects" with veterinarian and environmental aspects in addition to medicine caring for humans.

Recently, in collaboration with the International Society for Atopic Dermatitis ISAD (www.isad.org) and the WHO we have also started to implement, evaluate and improve educational tools to promote knowledge and training in Atopic Dermatitis. We have also started the process to include possibly emollients and topical anti-inflammatory drugs into the Essential Medicine List EML of the WHO (<https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists>).

Finally digital tools and AI are moving into all areas of medicine. Thus establishing digital tools to counsel also allergy patients under the "Derma2go" umbrella as "Allergy2Go" and well defined activities in the social media to spread solid and relevant information among a wider community are also addressed.

Selected References

Nolting A, Hasler S, Probst-Mueller E, Schmid-Grendelmeier P, Lanz J, Guillet C. Hen's egg white allergy in adults leading to strong impairment of quality of life. *Sci Rep.* 2024 Nov 26;14(1):29401

Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Bärenfaller K, Schmid-Grendelmeier P. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. *Allergy.* 2024 Oct;79(10):2605-2624

Chabot A, Lang C, Kündig TM, Schmid-Grendelmeier P, Johansen P. Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy. *Int Arch Allergy Immunol.* 2023;184(10):985-993

Schmid-Grendelmeier P, Rapelanoro Rabenja F, Beshah AM, Ball MD, Dlova N, Faye O, Flohr C, Hsu C, Mavura D, Manuel RC, Ramarozatovo LS, Sendrasoa F, Wollenberg A, Ruiz Postigo JA, Taieb A. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in Sub-Saharan Africa? *J Eur Acad Dermatol Venereol.* 2023 Apr 5. doi: 10.1111/jdv.19096.

7 Quality Management

The highly motivated quality management core team, along with the ongoing support from the clinic management and the management team, has contributed to the successful implementation of our ambitious goals.

This effort has resulted in four successful re-certifications (see below) and a new award from Selbsthilfe Zürich/Switzerland, namely the "Self-Help Friendly" designation. In May 2024, the Department of Dermatology at USZ renewed this award for the first time. Self-help friendly hospitals meet six quality criteria that are recognized throughout Switzerland, which are implemented through corresponding measures.

The implementation is carried out in collaboration with Selbsthilfe Zürich and self-help groups in the field of dermatology. The award is presented by Self-Help Switzerland. The award ceremony took place during the public information event on "Skin Cancer" on May 7, 2024. Also present at the event were the Cancer League Zurich and patient organizations such as "Melanoma" (Melanom – Selbsthilfe), "Cutaneous Lymphoma" (lymphome.ch) – Patient Network Switzerland, and Mastozytosis SELMAS – Mastozytose Schweiz.



QM-Team Department of Dermatology USZ (as per January 2025)

| | |
|---|--|
| Overall Responsibility, Head | Prof. Dr. Thomas Kündig |
| QM – Management, Overall Coordination | Catherine Frey-Blanc |
| Dermatooncology/Skin Tumor Center | PD Dr. Joanna Mangana & PD Dr. Lara Maul-Duwendag (until November 2024: Dr. Lukas Krähenbühl) |
| QM – Clinical/Medical Aspects (incl. CIRS*) | Dr. Mirjam Nägeli |
| QM – Morbidity & Mortality-Conferences | Dr. Sara Micaletto (until Dec. 2024: Dr. David Muggli) |
| QM – Complaints Medical Aspects | Dr. Andrea Boesch |
| QM – Nursing | Dermatology USZ Campus: Heiko Müller Dermatology USZ Circle: Dina Zlatic |
| QM – Research | Prof. Pål Johansen, PhD |
| QM – Clinical Trials | Prof Dr. Julia-Tatjana Maul, Dr. Dr. Egle Ramelyte, Michelle Ackermann |
| Accreditation Laboratories ISO 15189:2013 | PD Dr. Philipp Bosshard |
| QM – Manual/Directory & Complaint Management | Catherine Frey-Blanc |



Keyfacts

Mortality und Morbidity Conferences

4 times a year: inpatient setting and open care units

CIRS (Critical Incidence Reporting)

Meetings all 6 weeks; evaluation of reporting and taking measures accordingly

Quality "Handbuch", based on DMS (data management system)

Continuing update of documents if needed or implementation of new SOP's

Push-Up-Reports

With all physicians, 6 times per year: focus on actual medical issues, e.g., data protection management, compliant management, new SOP's

Risk Management

RRe-Evaluation of defined main risks for the department subordinated and per unit 2x per year

QM-Reports with complete Management-Team

5 times per year

QM-Reports with Key QM-Team

All 2 months

Patient-Survey

Yearly; 2023: 320 outpatients; evaluation and measures for management of issues ongoing

Survey with Referring Physicians

Yearly at ZDFT (s. page): inpatient setting and dermatooncology; evaluation and taking measures

Management QM-Report/Evaluation

1x a year

Successfull Re-Certification 2023 (September) und 2024 (September)*:



ISO TÜV SÜD* ISO 9001:2015



OnkoZert / DKG (Deutsche Krebsgesellschaft)*



SAKK re-qualification as a phase 1 clinical research study center.



GA2LEN:

«Network Center of Excellence»

- Allergy: GA²LEN ANACARE
- Atopic Dermatitis GA²LEN ADCARE
- Asthma: GA²LEN ADCARE



Prüflaboratorium SMTS
0047 akkreditiert nach
ISO 15189:2012

Medical education is essential for ensuring a high level of professionalism among physicians and healthcare professionals. Our continue commitment to education is reflected in the following areas:

1. Student education at the University of Zurich's Medical Faculty and ETH Zurich.
2. Specialist training for resident physicians in dermatology and venereology, allergology, clinical immunology, and phlebology.
3. Ongoing medical education for private practitioners, primarily dermatologists and allergologists, as well as general practitioners and, to a lesser extent, other healthcare professionals.
4. Our commitment to and participation in international educational programs for medical professionals.

Student education

Senior physicians in our department offer an introductory dermatology and allergology course for third-year medical students, as well as an annual core dermatology course (part of an eight-day block) for fourth-year medical students. The sixth year of the medical curriculum at the University of Zurich includes a case-based thematic lecture series and a practical training course in dermatology and allergology. Since 2017, ETH Zurich has offered a Bachelor's degree in medicine, and as part of this program, several members of our department are involved in teaching introductory modules in dermatology, immunology, and allergology.

Following Dr. Maya Wolfensperger's move to the Institute for Dermatology and Venereology at Stadtspital Zurich, Europaallee, a much closer collaboration between our department and Stadtspital Zurich has been established, benefiting both institutions, as well as trainees and residents. This collaboration extends to teaching and training students and residents at both levels.

These ex-cathedra and bedside teaching activities have been complemented by web-based learning modules, including an online platform (Dermatology Online with Interactive Technology; DOIT) developed by our department under the direction of former chairman Prof. Gunter Burg, in close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena, Stadtspital Zurich,



“Modern education tools based on interaction allow us to enhance the transfer of knowledge and skills with higher efficacy and -last but not least – also more fun.”

Schmid-Grendelmeier Peter, Prof. Dr. med.

and the European Dermatology Forum; see also www.cyberderm.net). The platform has been further improved under the direction of Prof. Peter Itin, with support from the European Dermatology Forum, and is currently available in seven languages, with two more languages planned. It is updated annually and is highly appreciated by students at several universities due to its interactive nature. In 2009, the DOIT platform was awarded the Medida Prize (worth EUR 50,000) as the best internet-based teaching platform.

Since the COVID-19 pandemic, all lectures have been offered in a hybrid format. The live lectures held in the auditorium are recorded and made available as podcasts for students online. Students can follow the lessons either live (with the option to submit questions via chat) or, increasingly, as recorded podcasts.

A great deal of effort and time was invested in creating a joint Master's program, which includes the Department of Dermatology at Cantonal Hospital Lucerne (Prof. Christoph Brand) and Cantonal Hospital St. Gallen (Prof. Antonio Cozzio). The program started in 2020 and, under the guidance of the Dean of the Medical Study Office, a common, revised, and updated lecture program was established, based on modern educational methods and enhanced interaction. While some lectures are still given in the classical



format as plenary sessions and shared digitally across all three sites, part of the teaching material is presented through interactive case discussions and problem-solving approaches. This joint Master's program has been fully implemented but was terminated due to differing expectations in the curriculum between the University of Zurich and St. Gallen.

In addition to a variety of lectures and courses, a new course on "Translational Allergy" was launched with great success in 2017 and is now being organized for the 6th time. Held at the Medical Campus Davos, this course has become very popular and is rated as 'very useful' by participants. In 2023 and 2024, we again received excellent feedback from the students.

The coming years will present significant challenges for teaching and training. The number of students is expected to nearly double, and the so-called 'Wahl-Studien Jahr' (Practical Year during the MMed part of the program) will

be moved from the beginning of the 5th year (fall semester) to the middle of the 5th year (spring semester). Considering the increasing shortage of physicians in Switzerland and the importance of practical experience in the curriculum, this shift makes perfect sense. However, it will require substantial additional resources in terms of staff, space, and time from the departments.

Resident physicians

Resident candidates must meet the following requirements:

- Two years of medical training at a Swiss hospital: either two years in internal medicine or one year in internal medicine and one year in surgery.
- A finalized or nearly finalized MD thesis.

Our staff offers opportunities for scientific work alongside an MD thesis or a master's thesis.



Four training positions are also available, which contribute to board certification in allergology, clinical immunology, and angiology.

During their residency in our department, residents benefit from the most comprehensive program in Switzerland, including a rotation plan of 20 units and specialist clinics covering all dermatology and allergology subspecialties, such as dermato-oncology, autoimmune skin diseases, trichology (hair diseases), dermatosurgery, dermatopathology, physical skin therapy (radiotherapy, UV therapy, laser therapy), phlebology, and more.

As a new initiative, a pilot course on “Patient-Centered Communication and Shared Decision Making” was offered by the Education team of CK-CARE in Davos. Based on case scenarios, residents were able to learn how to interact with patients in difficult situations during a 1.5-day course—skills that are highly valuable in daily practice. The participants highly appreciated this course and rated it with excellent feedback, leading to plans for further courses of this kind.

Dermoscopedia

With almost 2.5 million page visits in 3 years, Dermoscopedia is the online reference work for skin cancer early diagnosis worldwide. The platform uses the same technology as Wikipedia and is constantly updated and supplemented by 277 authors and 44 editors. The key to success here is that the content can be adapted very quickly and without much computer knowledge by any car. It was conceived and developed by Prof. Ralph. Braun.



https://academy.dermoscopedia.org/Main_Page



Dermatosurgery

In addition to experienced and enthusiastic teachers, a solid clinical teaching program also requires a sufficient case load, which we have consistently been able to provide in recent years. Our residents have the opportunity to learn skin cancer surgery from the ground up, ensuring they are proficient when they move on to other hospitals or private practice. Prof. Jürg Hafner: “In recent years, we have also seen an increasing number of fellows and visiting physicians from Europe and overseas who come to learn dermatosurgery with us. The joint ESMS* Fellowship Program, established in collaboration with Stadtspital Zürich Europaallee (Chair PD. Dr. Severin Lächli), has been particularly rewarding.”

* European Society for Mohs Surgery



“We combine cutting-edge scientific expertise with compassionate patient care. Our commitment to evidence-based medicine and innovation ensures the highest standard of treatment and healing.”

Boesch Andrea, Dr. med.

Guest Speakers 2023 and 2024

| Speaker | Institution | Topic |
|--|--|---|
| Andor Michael, Dr. med. | Aerztegesellschaft des Kantons Zürich, Zürich (CH) | ZDFT 2023, 223. Juni: AGZ: Was macht die AGZ für ihre Mitglieder |
| Anzengruber Florian, PD Dr. med. | Dermatologie, Bündner Kantonsspital, Chur (CH) | ZDFT 2023: What's New: Hidradenitis suppurativa |
| Arnold Denis, Dr. med. | IDV Stadtpital Zürich (CH) | ZDFT 2024, 20.6.: Praktische Fälle: Fall 2: Aus dem IDV Stadtpital Zürich Europaallee |
| Ashfaq Marghoob, Prof. Dr. med. | Dermatology Service, Memorial Sloan Kettering Cancer Center, New York (USA) | 15. Internat. Dermoscopy Course: 2 Step algorithm and benign nevus patterns; Melanoma specific structures; Nevi in context |
| Balermipas Panagiotis, Prof. Dr. med. | Klinik für Radio-Onkologie, USZ (CH) | ZDFT 2024, 20.6.: Tandem: Merkelzellkarzinom - Bestrahlung und Operieren |
| Ballmer-Weber Barbara, Prof. Dr. med. | Klinik für Dermatologie und Allergologie, Kantonsspital St. Gallen (CH) | ZDFT 2023, 23. Juni: Chair Block Allergologie Update |
| Berking Carola, Prof. Dr. med. | Hautklinik, Uniklinikum Erlangen (D) | Lecture, 20. Juli 2023: New Horizon – Zukunftsweisende Errungenschaften in Melanom-Therapie: 1 Jahr neoadjuvante Therapie im Stadium IIB/IIC |
| Berking Carola, Prof. Dr. med. | Hautklinik, Uniklinikum Erlangen (D) | Interdisz. Dermoonkologie-Fortbildung mit CCCZ, 23.5.2024: Keynote Lecture: Meine persönlichen Highlights bei der Behandlung von Hautkrebskrankungen im Jahr 2024 |
| Bieber Thomas, Prof. Dr. med. | CK-Care, Bonn (D) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Neurodermitis kurz und bündig (Neurodermitis in a nutshell) |
| Bonderer Luc, Dr. iur. | Rechtendienst, USZ, Zürich (CH) | ZDFT 2024, 20.6.: Antworten auf juristische Fragen aus dem Praxisalltag |
| Borelli Siegfried, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | 1. Grosse Semesterfortbildung, 11.4.2024: Balanitis – Differentialdiagnose und Management |
| Borrelli Siegfried, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | Dermatologie für Grundversorger, 3.10.2024: Hautcheck – wichtige Änderungen für die Patienten |
| Borrelli Siegfried, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | 2. Grosse Semesterfortbildung, 28.11.2024: Nagelveränderungen konservativ vs chirurgische Massnahmen |
| Dahmen Robert, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | ZDFT 2024, 21.6.: Update Kurs 6 – Dermatochirurgie, Live Streaming, Moderation ? |
| Detmar Markus, Prof. Dr. sc. nat. | Institute of Pharmaceutical Swiss Federal Institute of Technology, ETH Zürich (CH) | ZDFT 2024, 20.6.: Eine wichtige Rolle der kutanen Lymphgefässe für die Homöostase, Entzündung und Alterung der Haut |
| Elsener Peter, Prof. Dr. med. | Dermatologische Praxis Uster und Stadtpital Schlieren (CH) | ZDFT 2024, 20.6.: Abklärung der Kontaktallergie: Testung mit Standardreihen versus Eigensubstanzen und neue relevante Allergene |

Guest Speakers 2023 and 2024

| Speaker | Institution | Topic |
|----------------------------------|--|--|
| Felcht Moritz, Prof. Dr. med. | St. Josepshkrankenhaus, Fachklinik für Dermatochirurgie Heidelberg (D) | Dermatchirurgie Workshop, 6. Juli 2023, Das vielseitige App «FlapFinder» |
| Gaide Oliver, PD Dr. med. | Service de Dermatologie, CHUV, Lausanne (CH) | 15. Internat. Dermatoscopy Course: Squamous cell carcinoma and actinic keratosis |
| Garvey Lene, Prof. Dr. med. | Herlev und Gentofte Spital, Hellerup (DK) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Perioperative anaphylaxis |
| Gharbo Rahid, Dr. med. | Hochsgebirgsklinik Davos (CH) | ZDFT 2023, 23. Juni: Psychosomatik bei Dermatosen - wie vorgehen? |
| Grünherz Lisa, Dr. med. | Plastische Chirurgie & Hand- chirurgie, USZ (CH) | ZDFT 2023, 22. Juni: Tandem – Interpolierte Lap- penplastiken bei ausgedehnten Defekten an der Nase |
| Guggenheim Merlin, PD Dr. med. | Swissparc Zürich (CH) | ZDFT 2023, 22. Juni: Tandem – Plastische Chirurgie "Hauttumore" |
| Haase Ingo, Prof. Dr. med. | Private Dermatologische Praxis, Opfikon (CH) | ZDFT 2023, 22. Juni: Praktische Fälle Entzündliche Dermatosen |
| Hampel Benno, Dr. med. | Epidemiology, Biostatistics & Prevention Institute (EBPI), ETH (CH) | ZDFT 2024, 20.6.: Tandem: Dermatologie/ Infektiologie: STI |
| Hanneke Oude Elberink, Dr. med. | UMCG Research, Universität Groningen (NL) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Insect Stings |
| Hartmann Daniela, Prof. Dr. med. | LMU, München (D) | Dermatoskopie-Kurs, 1.2.2024: Zukunft der mikro- graphischen Chirurgie – Innovationen und KI/AI |
| Hess Schmid Monika, MD | Private Dermatologische Praxis, Zürich (CH) | ZDFT 2023, 22. Juni: Dermatochirurgie, Live Streaming |
| Hohl Daniel, Prof. Dr. med. | Service de Dermatologie & Allerologie, CHUV, Lausanne (CH) | ZDFT 2023, 22. Juni: SGD: was macht die SGD aktuell |
| Höller Christoph, Prof. Dr. med. | Ambulanz Melanomtherapie, AKH, Wien (A) | Lecture 20. Juli 2023: New Horizon – Zukunftsweisende Errungenschaften in Melanom-Therapie: Die Zukunft der individualisierten Neoantigen-Therapie |
| Huber Stephanie, Dr. med. | Dermatologie, Felix Platter Spital, Universitätsspital Basel (CH) | ZDFT 2023: What's New: Haare |
| Hunger Kaspar, Prof. Dr. med. | Department of Dermatology, Inselspital Berne (CH) | 15. Internat. Dermatoscopy Course: Benign non melanocytic lesions; Quiz cases |
| Jappe Uta, Prof. Dr. med. | Forschungszentrum Borstel (D) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Fine Food Allergies |

Guest Speakers 2023 and 2024

| Speaker | Institution | Topic |
|---------------------------------|--|--|
| Karbach Michael, Dr. med. | Klinik für Plastische und Handchirurgie, Universitätsspital Zürich | ZDFT 2024, 20.6.: Tandem: Intensivmedizin, TEN |
| Kempf Werner, Prof. Dr. med. | Histologische Diagnostik Zürich & Dermatologische Klinik, USZ (CH) | ZDFT 2023/2024: What's New in Dermatopathology; Praktische Fälle Dermatopathologie |
| Kempf Werner, Prof. Dr. med. | Kempf und Pfaltz Diagnostik AG, Zürich (CH) | ZDFT 2024, 21.6.: 3 Fälle aus der Histopathologie; Clinicopathologische Korrelation |
| Krasovec Rahmann Marguerite, MD | Private Dermatologische Praxis, Schlieren (CH) | Entzündliche Dermatosen: Klinische Fälle aus der Praxis (ZDFT 2023 und 2024) |
| Kuonen François, PD Dr. med. | Service de Dermatologie, CHUV, Lausanne (CH) | Dermatochirurgie-Kurs, 19.1.2023: Deep breathing reduces anxiety and pain |
| Kuonen François, PD Dr. med. | Service de Dermatologie, CHUV, Lausanne (CH) | Dermatochirurgie Workshop, 19. Januar 2023: Deep breathing reduces anxiety and pain; Molecular mechanisms of basal cell carcinoma progression and plasticity |
| Larkin James, Prof. Dr. med. | The Royal Marsden Hospital London (UK) | Lecture 25. Mai 2023: Dual immune checkpoint inhibition in kidney and melanoma |
| Läuchli Severin, PD Dr. med. | IDV Stadtspital Zürich (CH) | Dermatologie für Grundversorger, 3.10.2024: Akne - Neue Leitlinien |
| Läuchli Severin, PD Dr. med. | IDV Stadtspital Zürich (CH) | 2. Grosse Semesterfortbildung, 28.11.2024: Nagelveränderungen konservativ vs chirurgische Massnahmen |
| Lauener Roger, Prof. Dr. med. | CK-Care und Ostschweizer Kinderspital, St. Gallen (CH) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Prävention und Bildung in der Kindheit (Prevention and education in childhood) |
| Luchsinger Isabelle, Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | ZDFT 2023: Praktische Fälle pädiatrische Dermatologie |
| Luchsinger Isabelle, Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | ZDFT 2024, 21.6.: Pädiatrische Dermatologie, Fälle aus dem KISPI |
| Marghoob Ashfaq, Prof. | Memorial Sloan Ketterin Cancer Center, New York (USA) | Int. Dermatoscopy Course; Benign melanocytic lesions (including congenital nevi, Spitz) |
| Masenga John, Prof. Dr. med. | Regional Dermatology Training Center, Moshi, Tanzania | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Dermatological Quiz |
| Micheroli Raphael, Dr. med. | Klinik für Rheumatologie, USZ (CH) | ZDFT 2023, 22. Juni: Tandem - Psoriasis und Psoriasis-arthritis; Psoriasis-Patienteninformation, 4. Oktober 2023: TBD |
| Mutter Bettina | Mutter & Partner, Consulting AG, Bern (CH) | ZDFT 2023, 22. Juni: Standespolitik: Wer entscheidet was. Was haben wir erreicht. Was kommt als nächstes |

Guest Speakers 2023 and 2024

| Speaker | Institution | Topic |
|--|---|--|
| Mutter Bettina | Mutter & Partner, Consulting AG, Bern (CH) | ZDFT 2024, 20.6.: Antworten auf Fragen zur aktuellen Politik |
| Navarini Alexander, Prof. Dr. med. Dr. sc. nat. | Dermatologische Klinik, Universitätsspital Basel | What's New: Entzündliche Hautkrankheiten; Digitale Dermatologie (ZDFT 2019 resp. 2020) |
| Nienhold Ronny, PhD | Institut für Pathologie und Molekularpathologie, USZ (CH) | ZDFT 2023, 22. Juni: Tandem – Molekularpathologie bei melanozytären Hautläsionen |
| Oeggerli Martin, Dr. | Micronaut | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Into the Deep: Micronautic Visions of Allergens Teil 2 |
| Pinter Andreas, PD Dr. med. | Klinik für Dermatologie, Venerologie & Allergologie Universitätsklinikum Frankfurt (D) | ZDFT 2023, 23. Juni 2023: Behandlung der Hidradenitis suppurativa im Jahr 2023 |
| Plaza Tobias, Dr. med. | Hautzentrum Uster (CH) | ZDFT 2023, 22. Juni: Praxiszertifizierung: Warum und wie |
| Puhan Milo, Prof. Dr. med. PhD | Universität Zürich, Institut für Epidemiologie, Biostatistik und Prävention | ZDFT 2023, 22. Juni: Tandem: Long COVID / Impfung |
| Ring Johannes, Prof. Dr. med. | Technische Universität München und CK-Care, München (D) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: History of 30 and more years of Allergy |
| Scharl Michael, Prof. Dr. med. | Klinik für Gastroenterologie, USZ (CH) | 2. Grosse Semesterfortbildung, 30.11.2023: Darm-Mikrobiom in der Dermatologie |
| Schlagenhauff Bettina, Dr. med. | Dermacenter, Küssnacht am Rigi, (CH) | ZDFT 2023, 22. Juni: Aktueller Stand: Tardoc und ambulantes Pauschalensystem |
| Schlagenhauff Bettina, Dr. med. | Hautcenter, Küssnacht am Rigi, (CH) | ZDFT 2024, 20.6.: Aktuelles zur Tarifpolitik |
| Schwerzmann Martina, Dr. med. dent. | Klinik für Mund-, Kiefer und Gesichtschirurgie, USZ (CH) | ZDFT 2023, 22. Juni: Tandem – Mundschleimhaut |
| Schwieger Briel Agnes, Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | Therapie entzündlicher Krankheiten bei Kindern* |
| Schwieger Briel Agnes, Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | ZDFT 2024, 21.6.: Pädiatrische Dermatologie, Fälle aus dem KISPI |
| Silverberg Jonathan, Prof. Dr. med. | The George Washington University; School of Medicine and Health Services, Washington DC (USA) | Road-Show by AbbVie AG: 5.2.2024: Is good still good enough for you and your AD patients? Raising the standards of care in Atopic Dermatitis |
| Simon Dagmar, Prof. Dr. med. | Universitätsklinik für Dermatologie, Inselspital Bern (CH) | ZDFT 2023, 23. Juni 2023: Prurigo nodularis |

Guest Speakers 2023 and 2024

| Speaker | Institution | Topic |
|--|--|---|
| Soyka Michael, Prof. Dr. med. | Klinik für ORL, Universitätsspital Zürich (CH) | ZDFT 2024, 20.6.: Tandem: Dematochirurgie |
| Staub-Buset Caroline, Dr. med. | Immunologie-Zentrum Zürich (CH) | 1. Grosse Semesterfortbildung, 11.4.2024: Phlebologie – ein Update |
| Theiler-Peng Martin, Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | ZDFT 2023: Praktische Fälle pädiatrische Dermatologie & Whats New in Pädiatrischer Dermatologie und "Diagnostik und Therapie der Tinea capitis" |
| Thomas Luc, Prof. Dr. med. | Centre Hospitalier Universitaire de Lyon (F) | 15. International Dermatoscopy Cours: Acral lesions; Nail Dermatoscopy |
| Traidl-Hoffmann Claudia, Prof. Dr. med. | Universitätsklinikum Augsburg und CK-Care (D) | Abschiedssymposium Prof. Schmid-Grendelmeier, 29.2.2024: Umwelt und Bedrohungen (Environment and threats) |
| Trüeb Ralph, Prof. Dr. med. | Dermatologische Praxis und Haarcenter Wallisellen (CH) | ZDFT 2024: 20.6.: Praktische Fälle: Fall 1, Haarcenter Wallisellen: Trichologie |
| Weibel Lisa, PD Dr. med. | Dermatologie, Universitäres Kinderspital Zürich (CH) | Praktische Fälle pädiatrische Dermatologie & Whats New in Pädiatrischer Dermatologie (je an ZDFT 2023 und 2024) |
| Wilhelm Stolz, Dr. med. | Department of Dermatology, Munich Clinic Thalkirchner-Str., München (D) | 15. International Dermatoscopy Cours: Quiz cases; Lesions of the face |
| Wolfensperger Maya, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | 1. Grosse Semesterfortbildung "Brücken zwischen USZ und IDV Stadtpital Zürich Europaallee": News und Anwendung der Therapien bei autoimmunbullösen Dermatosen |
| Wolfensperger Maya, Dr. med. | IDV Stadtpital Zürich Europaallee (CH) | Dermatologie für Grundversorger, 3.10.2024: Aesthetik im Stadtpital Zürich |
| Zimmerli Lukas, PD Dr. med. | EMBA, Leiter Department Medizin/Chefarzt Medizinische Klinik, Kantonsspital (CH) | 2. Grosse Semesterfortbildung, 28.11.2024: Medizinische Check-up – was ist sinnvoll? |
| Zink Alexander, PD Dr. med. | Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München (D) | ZDFT 2023, 23. Juni 2023: Artificial Intelligence in der Dermatologie |

Guest Speakers (ZDFT)

Aktuelles zum Tarif

B. Schlagenhauff

ZDFT
Zürcher Dermatologische
Fortbildungstage

SSDV
dermo.natur
SGDV

20.06.2024

Standespolitisches / Aus der Praxis

Aktueller Stand der ambulanten Tariffreivision:
TARDOC und ambulantes Pauschalensystem

Bettina Schlagenhauff, Tariffdelegierte der SGDV
Dermacenter AG, Küssnacht am Rigi

1/17 2/17 3/17 4/17 5/17 6/17 7/17 8/17 9/17 10/17 11/17

00:00:00 1.0x 00:18:24

Fälle aus der Praxis - Klinisch-pathologische Korrelation (2)

Werner Kempf

ZDFT
Zürcher Dermatologische
Fortbildungstage

ZDFT 2024

Fälle aus der Praxis - Klinisch-pathologische Korrelation

Werner Kempf

Kempf und Pfaltz
Histologische Diagnostik, Zürich

Dermatologische Klinik
UniversitätsSpital Zürich

kempf und pfaltz
histologische diagnostik

Dermatologische Klinik
Universität
Zürich

1/39 2/39 3/39 4/39 5/39 6/39 7/39 8/39 9/39 10/39

00:00:00 1.0x 00:13:42

Continuing Medical Education 2023 and 2024

| Subject/Title | Type of education | Date | Organisation |
|---|---|-------------------|--|
| Dermatochirurgie Workshop: Tipps & Tricks | Dermatology | January 19, 2023 | Prof. Dr. med. Jürg Hafner |
| 1. Grosse Semesterfortbildung: News in Therapien | Dermatology | March 30, 2023 | Dr. med. Maya Wolfensperger & Prof. Dr. med. Thomas Kündig |
| Interdisziplinäre Dermatoonkologie-Fortbildung: Neues zu Hautkrebs – Diagnose und Therapie | Dermatology, Oncology, Dermatopathology | May 11, 2023 | Prof. Dr. med. Reinhard Dummer & PD Dr. med. Joanna Mangana |
| International Dermacopy Course | Dermatology | June (online) | Prof. Dr. med. Ralph Braun |
| 13. Zürcher Dermatologische Fortbildungstage ZDFT, Jahresthema: Interdisziplinäre Schnittstellen in der Dermatologie, Teil I | Dermatology | June, 22–23, 2023 | Prof. Dr. med. Thomas Kündig & Prof. Dr. med. Reinhard Dummer |
| Dermatologie für Grundversorger: Therapie und Diagnostik; together with Institut für Hausarztmedizin UZS/UHZ & medix | General Practicionars | October 5, 2023 | Dr. med. Dr. sc. nat. Barbara Meier-Schiesser & Dr. med. Maya Wolfensperger |
| 2. Grosse Semesterfortbildung: Neues und Update zu Hautkrebs und Entzündliche Hautkrankheiten | Dermatology, Oncology | November 30, 2023 | Dr. med. Maya Wolfensperger & Prof. Dr. med. Thomas Kündig |
| Dermatochirurgie Workshop: Tipps & Tricks | Dermatology | February 1, 2024 | Prof. Dr. med. Jürg Hafner |
| Abschiedssymposium Prof. Dr. med. Peter Schmid-Grendelmeier | Allergology | February 29, 2024 | Prof. Dr. med. Charlotte Brüggem & Dr. med. Claudia Lang |
| 1. Grosse Semester-Fortbildung: Brücken zwischen Stadtpital Zürich und Dermatologische Klinik USZ | Dermatology | April 14, 2024 | Dr. med. Dr. sc. nat. Barbara Meier-Schiesser & Dr. med. Maya Wolfensperger |
| Interdisziplinäre Dermatologie-Fortbildung: Neues zu Hautkrebs - Diagnostik und Therapie | Dermatology, Oncology, Dermatopathology | May 23, 2024 | PD Dr. med. Joanna Mangana & Prof. Dr. med. Reinhard Dummer |
| 14. Zürcher Dermatologische Fortbildungstage: Jahresthema: Interdisziplinäre Schnittstellen in der Dermatologie, Teil II | Dermatology | June 20–22, 2024 | Prof. Dr. med. Thomas Kündig & Prof. Dr. med. Reinhard Dummer |
| Dermatologie für Grundversorger – Therapie und Diagnostik* | General Practicionars | October 3, 2024 | Prof. Dr. med. Thomas Kündig, PD Dr. med. Severin Lächli, Dr. med. Maya Wolfensperger & Dr. med. Christian Greis |
| 2. Grosse Semester-Fortbildung: Neues und Update zu Hautkrebs und Entzündlichen Hautkrankheiten | Dermatoloy, Oncology | November 28, 2024 | Dr. med. Dr. sc. nat. Barbara Meier-Schiesser & Dr. med. Maya Wolfensperger |

* in collaboration with Institute for Dermatology & Venerology, Stadtpital Zürich (CH)

9 Research collaborations – Foundations and associates

SKINTEGRITY.CH

SKINTEGRITY.CH

Chronic skin ulcers, inflammatory skin diseases, and skin cancer are very common pathologies. They are often associated with high morbidity, and some of these diseases may even cause mortality. The development of innovative diagnostic and therapeutic approaches for these disorders requires a thorough understanding of the underlying pathomechanisms and close collaboration between experts from different disciplines.

For almost a decade, the Swiss interdisciplinary research consortium SKINTEGRITY.CH has provided the framework for the development of such innovative diagnostics and therapeutics. Over 50 principal investigators of the consortium, including six from the USZ Department of Dermatology, work at the forefront of skin research. Their highly interdisciplinary projects have resulted in over 130 collaborative publications, covering basic biomedical research, (bio)engineering, and clinical dermatology, rheumatology and surgery.

The success of the consortium is also reflected by over 15 patents and ongoing clinical trials as well as a thriving Young Investigator Program. The latter includes around 60–70 MD and PhD students and postdocs from the teams at 15 universities and university hospitals that are partners in the consortium. The young investigators meet for technical workshops, guest lectures, panel discussions, etc. and build their network of interdisciplinary experts of the future generation.

In the past years, SKINTEGRITY.CH has initiated exchange between skin research hubs in Singapore (SRIS) and Boston (CBRC), and thereby extended their international network. They also established a collaboration with the Swiss magazine *Dermatologica Helvetica* for regular contributions. An update of the consortium's latest activities and achievements is available on the SKINTEGRITY.CH website (www.skintegrity.ch) or the LinkedIn channel ([linkedin.com/company/skintegrity-ch](https://www.linkedin.com/company/skintegrity-ch)).

The consortium at various Annual Meetings throughout the years:





Bruno Bloch Foundation
www.brunoblochstiftung.ch



Catherine Frey-Blanc took over the administrative management of the Bruno Bloch Foundation on 1.1.2023: "I would like to thank my predecessor Patrick Schaffter, who gave me the opportunity to continue and expand the beautiful and enriching task of management with pleasure. Our guiding principle is: "in the spirit of the founders" (widow of Prof. Bruno Bloch, in 1935). Our aim is not to accumulate wealth, but to MAKE A DIFFERENCE.

In collaboration with our team and our assistant, Stefanie Widmer, we focus on the most important activities to create visibility and offer concrete opportunities:

- Project Donations: We have already identified 9 projects, which we present on our homepage and via a video screen in the waiting areas.
- Donor events: We organized two inspiring information evenings in the Uniturm restaurant in 2023 and 2024, where we presented the projects – in 2024 in the form of a poster walk. These events offered interesting dialog with our donors and potential supporters.

Memorial Lectures Prof. Bruno Bloch



32th Memorial Lecture, February 27, 2023

Guest-Speaker:
Prof. Dr. med. Peter Schmid-Grendelmeier

Topic: «Eine Dermatologische Reise in die Tropen»

A highly fascinating kaleidoscope of dermatological conditions, as commonly seen in the tropics or after returning from travel.

Memorial Lectures Prof. Bruno Bloch



33th Memorial Lecture, February 26, 2024

Guest-Speaker:

Prof. Dr. med. Reinhard Dummer

Topic: «Hautkrebs – eine Volkskrankheit»

A highly engaging and dynamic presentation on the latest advances in the early detection and treatment of melanoma.

- Arranging contacts: We initiate and arrange contacts with foundations for the submission of funding applications by researchers at the Department of Dermatology USZ. So far, 3 projects have already been successful and around five more are pending.
- Long-term collaboration: An intensive exchange with the heads of external foundations, family offices and private banks is sought in order to build sustainable partnerships.
- Visibility through social media: We are working on building our presence on social media to make our projects and initiatives more visible.
- Concert for donators in 2025: In February we are planning again a concert with the fabulous soloists Sol Gabetta, Violoncello, and Kristian Bezuidenhout, Fortepiano.

Association for Research on Cancer of the Skin

www.skincancer.ch



Founded in 2004, the Association for Research on Cancer of the Skin (Verein für Hautkrebsforschung; VHKF) aims to coordinate and stimulate skin cancer research in Switzerland by supporting the research of rare and severe forms

of skin cancer (e.g. melanoma, cutaneous lymphoma, etc.). The board consists of Prof. R. Dummer (President), Prof. K. Hunger, Prof. R. Kaufmann (Frankfurt), Prof. M. Levesque, Prof. A. Navarini and C. Frey-Blanc (Treasurer). The current aim is to generate a substantial contribution for clinical and experimental skin cancer research in Zurich and other institutions in Switzerland. VHKF consists of more than 60 members and its number is continuously growing: in 2023/2024: 6 new members: Dr. Florentia Dimitriou, Dr. Christian Greis, PD Dr. Joanna Mangana, Dr. Mirjam Nägeli (for 2025: already 3 applicants).

The new members are contributing to bring in valuable new impetus, e.g. the VHKF has entered into a partnership with derma2go regarding digital skin checks.

The most important activities in 2023/2024 were:

- **Podcast Melanom, see 17. Chapter Public Relations**
- **Skin Cancer Research Award, donated by Pierre Fabre**
Many thanks at this point to Tanja Ruppen, Brand Manager Dermatology, Pierre Fabre Suisse SA. The Winners of the Award 2023/2024 (price giving at the Annual Assembly of SSDV, Swiss Society for Dermatology and Venereology) were:



2023

Dr. Annalisa Santari

Department of Dermatology USZ
(Group Prof. M. Levesque)

Project: Targeting neurotrophic receptors:
a new strategy for therapy resistant melanomas
(105th Annual Assembly SSDV, Lausanne)



2024

Dr. sc. nat. Peter Renz

Institute for Regenerative Medicine, University of Zurich
Project: Screening for novel autocrine TNF- α
inhibitors to prevent tumor invasion
(106th Annual Assembly SSDV, Lausanne)



“The first step for successful cancer therapy is a profound understanding of the cancer subtype. The clinical trial of today is the treatment of tomorrow.”

Dummer Reinhard, Prof. Dr. med.

Christine Kühne-Center for Allergy Research and Education (CK-CARE)
www.ck-care.ch

The Christine Kühne-Center for Allergy Research and Education (CK-CARE) is dedicated to researching allergic diseases, with a particular focus on atopic dermatitis. Founded in Davos in 2009, it has led to the creation of a network of research groups in Davos, Bonn, Munich, St. Gallen, and the UZH’s allergy unit (see www.ck-care.ch). Over the past decade, the foundation has become part of a larger initiative focusing on various allergic diseases, with the Medicine Campus Davos serving as its core (<https://medizincampus-davos.ch/en/>). New research buildings equipped with state-of-the-art technology and several professorships have been established. In 2019, a highly competitive professorship for translational allergy research was awarded to Professor Marie-Charlotte Brügggen from our Department. Since then, she has built a successful and dynamic research group focused on inflammatory skin diseases, their comorbidities, global relevance, and cutaneous drug reactions (see also www.bruggenlab.com).

Another new building with state-of-the-art research and educational facilities was recently opened on October 15, 2024. This building offers additional space and advanced equipment for three research groups and an expanding education team, both of which closely collaborate with the University Hospital of Zurich and our Department.

Among other activities, CK-CARE has built a cohort of more than 1,600 patients with atopic dermatitis since 2017 (Pro-RaD Study). These patients are followed for five years, with plans to extend this duration. In addition to extensive data collection, in-depth investigations such as immunological

signatures, sensitization patterns, and the skin and gut microbiomes are conducted. Furthermore, a wide range of educational activities is offered, including interactive courses for students and medical students, residents and medical professionals. These “flipped-classroom” courses include “Allergic Diseases in Daily Pediatric Practice” in collaboration with Kinderärzte Schweiz, annual courses for students from the universities of Zurich, Basel, and Munich on “Translational Allergy,” and a newly established course on “Patient-Centered Communication and Shared Decision Making” for residents in allergy or dermatology training programs. The “Allergy Online Campus” (AOC) offers a variety of short teaching videos for participants in these courses, with plans to expand it to a broader local and international audience.

Additionally, a patient counseling service by a specially trained nurse for individuals with atopic dermatitis has been established. On an individual basis, patients can consult an allied health expert for 20-50 minutes to discuss all aspects of skin care. This service is made possible through the generous support of CK-CARE (more details can be found at <https://www.usz.ch/fachbereich/dermatologie/angebot/neurodermitis/>). The next step involves establishing a training curriculum for “Allergy for Allied Health Workers,” which will include tools for allergy testing, management, and patient communication skills.



Medizincampus Davos: Inauguration of the new building RESEARCH II, October 24, 2024 / Foto: Clemens Güdel, Davos

Truus and Gerrit van Riemsdijk Foundation

Since many years the Department of Dermatology UZH receives a yearly generous support from the Truus and Gerrit van Riemsdijk Foundation. This precious support enables us to pursue our ambitious clinical research projects in severe inflammatory skin diseases.



10 Collaborations with other dermatology centers

Zuger Kantonsspital www.zgks.ch

In close collaboration with the Department of Dermatology at the University Hospital Zurich (USZ), Dr. Elisabeth Hohenstein Jaccard runs a highly sought-after two-day dermatology service at the Kantonsspital Zug, providing consultations for both referred outpatient and internal cases. Additionally, Prof. Peter Schmid-Grendelmeier, now serving as Senior Consultant, and Dr. Sara Micaletto both act as consultants at the Kantonsspital Zug for allergic diseases. The Allergy Outpatient Clinic is now available 1–2 days per week, addressing a growing demand for specialized allergy services in the region. Furthermore, regular training opportunities in dermatology and allergology for local residents and practitioners can now be established).

Hochgebirgsklinik Davos www.hochgebirgsklinik.ch

USZ collaborates closely with the Hochgebirgsklinik Davos and CK-CARE (www.ck-care.ch), both of which are members of the Medicine Campus in Davos. The Kühne Foundation played a key role in establishing the Medicine Campus Davos, which offers state-of-the-art research and educational facilities in various fields, including cardiovascular rehabilitation, dermatology, and allergy. A new research and education building opened on October 15, providing additional space and cutting-edge equipment for three research groups and a growing education team. Both are closely collaborating with the University Hospital Zurich and our department.

Special programs are available for patients with allergic and inflammatory skin diseases, as well as food intolerances (especially histamine intolerance). These programs combine high-level patient care with targeted educational initiatives and professional psychosomatic and nutritional support, offering a unique hospitalization experience in a specially designed setting with fully renovated private rooms. This service is led by PD Dr. M. Möhrenschrager, and until the end of July 2024, also by Prof. M.-C. Brügggen, MD, PhD, whose professorship, founded by CK-CARE, is shared between the Medicine Campus Davos, the Department of Dermatology at USZ, and UZH. As the head of the Allergy Unit at USZ, Prof. Brügggen continues her research collabo-

rations, benefiting from the excellent facilities and interaction with the Davos-based research groups, in addition to her own established research group in Schlieren (www.brugggenlab.com).

Prof. P. Schmid-Grendelmeier has been appointed as Senior Consultant for Dermatology and Allergology in a part-time role, stepping in for PD Dr. Möhrenschrager during his vacations. He supervises both admitted dermatology patients and the rapidly growing outpatient clinic. Additionally, he continues his activities at CK-CARE, leading the education team in collaboration with professional MME experts Doris Straub Picirillo and Dr. Miriam Uhlman, as well as Prof. Roger Lauener (Head of the Children's Hospital of St. Gallen) and Dr. Claudio Rhyner (Managing Director of CK-CARE).

Kantonsspital Frauenfeld/Thurgau www.hochgebirgsklinik.ch

Since 2011 a dermatological outpatient clinic at the Kantonsspital Frauenfeld (cantonal hospital) has been in operation in close collaboration with the USZ Department of Dermatology. The clinic is run by senior dermatologists from the Department of Dermatology. The team of physicians receives support from a dermatology resident from USZ who is sent to Frauenfeld for a six-month rotation. Dr. S. Nobbe serves as head of the clinic. Other senior dermatologists include Dr. A. Vonrüti (since 2018), Dr. A. Cicha (since 2020), Dr. V. Del Prete (since 2021) and Dr. L. Meier (since 2023).



Picture Team Dermatology Kantonsspital Frauenfeld 2024: from left to right Dr. M. Klinger, A. Schaub, K. Leutenegger, Dr. S. Nobbe, V. Todorovic, Dr. V. Del Prete, S. Varga, Dr. L. Meier, Dr. A. Vonrüti, J. Dobler (missing: Dr. A. Cicha)

11 Congresses/ scientific meetings

The Department of Dermatology at USZ organizes 3-4 large, partly interdisciplinary training courses annually, including one for primary care providers/GPs, the ZDFT (Zürcher Dermatologische Fortbildungstage) in June, as well as numerous smaller events for various specialist groups.

In addition, 2024 saw a special and even touching event: **The Welfare Symposium in honor of Prof. Peter Schmid-Grendelmeier**

Prof. Schmid-Grendelmeier led the Allergy Department and the Allergology Research Department for 21 years, following Prof. Brunello Wüthrich.



“I would like to thank our team, our colleagues in the other specialist disciplines and, above all, our patients.”

Hafner Jürg, Prof. Dr. med.


Symposium, February 29, 2024

The symposium afternoon was highly meaningful, impactful, almost touching making it difficult to find the right words to describe the experience.

Around 300 attendees enjoyed the excellent presentations from long-time friends and colleagues of Prof. Schmid-Grendelmeier.

Colleagues from Switzerland, Europe, and even Prof. John Masenga (Research Leader at the Regional Dermatology Training Center, Moshi/Tanzania), who shares a decades-long relationship and collaboration with Prof. Schmid-Grendelmeier in Tanzania, provided highly interesting insights into a whole kaleidoscope of topics.

For us, a comforting thought – several very promising projects with Prof. Schmid-Grendelmeier are already taking shape, even after his retirement at the end of July. We're looking forward to it very much.



A Anfang
S Science/Suerte
A Ash
N Nothing
T Tanzania/Teaching/Teledermatolog, TEAM
E Encounters/Not the End

Asante Danke Thank you



A Selection of our other mentioned regular training courses for primarily dermatologists:

Dermatoscopy Course 2023

June 5, 2023

Chair: Prof. Ralph Braun



The Dermatoscopy course in Zurich was a great success, with over 325 participants from Switzerland and across Europe.

It was the first course held in person after the COVID pandemic and was met with enthusiasm both in terms of content and organization.

Renowned speakers included Prof. L. Thomas from Lyon, Prof. A. Marghoob from New York, Prof. O. Gaide from Lausanne, and Prof. W. Stolz from Munich. Their lectures provided participants with valuable insights into the latest developments and standards in dermatoscopy. The course was a milestone in dermatological education and emphasized the importance of personal interaction and expertise in skin cancer diagnosis.

Interdisziplinäre Dermatoonkologie-Fortbildung «Neues zu Hautkrebs – Diagnostik und Therapie»

(in collaboration with Comprehensive Cancer Center Zurich)

May 23, 2024

Chairs: Prof. Dr. Reinhard Dummer &
PD Dr. Joanna Mangana



Keynote Lecture:

«Meine persönlichen Highlights bei der Behandlung von Hautkrebserkrankungen im Jahr 2024»

Prof. Dr. med. Carola Berking
Chefärztin, Uniklinikum Erlangen (D)

Grosse Semesterfortbildung – News in Therapien

For the 1st time together with the Institute
for Dermatology and Venereology,
Städtspital Zurich: «Brücken»

April 4, 2024

Chairs: Dr. Dr. Barbara Meier-Schiesser (Derma
USZ) & Dr. Maya Wolfensperger (IDV Städtspital
Zürich)



Fortbildung for General Practitioners in collaboration with Institute of “Hausarztmedizin”,
UHZ and University of Zurich & mediX Zürich:
«Therapien und Diagnostik für Grundversorger»

October, 2024

Chairs: Dr. Christian Greis (Derma USZ) & Dr. Maya Wolfensperger (IDV, Städtspital Zurich)

For the 9th time we organized the symposium on request of our partners*”; it is the only training on Dermato-
logy especially for General Practitioners in the German part of Switzerland in this targeted format.

Dermatosurgery Workshop “TIPPS and TRICKS” – Hand-on-Workshop

February 1, 2024

Chair: Prof. Jürg Hafner

Guest Speaker:

Prof. Daniela Hartmann MD, PhD, LMU Munich
«Zukunft der mikropgraphischen Chirurgie – KI/AI»



13th and 14th Zürcher Dermatologische Fortbildungstage

The Zürcher Dermatologische Fortbildungstage (ZDFT) were launched in 2011 and quickly proved to be highly successful, as reflected by the feedback and number of participants – primarily practicing dermatologists. Over 350 dermatologists attended, confirming the event's establishment as one of the most important dermatology congresses in the German-speaking region of Switzerland.

The three day intensive continuing medical education event offers a mix of plenary lectures, hands-on workshops at the Department of Dermatology, and a half-day session on "What's New." Each year, the congress focuses on a specific theme. The "Jahresthema" for both 2023 and 2024 was "Interdisciplinary Interfaces in Dermatology". Due to the wide range of collaborations with other clinics/institutes at USZ and external centers, this theme continued in 2024.

Topics included: Dermatologic Surgery (with Plastic Surgery and ENT), Radiotherapy, TEN (with Intensive Care Medicine), Artifacts in Dermatology (with Psychiatry), Psoriasis/Psoriatic Arthritis (with Rheumatology), Oral Mucosa, Molecular Pathology in Skin Cancer (with the Institute of Pathology), and Long Covid (Epidemiology, Biostatistics and Prevention Institute, University of Zurich).

ZDFT 2024: **Jahresthema, Interdisziplinäre Schnittstellen in der Dermatologie, Teil II**, Tandem: Merkelzellkarzinom – Bestrahlung und Update, PD Dr. Joanna Mangana, mit Prof. Dr. Panagiotis Balermipas

The screenshot shows a video player interface. At the top, the title "Merkelzellkarzinom - Bestrahlung und Operieren" is displayed. On the left, a video feed shows a woman in a white lab coat speaking into a microphone, with the name "J. Mangana, P. Balermipas" below. The main content area on the right is a slide with the following text:

USZ Universitäts Spital Zürich

20. - 22. Juni 2024
ZDFT
Zürcher Dermatologische Fortbildungstage

Merkelzellkarzinom - Bestrahlung und Operieren

PD Dr. med. Joanna Mangana & Prof. Dr. med. B. Balermipas
Oberärztin meV, Stv. Leiterin des Hauttumorzentrums
Leitender Arzt, RadioOnkologie USZ

Interdisziplinäre Schnittstellen Dermatologie, Teil II
Zürcher Dermatologische Fortbildungstage 20-22.06.2024

DKG Krebsgesellschaft
Zertifiziertes Hautkrebszentrum

cancer network zürich

translational CANCER research
University Research Priority Project

Universität Zürich

At the bottom, a navigation bar shows a sequence of 11 slide thumbnails, with the first one (1/35) selected. A progress bar at the very bottom indicates a duration of 00:00:08 and a total time of 00:32:57.

12 Public relations

Overview of the various PR-Activities

- Events for Patients and the Public
Specific illnesses / "Tag Offene Tür"
- Patient Information Brochures and online-Information
- Media Relations: Various interviews and presence in TV editions
- Homepage
- Social media: posts primarily through the "Bruno Bloch Foundation"

Events for the public and patients

The Dermatological Clinic at USZ organizes 3 events each year for the general public, always in collaboration with relevant patient organizations. The consistently high level of interest demonstrates that these events are greatly appreciated by the public, patients, and their families. Typically, we have around 80–120 participants.

A selection:



“Whether in quality management, the Bruno Bloch Foundation, or other areas – how enriching to work with our team with its exceptional competence and professionalism.”

Frey-Blanc Catherine

USZ Universitäts Spital Zürich

**Allergien:
Was tun, wenn es juckt und brennt?**

Allergien sind zur Volkskrankheit geworden: Heuschnupfen, Nesselfieber, Ekzeme oder Allergien auf Lebensmittel oder Bienenstiche plagen mehr als ein Drittel der Schweizer Bevölkerung. Juckreiz ist dabei ein typisches Symptom.

Am Forum zeigen wir Ihnen auf, wie Sie Allergien erkennen und abklären können. Ist ein Gang zum Arzt jederzeit notwendig oder kann man auch selber etwas dagegen unternehmen? Was für Therapien stehen heutzutage zur Verfügung?

Der Eintritt ist frei. Wir freuen uns auf Sie.

Forum
Öffentliche Vorträge

Allergie FORUM

Was tun, wenn es juckt und brennt?

September 20, 2023

Live Streaming Facebook

Chair: Prof. Dr. Peter Schmid-Grendelmeier

Prof. Dr. Thomas Kündig

USZ Universitäts
Spital Zürich



Comprehensive Cancer Center Zürich (CCGZ)

Patientenakademie – Hautkrebs

Dienstag, 7. Mai 2024, 18.00 – 19.25 Uhr
Grosser Hörsaal OST, Universitätsspital Zürich

CCGZ – Gemeinsames onkologisches Exzellenzzentrum

USZ Universitäts
Spital Zürich



Universität
Zürich

Balgrist
Universitätsklinik



Kinderspital
ZÜRICH

Patientenakademie – Hautkrebs

May 7, 2024

Chair: Prof. Dr. Reinhard Dummer


Latest Information about the various forms of skin cancer; with presentations of patient organisations:

- Melanom-Organisation
- Krebsliga des Kantons Zürich
- lymhom.ch

Against 200 participants



USZ Universitäts
Spital Zürich



Dermatologische Klinik

Akne inversa – die versteckte Plage

Montag, 28. Oktober 2024, 18.30 – 19.45 Uhr
Online-Veranstaltung

Wir wissen weiter.

Patient Information Acne Inversa

October 28, 2024

Online

Chair: Prof. Dr. med. Julia-Tatjana Maul

Information on key facts about Hidradenitis Suppurativa (Acne Inversa) with an interdisciplinary focus. Speakers from the Departments of Dermatology, Dermatosen, and Internal Medicine

Therapy of HS


Hurley I - IHS¹ ≤ 3

Single or multiple nodules and/or abscesses, no fistulas, no scarring

- Topical therapy is usually sufficient
- Risk of recurrence of inflammation lower
- Suffering (usually) mild
- Excision may be considered




USZ Universitäts
Spital Zürich



Patient information brochures for specific illnesses

We create our own patient information brochures on the most common skin diseases, including skin cancer, atopic dermatitis, psoriasis, hand eczema, hidradenitis suppurativa, laser medicine, and more. Our goal is to provide balanced and objective information to our patients. These brochures are available free of charge on our website and are regularly requested by practicing dermatologists for distribution to their patients.

A selection:



All available brochures:



Podcast on Melanoma (issued by Verein für Hautkrebsforschung)

Thanks to a generous donation to the Association for Skin Cancer Research, the dermato-oncology team has successfully launched a podcast project focused on melanoma. This series includes 19 podcasts that address the most important questions about melanoma. The authors and speakers are all members of the dermato-oncology team at the Dermatology Clinic USZ, including doctors and nursing staff. The goal is to provide patients, their families, and interested individuals with the opportunity to listen to or access information at any time and from anywhere, serving as a supplement to the printed patient information brochures printed patient information brochures.

Melanom Podcasts

Expertinnen und Experten des Hauttumorzentrums des Universitätsspitals Zürich besprechen die wichtigsten Fragen zur Diagnose, Behandlung und Nachsorge des Melanoms.



 Verein für
Hautkrebsforschung

www.skincancer.ch

Podcast:
www.skincancer.ch



Podcast USZ 2023 – Digital Consultation by Dr. Ch. Greis

Neue Podcast-Episode:

«Der analoge und digitale Hautarzt»

Christian Greis, Dr. med.
Oberarzt, Dermatologische Klinik


Reinhören unter: usz.ch/direkt



Internet/intranet/social media/media relations

We update our website (www.dermatologie.usz.ch) almost daily to ensure that the content remains relevant and engaging. We provide various videos for patients to help them prepare for their medical consultations and treatments.

Our senior of physicians is available to the media (both general and specialized press) for targeted topics and interviews on a regular basis.



13 Museum of Wax Moulages



Welcoming speech by the dean of the medical faculty Prof. Frank Rühli in front of the Museum of Wax Moulages.

In 1993, 30 years ago, the Museum of Wax Moulages opened its doors at Haldenbachstrasse 14 in Zurich. Since then, many moulages from the extensive Zurich collection have been featured in various themed special exhibitions. The permanent exhibition has been enhanced, and a teaching collection has been established. The popular introductory dermatology course for medical students has become as well-established as the study module for medical collections, the CAS Medlaw course, and the numerous guided tours for nursing schools.

A small exhibition was dedicated to the 30-year history of exhibitions, which opened on the occasion of the "Lange Nacht der Museen" in September 2023. Various artefacts from past exhibitions were once again displayed in the showcases alongside the moulages. These included a prepared chipmunk to illustrate historical concepts regarding the cause of skin "Spots and Patches" a mousepad for the computer game "Catch the Sperm" from the exhibition "Feind im Blut", which compared the fight against syphilis

and gonorrhoea at the beginning of the 20th century with the HIV prevention campaign of 2002, and vaccination cassettes for cowpox vaccination that led to the eradication of smallpox. At this event, we set a record with 1,072 visitors. This record was surpassed a year later during the "Lange Nacht der Museen" 2024 with 1,207 visitors, when we presented wax moulages with glass eyes from the Zurich Eye Clinic in the exhibition "Auf das Auge geblickt", along with explanations on their historical use and the process of making glass eyes.

The Sinergia-SNF project "The Case of Syphilis", a collaboration between the Universities of Geneva and Strasbourg, in which the Museum of Wax Moulages participated as a partner, concluded in January 2024 with a conference in Geneva. As part of this project, Sabina Carraro restored several moulages depicting syphilis from the collections in Geneva and Zurich, which were then digitally recorded for 3D presentation. During various meetings and congresses throughout the project, conservation and restoration, as

well as different aspects of the historical and future impact of wax moulages on the perception and communication of the disease, were discussed.

A particular highlight was the international conference “Collections Coming Together – Wax Moulages, Human Remains, and Their Common Concerns,” organized in Zurich in June 2023 by Michael Geiges and Sabina Carraro with the support of the Bruno Bloch Foundation. Over two days, directors of institutes and collections with wax moulages and human remains, along with specialists in conservation and restoration, presented their collections and projects, discussing current issues related to the use and care of moulage or human remains collections. The meeting led to the founding of the International Working Group on Wax Moulages, which aims to promote cooperation between specialized collections to ensure professional conservation and restoration, address ethical aspects, improve funding opportunities, and support international research projects.



Conference „Collections coming together”: workshop at the UZH Irchel Campus

**medical
collection**
University of Zurich

COLLECTIONS COMING TOGETHER
Wax Moulages, Human Remains and their common concerns
June 8th and 9th 2023 / Museum of Wax Moulages

**museum of
wax moulages**
University of Zurich and
University Hospital Zurich



14 Promotions, grants honors and awards

Promotions

Titular Professorship

- Prof. Dr. Julia-Tatjana Maul
December 2024

Venia legendi

- PD Dr. Lara V. Maul-Duwendag
December 2024

Associate Physicians

- Prof. Dr. PhD Marie-Charlotte Brüggem

Appointment

- PD Dr. Severin Läuchli
Head of Dermatology, Institute for Dermatology and Venereology, Stadtspital Zürich
- Dr. Maya Wolfensperger
Associate Physicians Institute for Dermatology and Venereology, Stadtspital Zürich
- Dr. Lukas Krähenbühl
Head of Dermatology, Kantonsspital Aarau

Attending Physicians with Extended Responsibility

- Dr. Dr. Barbara Meier Schiesser
- PD Dr. Joanna Mangana

Attending Physicians

- Dr. Fabio Bertoldo
- Dr. Fabienne Fröhlich
- Dr. Carole Guillet
- Dr. Omar Hasan Ali
- Dr. Diana Lazarevic
- PD Dr. Lara Maul-Duwendag
- Dr. Johanna Ziegler

Attending Physicians i.V

- Dr. Fabienne Huber
- Dr. Ramtin Lichtenberger
- Dr. Marina Schneider
- Dr. Madleina Senn
- Dr. Johanna Ziegler

FMH board exam (specialist examinations)

FMH Board Exam, Dermatology and Venereology

2023:

- Dr. Jacqueline Bazerol
- Dr. Tobias Berger
- Dr. Corinne Eggenschwiler
- Dr. Fabienne Fröhlich
- Dr. Stefan Furrer
- Dr. Tobias Murer
- Dr. Patrick Schmithausen
- Dr. Marina Schneider
- Dr. Dario Simic
- Dr. David Spitzmüller

2024:

- Dr. Melike Ak
- Dr. Natalie Anasiewicz
- Dr. Jamila Hess
- Dr. Marie-Louise Hilbers
- Dr. Fabienne Huber
- Dr. Laura Lieger
- Dr. Madleina Senn
- Dr. Johanna Ziegler

FMH Board Exam, Allergology and Clinical Immunology

2023:

- Dr. Jacqueline Dülgeroglu
- Dr. Zara Liniger
- Dr. Larissa Meier
- Dr. Andrina Neff
- Dr. Ayla Yalamanoglu

2024:

- Dr. Sayaka Aeschbacher
- Dr. Marco Fischer
- Dr. Alexandra Cristina van der Staal

Honorarys, Awards and Grants (a selection)

Prof. Dr. med. PhD Marie-Charlotte Brügger

- Election as member of the Board of Foundation of SSAI Swiss Society of Allergology and Immunology* in June 2023

Prof. Reinhard Dummer

- Reward Certificate “Highly Recited Researcher 2023 in the field of Clinical Medicine” of Web of Science researcher profiles/Clarivate
- The 5th most cited cancer researcher in the German-speaking world on the Labor Journal’s Raking List.
www.laborjournal.de/rubric/ranking/R24_11/index2.php
www.laborjournal.de/rubric/ranking/R19_11/rang.php

Dr. med. Florentia Dimitriou

- Georg Friedrich Götz Preis 2022: «Immuntherapie bei fortgeschrittenen mukosalem Melanom»; Award Ceremony, May 25, 2023
- Siegenthaler Stiftung University of Zurich: Reserach Stipendium 2023 for Research Stay, Topic: Translational Research, MD Anderson Center, Houston, Texas

Dr. med. Christian Greis

- Grant Foundation MONSOL, December 2024: “Hybride Versorgungsforschung”, Research Grant

Prakt. Ärztin Danielle Fehr

- Posterprize Annual Meeting of SSAI*, in June 2024: “Best Poster Presentation for Epidemiological, Clinical or Immunological Research in Atopic Dermatitis”; Title: “No Grass Pollen Allergy in sub-Saharan Africa?” Analysis of Sensitization Patterns to Pollen in Swiss and sub-Saharan African Patients
- Posterprize Bruno Bloch Foundation “Dermato-allergology – Contact Eczema” at the Annual Meeting SSDV Swiss Society of Dermatology and Venerology in September 2024

Prof. Dr. med. Jürg Hafner

- Election as President of the International Society for Dermatologic Surgery, August 2023

PD Dr. med. Antonios Kolios

- Nomination as Principle Investigator of SKINTEGRITY.CH and National Principle Investigator of Swiss Registry “Hidradenitis suppurativa”, August 2023

PD Dr. med. Laurence Imhof

- Master Certificat ETH “Medizinphysik”, February 2023

- Election as President of the Swiss Laser Commission FMCH, 2023
- Election as President of Arbeitsgruppe Radiotherapie SSDV, August 2023

Dr. med. Lukas Krähenbühl

- L’Oréal Prize: Annual Meeting SSDV: La Roche Posay Award “Dermatologie aus ganzem Herzen 2024”, September 2024

Prof. Dr. med. Julia-Tatjana Maul

- Nomination as Principle Investigator of SKINTEGRITY.CH
- Nomination as Editor for BJD – British Journal of Dermatology (Associate Editor for Epidemiology and Inflammatory Skin diseases)
- Nomination as Section Editor for JEADV: Inflammatory skin diseases 1 (psoriasis, adverse reactions to drugs, auto-inflammatory diseases), October 2023
- Election as Chair of EADV Task Force Skin Diseases in Pregnancy (before: 3 years Co-Chair), EADV Amsterdam, October 2024

PD Dr. med. Lara V. Maul-Duwendag

- Nomination as Co-Chair of the EADV Task Force Tropical Dermatology, October 2024

Dr. med. Dr. sc. nat. Barbara Meier-Schiesser

- AbbVie Fellowship Programm 2024, September 2024

Dr. med. Dr. sc. med. Egle Ramelyte

- Grant Hedy Glor Meier-Stiftung; Projekt Uveales Melanom, 2024

Andrea Roggo

- National MD-PhD grant application. The committee decided to support our Pruritus project! Swiss Academy of Medical Sciences, September 2023
- Young Investigator Travel Award during WCCL (World Congress on Cutaneous Lymphoma), April 2024 “selected as outstanding by our Scientific Review Council”

Prof. Dr. med. Peter Schmid-Grendelmeier

- Nomination as Honorary Member of the Polish Society of Dermatology and Venereology, at the Rajka-Symposiums of International Society for Atopic Dermatitis ISAD, Gdansk/Poland, September 2023



15 Partners, sponsors, collaboration with industry, fundraising



Our ongoing efforts in medical education, public relations, marketing, and networking with private practitioners are made possible only through external funding. We collaborate with industry partners on postgraduate education, providing both private practitioners and the industry with a platform for communication and exchange. Additionally, external funding enables us to organize various public relations activities, including informational events for the public and patients, patient information brochures, and targeted support for selected patient organizations. Opportunities are also provided by our two charitable foundations: the Bruno Bloch Foundation and the Association for Skin Cancer Research (Verein für Hautkrebsforschung).

We would like to express our sincere gratitude for the support of our industrial partners. Their collaboration enhances the quality and scope of our postgraduate teaching offerings. The Department of Dermatology at USZ is thankful to the following sponsors and donors for their generous support.

With special acknowledgement to our partners

Schwerpunkt «Hautkrebs»

- Amgen Switzerland AG
- Bristol Myers Squibb SA
- Galderma SA
- KIOVA Kirin GmbH
- L'Oréal/Cosmétique Active (LaRoche Posay & Vichy Laboratoires)
- MSD Merck Sharpe & Dohme AG
- Novartis Pharma Schweiz AG
- Pierre Fabre Suisse SA
- Pierre Fabre Pharma SA
- Roche Pharma (Schweiz) AG
- sanofi-aventis (schweiz) AG/Regeneron

Schwerpunkt «Entzündliche Hautkrankheiten»

- AbbVie AG
- Almirall AG
- Bristol Myers Squibb SA
- Eli Lilly Suisse SA
- Janssen-Cilag AG
- LEO Pharmaceuticals Sarath Ltd.
- Novartis Pharma Schweiz AG
- Pfizer AG
- Sandoz Pharmaceuticals AG
- sanofi-aventis (schweiz) AG/Regeneron
- UCB Pharma AG

Other corporate sponsors

- A. Menarini AG
- ALK-Abello AG
- Allergopharma AG
- AstraZeneca AG
- Beiersdorf AG / Eucerin
- Gebro Pharma AG
- GlaxoSmithKline AG
- Immunocore GmbH
- JCE Hottinger AG
- Klewel GmbH
- Lasermed AG
- Louis Widmer AG
- MEDISYN AG
- Merck (Schweiz) AG
- Merz Pharma (Schweiz) AG
- Octapharma AG
- Orcos AG
- Qualiderm AG
- Permamed AG
- RECORDATI AG
- SUN Pharmaceuticals Germany GmbH
- Takeda AG
- Ultrasun AG
- Viatris Pharma AG

2023

Original Papers 2023

Aebischer V, Abu-Ghazaleh A, Metzler G, Riedl L, Garbe C, Flatz L, Eigentler T, Forchhammer S. Histopathologic abundance of pigmentation correlates with disease-specific survival in malignant melanoma but is not independent of current AJCC pT stage. *Pigment Cell Melanoma Res.* 2023 Nov;36(6):512-521. doi: 10.1111/pcmr.13114. Epub 2023 Jul 20. PMID: 37469279. **IF 4.3**

Adlany YK, Šošić L, Senti G, Lang CCV, Wüthrich B, Kündig TM, Johansen P. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up. *J Allergy Clin Immunol Glob.* 2023;2(1):43-50. **IF 14.2**

Alberto C, Lambeng N, Deffert C, Breville G, Gayet-Ageron A, Lalive P, Calmy A, Coste A, Papadimitriou-Olivgeris M, Braun D, Lienhard R, Bosshard PP, Fontao L, Toutous Trelu L. Multicentric evaluation of a specific intrathecal anti-*Treponema pallidum* IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case-control study. *Sex Transm Infect.* 2023. **IF 3.6**

Amaral T, Pop OT, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring SS, Joerger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch CM, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. *J Am Acad Dermatol* 2023;22;S0190-9622(23)02392-7. **IF 15.487**

Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). *Eur J Cancer.* 2023 Mar;182:155-162. doi:10.1016/j.ejca. 2022.12.021. Epub 2022 Dec 30. PMID: 36739215. **IF 8.4**

Ascierto PA, Dummer R, Gogas HJ, Arance A, Mandala M, Liskay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Robert C, Flaherty KT. Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023;10;41(29):4621-4631. **IF 50.73**

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. *JCO.* 2023 May;41(15):2724-2735. **IF 50.739**

Banik I, Ghosh A, Beebe E, Burja B, Bertoncelj M, Dooley C, Markkanen E, Dummer R, Busch-Nentwich E, Levesque M. P38 Mediates Tumor Suppression through Reduced Autophagy and Actin Cytoskeleton Changes in NRAS-Mutant Melanoma. *Cancers.* 2023. **IF 6.86**

Berner F, Flatz L. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis. *Immunol Rev.* 2023 Sep;318(1):37-50. doi: 10.1111/imr.13258. Epub 2023 Aug 7. PMID: 37548043. **IF 10.09**

Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, Dulgar O, Eroglu Z, Yeoh HL, Haydon A, Lodde GC, Livingstone E, Khattak A, Kähler K, Hausschild A, McArthur GA, Menzies AM, Long G, Wang W, Carlino MS. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. *J Immunother Cancer.* 2023;11(3):e00662. **IF 8.374**

Bousquet J, Melén E, Haahtela T, Koppelman GH, Togias A, Valenta R, Akdis CA, Czarlewski W, Rothenberg M, Valiulis A, Wickman M, Akdis M, Aguilar D, Bedbrook A, Bindeslev-Jensen C, Bosnic-Anticevich S, Boulet LP, Brightling CE, Brussino L, Burte E, Bustamante M, Canonica GW, Cecchi L, Celedon JC, Chaves Loureiro C, Costa E, Cruz AA, Erhola M, Gemicioglu B, Fokkens WJ, Garcia-Aymerich J, Guerra S, Heinrich J, Ivancevich JC, Keil T, Klimek L, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Lemonnier N, Lodrup Carlsen KC, Louis R, Makela M, Makris M, Maurer M, Momas I, Morais-Almeida M, Mullol J, Naclerio RN, Nadeau K, Nadif R, Niedozytko M, Okamoto Y, Ollert M, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pfaar O, Regateiro FS, Ring J, Rouadi PW, Samolinski B, Sastre J, Savouré M, Scichilone N, Shamji MH, Sheikh A, Siroux V, Sousa-Pinto B, Standl M, Sunyer J, Taborda-Barata L, Toppila-Salmi S, Torres MJ, Tsiligianni I, Valovirta E, Vandenplas O, Ventura MT, Weiss S, Yorgancioglu A, Zhang L, Abdul Latiff AH, Aberer W, Agache I, Al-Ahmad M, Alobid I, Ansotegui IJ, Arshad SH, Asayag E, Barbara C, Baharudin A, Battur L, Bennoor KS, Bergheda EC, Bergmann KC, Bernstein D, Bewick M, Blain H, Bonini M, Braidó F, Buhl R, Bumbacea RS, Bush A, Calderon M, Calvo-Gil M, Camargos P, Caraballo L, Cardona V, Carr W, Carreiro-Martins P, Casale T, Cepeda Sarabia AM, Chandrasekharan R, Charpin D, Chen YZ, Cherrez-Ojeda I, Chivato T, Chkhartishvili E, Christoff G, Chu DK, Cingi C, Correia de Sousa J, Corrigan C, Custovic A, D'Amato G, Del Giacco S, De Blay F, Devillier P, Didier A, do Ceu Teixeira M, Dókic D, Douagui H, Doulaptsi M, Durham S, Dykewicz M, Eiwegger T, El-Sayed ZA, Emuzyte R, Fiocchi A, Fyhrquist N, Gomez RM, Gotua M, Guzman MA, Hagemann J, Hamamah S, Halken S, Halpin DMG, Hofmann M, Hossny E, Hrubisko M, Irani C, Ispayeva Z, Jares E, Jartti T, Jassem E, Julge K, Just J, Jutel M, Kaidashev I, Kalayci O, Kalyoncu AF, Kardas P, Kirenga B, Krapner H, Kull I, Kulus M, La Grutta S, Lau S, Le Tuyet Thi L, Levin M, Lipworth B, Lourenço O, Mahboub B, Martinez-Infante E, Matricardi P, Miculinic N, Miguères N, Mihaltan F, Mohammad Y, Moniuszko M, Montefort S, Neffen H, Nekam K, Nunes E, Nyembue Tshipukane D, O'Hehir R, Ogulur I, Ohta K, Okubo K, Ouedraogo S, Olze H, Pali-Schöll I, Palomares O, Palosuo K, Panaitescu C, Panzner P, Park HS, Pitsios C, Plavec D, Popov TA, Puggioni F, Quirce S, Recto M, Repka-Ramirez MS, Robalo Cordeiro C, Roche N, Rodriguez-Gonzalez M, Romantowski J, Rosario Filho N, Rottem M, Sagara H, Serpa FS, Sayah Z, Scheire S, Schmid-Grendelmeier P, Sisul JC, Sole D, Soto-Martinez M, Sova M, Sperl A, Spranger O, Stelmach R, Suppli Ulrik C, Thomas M, To T, Todo-Bom A, Tomazic PV, Urrutia-Pereira M, Valentin-Rostan M, Van Ganse E, van Hage M, Vasankari T, Vichayanond P, Viegi G, Wallace D, Wang DY, Williams S, Worm M, Yiallourous P, Yusuf O, Zaitoun F, Zernotti M, Zidam M, Zuberbier J, Fonseca JA, Zuberbier T, Anto JM. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis. *Allergy.* 2023;78(5):1169-1203. **IF 12.4**

Buhl T, Fabri M, Stary G, Flatz L, Erpenbeck L, Eyerich S. [49. Jahrestagung der «Arbeitsgemeinschaft Dermatologische Forschung» (ADF) in Innsbruck]. *J Dtsch Dermatol Ges.* 2023 Jun;21(6):709-710. German. doi: 10.1111/ddg.15127_g. PMID: 37338827. **IF 3.9**

Chabot A, Lang CD, Kündig T, Schmid-Grendelmeier P, Johansen P. Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy. 2023. *INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOG.* 2023;184(10):985-993. **IF 2.8**

- Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez SS, Torres FM, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. *Am J Clin Dermatol*. 2023 May;24(3):453-467. doi: 10.1007/s40257-023-00775-7. Epub 2023 May 4. PMID: 37142875; PMCID: PMC10195722. **IF 7.4**
- Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuera LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases. *EBioMedicine*. 2023 Jul;93:104644. doi: 10.1016/j.ebiom.2023.104644. Epub 2023 Jun 7. PMID: 37295047; PMCID: PMC10363450. **IF 11.1**
- Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyingstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. 2023;41(3):528-540 *JCO*. **IF 50.739**
- Christensen MO, Barakji YA, Loft N, Khatib CM, Egeberg A, Thomsen SF, Silverberg JI, Flohr C, Maul JT, Schmid-Grendelmeier P, Halling AS, Vittrup I, Thyssen JP. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*. 2023;37(5):984-1003. **IF 9.2**
- Dramburg S, Hilger C, Santos AF, de Las Vecillas L, Aalberse RC, Acevedo N, Aglas L, Altmann F, Arruda KL, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilo MB, Blank S, Bosshard PP, Breiteneder H, Brough HA, Bublin M, Campbell D, Caraballo L, Caubet JC, Celi G, Chapman MD, Chruszcz M, Custovic A, Czolk R, Davies J, Douladiris N, Eberlein B, Ebisawa M, Ehlers A, Eigenmann P, Gadermaier G, Giovannini M, Gomez F, Grohman R, Guillet C, Hafner C, Hamilton RG, Hauser M, Hawranek T, Hoffmann HJ, Holzhauser T, Iizuka T, Jacques A, Jakob T, Janssen-Weets B, Jappe U, Jutel M, Kalic T, Kamath S, Kespohl S, Kleine-Tebbe J, Knol E, Knulst A, Konradsen JR, Korošec P, Kuehn A, Lack G, Le TM, Lopata A, Luengo O, Mäkelä M, Marra AM, Mills C, Morisset M, Muraro A, Nowak-Węgrzyn A, Nugraha R, Ollert M, Palosuo K, Pastorello EA, Patil SU, Platts-Mills T, Pomés A, Poncet P, Potapova E, Poulsen LK, Radauer C, Radulovic S, Raulf M, Rougé P, Sastre J, Sato S, Scala E, Schmid JM, Schmid-Grendelmeier P, Schrama D, Sénéchal H, Traidl-Hoffmann C, Valverde-Monge M, van Hage M, van Ree R, Verhoeckx K, Vieths S, Wickman M, Zakzuk J, Matricardi PM, Hoffmann-Sommergruber K. EAACI Molecular Allergy User's Guide 2.0. *Pediatr Allergy Immunol*. 2023;34 Suppl 28:e13854. **IF 5.464**
- Dummer R, Corrie P, Gutzmer R, Meniawy T, Del Vecchio M, Lebbé C, Guida M, Dutriaux C, Dreno B, Meyer N, Ferrucci P, Dalle S, Khattak M, Grob J, Briscoe K, Larkin J, Mansard S, Lesimple T, Guidoboni M, Sabatini S, Richtig E, Herbst R, Lobo M, Askelson M, Ascierto P, Maio M. First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401. *JCO* 2023. **IF 50.739**
- Dummer R, Gyorki D, Hyingstrom J, Ning M, Lawrence T, Ross M. Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial. *JAMA Oncology* 2023;10:e232789. **IF 33.012**
- Dummer R, Welti M, Ramelyte E. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. *Journal of Translational Medicine* 2023;5;21(1):529. **IF 8.448**
- Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Rieß O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. *J Cancer Res Clin Oncol*. 2023 Feb;149(2):833-840. doi: 10.1007/s00432-022-03939-w. Epub 2022 Feb 22. PMID: 35192052; PMCID: PMC9931777. **IF 4.3**
- Eichhoff O, Stoffel C, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng P, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan V, Wenzina J, Aloia A, Saltari A, Dzung A, Krauthammer M, Schreiber S, Hornemann T, Distel M, Snijder B, Dummer R, Levesque M. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma. 2023;83:1128-46. *Cancer Res*. **IF 13.312**
- Fieten KB, Maya-Manzano JM, Rückert B, Candeias J, Pusch G; CK-CARE Study Group; Buters J, Akdis CA, Traidl-Hoffmann C. Environmental exposure and sensitization patterns in a Swiss alpine pediatric cohort. *World Allergy Organ J*. 2023;16(12):100847. **IF 5.676**
- Freitag PC, Kauffuss M, Flüher L, Mietz J, Weiss F, Brücher D, Kolibius J, Hartmann KP, Smith SN, Münz C, Chijjoke O, Plückthun A. Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo. *Mol Ther Methods Clin Dev*. 2023;29:120-132. **IF 5.849**
- Fröhlich F, Micheroli R, Hebeisen M, Kissling S, Bürki K, Exer P, Bräm R, Niedermann K, Möller B, Nissen MJ, Kyburz D, Andor M, Distler O, Scherer A, Ciurea A. HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry. *Clin Rheumatol*. 2023;42(5):1267-1274. **IF 3.65**
- Fröhlich F, Ramelyte E, Turko P, Dzung A, Freiburger S, Mangana J, Levesque M, Dummer R. Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma. *Cancers*. 2023. **IF 6.575**
- Fromme J, Dummer R, Mauch C, Zigrino P. Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapy. *Wiley Experimental Dermatology*. 2023;32:707-709. **IF 9.349**
- Gassner M, Garcia JB, Tanadini-Lang S, Bertoldo F, Fröhlich F, Guckenberger M, Haueis S, Pelzer C, Reyes M, Schmithausen P, Simic D, Staeger R, Verardi F, Andratschke N, Adelmann A, Braun RP. Saliency-Enhanced Content-Based Image Retrieval for Diagnosis Support in Dermatology Consultation: Reader Study. *JMIR Dermatol*. 2023;10.2196/42129. **IF 7.4**
- Garbe C, Dummer R, Amaral T, Amaria R, Ascierto P, Burton E, Dreno B, Eggermont A, Hauschild A, Hoeller C, Kaufmann R, Lebbe C, Mandalá M, Menzies A, Moreno D, Michielin O, Nathan P, Patel S, Robert C, Schadendorf D, Lorigan P, Scolyer R, Tawbi H, van de Wiel B, Blank C, Long G. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. *Nature medicine* 2023. **IF 87.244**
- Gurri S, Siegenthaler B, Cangkrama M, Restivo G, Huber M, Saliba J, Dummer R, Blank V, Hohl D, Wener S. NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5. *EMBO Molecular Medicine*. 2023;9:e17761. **IF 13.783**

- Haake M, Haack B, Schäfer T, Harter P, Mattavelli G, Eiring P, Vashist N, Wedekink F, Genssler S, Fischer B, Dahlhoff J, Mokhtari F, Kuzkina A, Welters M, Benz T, Sorger L, Thiemann V, Almanzar G, Selle M, Thein K, Späth J, Gonzalez M, Reitinger C, Ipsen-Escobedo A, Wistuba-Hamprecht K, Eichler K, Filipiński K, Zeiner P, Beschoner R, Goedemans R, Hagen Gogolla F, Hackl H, Rooswinkel R, Thiem A, Romer Roche P, Joshi H, Pühringer D, Wöckel A, Diessner J, Rüdiger M, Leo E, Cheng P, Levesque M, Goebeler M, Sauer M, Nimmerjahn F, Schuberth-Wagner C, von Felten S, Mittelbronn M, Mehling M, Beilhack A, van der Burg S, Riedel A, Weide B, Dummer R, Wischhusen J. Tumor-derived GDF-15 acts as roadblock for LFA-1 dependent T cell recruitment and represents a new target for cancer immunotherapy. *Nature Communications*. 2023. **IF 6.6**
- Harkemanne E, Thomas L, Braun R, Baeck M, Tromme I. A new TADA-inspired decision algorithm for training primary care practitioners in dermoscopy. *J Eur Acad Dermatol Venereol*. 2023;37(11):e1295-e1297. **IF 9.2**
- Hassel J, Piperno-Neumann S, Rutkowski P, Baurain J, Schlaak M, Butler M, Sullivan R, Dummer R, Kirkwood J, Orloff M, Sacco J, Ochsenreither S, Joshua A, Gastaud L, Curti B, Piulats J, Salama A, Shoushtari A, Demidov L, Milhem M, Chmielowski B, Kim K, Carvajal R, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Paul N. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. *The new England journal of medicine*. 2023. **IF 176.082**
- Hoefsmit EP, Völlmy F, Rozeman EA, Reijers ILM, Versluis JM, Hoekman L, van Akkooi ACJ, Long GV, Schadendorf D, Dummer R, Altelaar M, Blank CU. Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. *Cancer Research Communications*. 2023;20;3(4):672-683. **IF 0.52**
- Hovaguimian F, Kouyos RD, Kusejko K, Schmidt AJ, Tarr PE, Bernasconi E, Braun DL, Calmy A, Notter J, Stoeckle M, Surial B, Christinet V, Darling KEA, Depmeier C, Lächli S, Reinacher M, Rasi M, Nicca D, Bruggmann P, Haerry D, Bize R, Low N, Vock F, El Amari EB, Böni J, Bosshard PP, Fehr JS, Hampel B. Incidence of sexually transmitted infections and association with behavioural factors: time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort. *HIV Medicine*. 2023. **IF 3.094**
- Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. Prognosis in stage II melanoma of the head and neck depends on the histological subtype. *J Dtsch Dermatol Ges*. 2023 Oct;21(10):1137-1146. doi: 10.1111/ddg.15164. Epub 2023 Jul 23. PMID: 37485634. **IF 3.9**
- Kallen EJJ, Revers A, Fernández-Rivas M, Asero R, Ballmer-Weber B, Barreales L, Belohlavkova S, de Blay F, Clausen M, Dubakiene R, Ebisawa M, Fernández-Perez C, Fritsche P, Fukutomi Y, Gislason D, Hoffmann-Sommergruber K, Jedrzejczak-Czechowicz M, Knulst AC, Kowalski ML, Kralimarkova T, Lidholm J, Metzler C, Mills ENC, Papadopoulos NG, Popov TA, Purohit A, Reig I, Seneviratne SL, Sinaniotis A, Takei M, Versteeg SA, Vassilopoulou AE, Vieths S, Welsing PMJ, Zwiderman AH, Le TM, Van Ree R. A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity. *Allergy* 2023;2497-2509. **IF 12.4**
- Kaulfuss M, Mietz J, Fabri A, Vom Berg J, Münz C, Chijioko O. The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells. *Sci Rep*. 2023;13(1):10555. **IF 4.6**
- Keller J, Danis J, Girousi E, Börold J, Szell M, French LE, Kündig TM, Mellett M. Cathelicidin peptide LL37 complexed to dsRNA induces the release of interleukin-36γ from human primary keratinocytes. 2023. *JOURNAL OF INVESTIGATIVE DERMATOLOGY*. **IF 6.5**
- Kentley J, Weber J, Liopyris K, Braun RP, Marghoob AA, Quigley EA, Nelson K, Prentice K, Duhaime E, Halpern AC, Rotemberg V. Agreement Between Experts and an Untrained Crowd for Identifying Dermoscopic Features Using a Gamified App: Reader Feasibility Study. *JMIR Med Inform*. 2023; 18:11:e38412. **IF 3.2**
- Konstantinos L, Navarrete-Dechent C, Marchetti MA, Rotemberg V, Apalla Z, Argenziano G, Blum A, Braun RP, Carrera C, Codella NCF, Combalia M, Dusza SW, Gutman DA, Helba B, Hofmann-Wellenhof R, Jaimes N, Kittler H, Kose K, Lallas A, Longo C, Malvey J, Menzies S, Nelson KC, Paoli J, Puig S, Rabinovitz HS, Rishpon A, Russo T, Scope A, Soyer HP, Stein JA, Stolz W, Sgouros D, Stratigos AJ, Swanson DL, Thomas L, Tschandl P, Zalaudek I, Weber J, Halpern AC, Marghoob AA. Expert agreement on the presence and spatial localization of melanocytic features in dermoscopy. *J Invest Dermatol*. 2023;7:S0022-202X(23)02577-0. **IF 7.59**
- Kortekaas Krohn I, Badloe FMS, Hermann N, Maintz L, De Vriese S, Ring J; CK-CARE Study Group; Bieber T, Gutermuth J. Immunoglobulin E autoantibodies in atopic dermatitis associate with Type-2 comorbidities and the atopic march. *Allergy*. 2023;78(12):3178-3192. **IF 12.4**
- Kraehenbuehl L, Schneider S, Pawlik L, Mangana J, Cheng P, Dummer R, Meier-Schiesser B. Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis. *Pharmaceuticals (Basel)*. 202;16(7):935. **IF 5.215**
- Krenger PS, Sobczak J, Paolucci M, Kündig TM, Johansen P, Vogel M, Bachmann MF. BALB/c and C3H mice are both suitable as peanut allergy models. 2023. *CLINICAL AND EXPERIMENTAL ALLERGY*. 2023;53(12):1310-1313. **IF 6.1**
- Kolm I, Konstantinova AM, Kutzner H, Barghorn A, Vanecek T, Mangana J, Kazakov DV. Cuticular Poroma: A Rare Poroma Variant Simulating a Malignant Neoplasm That Often Harbors YAP1::NUTM1 Fusions Similar to Their Conventional Counterparts. *Am J Dermatopathol*. 2023;1;45(8):544-548. **IF 1.1**
- Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, Gnani-decki R, Hodak E, Jonak C, Klemke C, Knobler R, Morris S, Nicolay J, Ortiz-Romero P, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Sca-risbrick J, Stadler R, Väkevö L, Vermeer M, Wehkamp U, Whittaker S, Willemze R, Trautinger F. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. *European Journal of Cancer*. 2023. **IF 10.002**
- Lear J, Robert C, Grob J, Dummer R, Guminski A, Squitieri N, Migden M. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. *Eur J Dermatol* 2023;1;33(3):280-286. **IF 2.805**
- Lehmann J, Caduff N, Krzywińska E, Stierli S, Salas-Bastos A, Loos B, Levesque MP, Dummer R, Stockmann C, Münz C, Diener J, Sommer L. Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. *Science Advances*. 2023;13;9(2):eadc8825. **IF 14.136**
- Lichtensteiger C, Koblichke M, Berner F, Jochum AK, Sinnberg T, Balciunaite B, Purde MT, Walter V, Abdou MT, Hofmeister K, Kohler P, Vernazza P, Albrich WC, Kahlert CR, Zoufaly A, Traugott MT, Kern L, Pietsch U, Kleger GR, Filipovic M, Kneilling M, Cozzio A, Pop O, Bomze D, Berghaler A, Hasan Ali O, Aberle J, Flatz L. Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. *J Autoimmun*. 2023 Oct 10;140:103118. doi: 10.1016/j.jaut.2023.103118. Epub ahead of print. PMID: 37826919. **IF 14.55**

- Longo C, Navarrete-Dechent C, Tschandl P, Apalla Z, Argenziano G, Braun RP, Bataille V, Cabo H, Hoffmann-Wellenhof R, Forsea AM, Garbe C, Guitera P, Raimond K, Marghoob AA, Malvey J, Del Mar-mol V, Moreno D, Nehal KS, Nagore E, Paoli J, Pellacani G, Peris K, Puig S, Soyer HP, Swetter S, Stratigos A, Stolz W, Thomas L, Tiodorovic D, Zalaudek I, Kittler H, Lallas A. Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna. *Dermatol Pract Concept*. 2023;13(3):e2023244. **IF 0.353**
- Loo L, Waller MA, Moreno CL, Cole AJ, Stella AO, Pop OT, Jochum AK, Ali OH, Denes CE, Hamoudi Z, Chung F, Aggarwal A, Low JKK, Patel K, Siddiquee R, Kang T, Mathivanan S, Mackay JP, Jochum W, Flatz L, Hesselton D, Turville S, Neely GG. Fibroblast-expressed LRRc15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs. *PLoS Biol*. 2023 Feb 9;21(2):e3001967. doi: 10.1371/journal.pbio.3001967. PMID: 36757924; PMCID:PMC9910744. **IF 9.8**
- Looman EL, Cheng PF, Lai-Kwon J, Morgan L, Wakkee M, Dummer R, Dimitriou F. Health-related quality of life in survivors of advanced melanoma treated with anti-PD1-based immune checkpoint inhibitors. *Cancer medicine*. 2023;29. **IF 4.711**
- Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy. *J Allergy Clin Immunol Pract*. 2023;11(6):1759-1770.e7. **IF 14.2**
- Magerl M, Sala-Cunill A, Weber-Chrysochoou C, Trainotti S, Mormile I, Spadaro G. Could it be hereditary angioedema?—Perspectives from different medical specialties. *Clin Transl Allergy*. 2023;13(9):e12297. **IF 5.657**
- Maintz L, Schmitz M, Herrmann N, Müller S, Havenith R, Brauer J, Rhyner C, Dreher A, Bersuch E, Fehr D, Hammel G, Reiger M, Luschkova D, Neumann A, Lang C, Renner E, Schmid-Grendelmeier P, Traidl-Hoffmann C, Akdis C, Lauener R, Brügggen M, Schmid M, Bieber T. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood. *Allergy*. 2023;22. **IF 14.710**
- Maintz L, Welchowski T, Herrmann N, Brauer J, Traidl-Hoffmann C, Havenith R, Müller S, Rhyner C, Dreher A, Schmid M, Bieber T; CK-CARE study group. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis. *Allergy*. 2023. **IF 12.4**
- Mallardo D, Woodford R, Menzies AM, Zimmer L, Williamson A, Rameylyte E, Dimitriou F, Wicky A, Wallace R, Mallardo M, Cortellini A, Budillon A, Atkinson V, Sandhu S, Olivier M, Dummer R, Lorigan P, Schadendorf D, Long GV, Simeone E, Ascierto PA. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. *J Transl Med*. 2023;21(1):753. **IF 8.448**
- Malvey J, Dreno B, Greis C, Barba E, et al. Smart e-Skin Cancer Care in Europe During and after the Covid-19 Pandemic: A Multidisciplinary Expert Consensus. *Dermatol Pract Concept*. 2023;13(3):e2023181. **IF 0.353**
- Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, Mengozzi A, Wang YJ, Kündig TM, Räber L, Ruschitzka F, Matter CM. Inflammation in acute myocardial infarction: the good, the bad and the ugly. 2023. *EUROPEAN HEART JOURNAL*. **IF 39.3**
- Maul JT, Fröhlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. *Dermatol*. 2023;188(4):533-541. **IF 10.3**
- Maul LV, Jahn AS, Pamplona GSP, Streit M, Gantenbein L, Müller S, Nielsen ML, Greis C, Navarini AA, Maul JT. Acceptance of Telemedicine Compared to In-Person Consultation From the Providers and Users Perspectives: Multicenter, Cross-Sectional Study in Dermatology. *JMIR Dermatol*. 2023;11;6:e45384. **IF 0.82**
- Moñino-Romero S, Kolkhir P, Szépfalusi Z, Schoepke N, Metz M, Asero R, Ferrer M, Gimenez-Arnau A, Grattan CEH, Jakob T, Konstantinou GN, Raap U, Staubach P, Zhang K, Bindslev-Jensen C, Daschner A, Kinaciyan T, Makris M, Marrouche N, Schmid-Grendelmeier P, Sussman G, Toubi E, Maurer M, Altrichter S. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria. *Clin Transl Allergy*. 2023;13(7):e12272. **IF 4.4**
- Nadeau SA, Vaughan TG, Beckmann C, Topolsky I, Chen C, Hodcroft E, Schär T, Nissen I, Santacrose N, Burcklen E, Ferreira P, Jablonski KP, Posada-Céspedes S, Capece V, Seidel S, Santamaria de Souza N, Martinez-Gomez JM, Cheng P, Bosshard PP, Levesque MP, Kufner V, Schmutz S, Zaheri M, Huber M, Trkola A, Cordey S, Laubscher F, Gonçalves AR, Aeby S, Pillonel T, Jacot D, Bertelli C, Greub G, Leuzinger K, Stange M, Mari A, Roloff T, Seth-Smith H, Hirsch HH, Egli A, Redondo M, Kobel O, Noppen C, du Plessis L, Beerenwinkel N, Neher RA, Beisel C, Stadler T. Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data. *Sci Transl Med*. 2023; 25;15(680):eabn7979. **IF 19.391**
- Nuñez NG, Berner F, Friebe E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Otten M, Greis C, Reinders P, Fleyder A., Reich K., Augustin M. (2023) Evaluation of a store-and-forward teledermatology application in Germany – patient and physician experiences. *J EADV*. **IF 9.228**
- Nuñez NG, Berner F, Friebe E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmaier S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med*. 2023 Feb 10;4(2):113-129.e7. doi: 10.1016/j.medj.2022.12.007. Epub 2023 Jan 23. PMID: 36693381. **IF 18**
- Pantelyushin S, Rhiner T, Jebbawi F, Sella F, Waldern N, Lam J, Chemnitzer A, Fricker A, Schoster A, Birkmann K, Widmer D, Canonica F, Fettelschoss-Gabriel A. Interleukin 5 dependent inflammatory eosinophil subtype involved in allergic insect bite hypersensitivity of horses. *Allergy* 2023; 22. Online ahead of print. **IF 14.71**
- Paolucci M, Homère V, Waeckerle-Men Y, Wullemmin N, Bieli D, Pengo N, Sonati T, Kündig TM, Johansen P. Strain matters in mouse models of peanut-allergic anaphylaxis: Systemic IgE-dependent and Ara h 2-dominant sensitization in C3H mice. 2023. *Clin Exp Allergy*. 2023;53(5):550-560. **IF 6.1**
- Paolucci M, Wullemmin N, Homère V, Bieli D, Köhli A, Ballmer-Weber B, Waeckerle-Men Y, Pengo N, Kündig TM, Sonati T, Johansen P. Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. 2023. *ALLERGY*. 2023;78(6):1605-1614. **IF 12.4**
- Paolucci M, Wullemmin N, Köhli A, Ballmer-Weber B, Severin Y, Waeckerle-Men Y, Arena C, Homère V, Bieli D, Kündig TM, Sonati T, Johansen P. Multivariate allergen-specific analysis and profiling of serum antibodies from patients with peanut allergy. *Clin Exp Allergy*. 2023;53(3):353-358. **IF: 5.401**
- Pawlik L, Morgenroth S, Dummer R. Recent Progress in the Diagnosis and Treatment of Melanoma and Other Skin Cancers. *Cancers (Basel)*. 2023;17;15(6):1824. **IF 6.575**

- Pham J, Joshua A, da Silva I, Dummer R, Goldinger S. Chemotherapy in Cutaneous Melanoma: Is There Still a Role? *Current Oncology Report* 2023. **IF 5.945**
- Pozzi L, Schläppi M, Livio F, Blatter S, Achermann Y, Wahl P. Joint fluid concentrations of amphotericin B after local application with calcium sulphate-report of 2 cases. *APMIS*. 2023;131(11):567-573. **IF 3.428**
- Prinz J, Wink M, Neuhaus S, Grob MC, Walt H, Bosshard PP, Achermann Y. Effective Biofilm Eradication on Orthopedic Implants with Methylene Blue Based Antimicrobial Photodynamic Therapy In Vitro. *Antibiotics (Basel)*. 2023; 8;12(1):118. **IF 5.222**
- Purde MT, Cupovic J, Palmowski YA, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou MT, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger KK, Bald T, Schietinger A, Schürch CM, Ring SS, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. *Mol Ther*. 2023 Dec 5:S1525-0016(23)00659-7. doi: 10.1016/j.ymthe.2023.11.026. Epub ahead of print. PMID: 38058126. **IF 12.4**
- Reese I, Schäfer C, Ballmer-Weber B, Beyer K, Dölle-Bierke S, v. Dullemen S, U. Jappe U, Müller S, Schnadt S, Treudler R, Worm M. Vegan diets from an allergy point of view – Position paper of the DGAKI working group on food allergy. *Allergo Select* 2023;31:57-83. **IF 1.5**
- Reiter S, Schroeder C, Broche J, Sinnberg T, Bonzheim I, Süsskind D, Flatz L, Forschner A. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report. *Front Oncol*. 2023 May 3;13:1167791. doi: 10.3389/fonc.2023.1167791. PMID: 37207136; PMCID: PMC10189013. **IF 6.24**
- Richter C, Hafner J, Schuermann M, Tanadini M, Trisconi N, Schmid-Grendelmeier P, Kündig T, Nägeli M, Brügglen MC, Guillet C. Dupilumab for chronic prurigo: case series on effectiveness, safety, and quality of life. 2023. *DERMATOLOGY*. **IF 3.4**
- Rodríguez I, Noda AA, Bosshard PP, Lienhard R. Anti-Treponema pallidum IgA response as a potential diagnostic marker of syphilis. *Clin Microbiol Infect*. 2023;29(12):1603.e1-1603.e4. **IF 14.2**
- Roshardt Prieto NM, Turko P, Zellweger C, Nguyen-Kim TDL, Staeger R, Bellini E, Levesque MP, Dummer R, Ramelyte E. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. *Melanoma Res*. 2023. **IF 2.2**
- Roshardt Prieto N, Wyss M, Dummer R. mRNA COVID 19 vaccine-induced recall dermatitis after topical imiquimod. *JDDG* 2023;1-2. **IF 5.231**
- Rossi V, Gawinecka J, Dimitriou F, von Eckardstein A, Dummer R, Ruschitzka F, Matter C. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge? *Wiley Online Library*. 2023. **IF 9.349**
- Rossi VA, Gawinecka J, Dimitriou F, von Eckardstein A, Dummer R, Ruschitzka F, Matter CM. Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge? *ESC Heart Failure*. 2023;10(4):2680-2685. **IF 3.612**
- Sangers TE, Kittler H, Blum A, Braun RP, Barata C, Cartocci A, Combalia M, Esdaile B, Guitera P, Haenssle HA, Kvorning N, Lallas A, Navarrete-Dechent C, Navarini AA, Podlipnik S, Rotemberg V, Soyer HP, Tognetti L, Tschandl P, Malvey J, EADV AI Task Force. Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease. *J Eur Acad Dermatol Venereol*. 2023;10.1111/jdv.19521. **IF 9.2**
- Santos AF, Riggioni C, Agache I, Akdis CA, Akdis M, Alvarez-Perea A, Alvaro-Lozano M, Ballmer-Weber B, Barni S, Beyer K, Bindeslev-Jensen C, Brough HA, Buyuktiryaki B, Chu D, Del Giacco S, Dunn-Galvin A, Eberlein B, Ebisawa M, Eigenmann P, Eiwegger T, Feeney M, Fernandez-Rivas M, Fisher HR, Fleischer DM, Giovannini M, Gray C, Hoffmann-Sommergruber K, Halken S, Hourihane JO, Jones CJ, Jutel M, Knol E, Konstantinou GN, Lack G, Lau S, Marques Mejias A, Marchisotto MJ, Meyer R, Mortz CG, Moya B, Muraro A, Nilsson C, Lopes de Oliveira LC, O'Mahony L, Papadopoulos NG, Perrett K, Peters RL, P odesta M, Poulsen LK, Roberts G, Sampson HA, Schwarze J, Smith P, Tham EH, Untersmayr E, Van Ree R, Venter C, Vickery BP, Vlieg-Boerstra B, Werfel T, Worm M, Du Toit G, Skypala I. EAACI Guidelines on the diagnosis of IgE mediated food allergy. *Allergy* 2023; 78:3057-3076. **IF 12.4**
- Sasaki M, Sundberg M, Frei R, Ferstl R, Heye KN, Willems EP, Akdis CA, Lauener R; CK-CARE Study Group; Roduit C. Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis. *Allergy*. 2023. **IF 12.4**
- Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med*. 2023;10;4(2):113-129.e7. 2023. **IF 16.048**
- Scherler G, Tomasse M, Cannizzaro V, Steppacher A, Zucol F, Theiler M, Toutous Trelu L, Labutin A, Bosshard PP, Berger C, Meyer Sauteur PM. Congenital syphilis in Switzerland: a retrospective cohort study, 2010 to 2019. *Swiss Medical Weekly*. 2023;153:40121. **IF 2.9**
- Schmid-Grendelmeier P, Gooderham MJ, Hartmann K, Konstantinou GN, Fellmann M, Koulias C, Clibborn C, Biswas P, Brunner PM. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies. *Allergy*. 2023;21. **IF 12.4**
- Schön V, Stocker D, Jüngst C, Dummer R, Ramelyte E. Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report. *J Immunother*. 2023;01;46(9):346-350. **IF 3.9**
- Schumann K, Mauch C, Klespe K, Loquai C, Nikfarjam U, Schlaak M, Akçetin L, Kölblinger P, Hoellwerth M, Meissner M, Mengi G, Braun A, Mengoni M, Dummer R, Mangana J, Sindrilaru M, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler J, Höller C, Eigentler T, Amaral T, Peitsch W, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul L, Läubli H, Debus D, Weishaupt C, Börger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen V, Wanner M, Gutzmer R, Terheyden P, Kähler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune K, Thoms K, Heinzerling L, Heppt M, Tratzmiller S, Hoetzenecker W, Öllinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posc C. Real-world outcomes using PD-1 antibodies and BRAF +MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. *J EADV* 2023;37:894-906. **IF 9.228**
- Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P, Wilson I, Korn R, Gonzalez-Menendez I, Quintanilla-Martinez L, Seith F, Forschner A, Eigentler T, Zender L, Röcken M, Pichler BJ, Flatz L, Kneilling M, la Fougere C. In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89/Zr] Zr-Df-IAB22M2C PET/MRI. *Theranostics*. 2023 Apr 17;13(8):2408-2423. doi: 10.7150/thno.79976. PMID: 37215571; PMCID: PMC10196830. **IF 11.56**

- Sinnberg T, Lichtensteiger C, Ali OH, Pop OT, Jochum AK, Risch L, Brugger SD, Velic A, Bomze D, Kohler P, Vernazza P, Albrich WC, Kahlert CR, Abdou MT, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat SM, Ruetalo N, Buehler PK, Scheier TC, Jochum W, Kern L, Henz S, Schneider T, Kuster GM, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy KD, Spengler W, Brutsche MH, Maček B, Twerenbold R, Penninger JM, Matter MS, Flatz L. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. *Am J Respir Crit Care Med*. 2023 Jan 1;207(1):38-49. doi: 10.1164/rccm.202201-0011OC. PMID: 35926164; PMCID: PMC9952873. **IF 24.7**
- Sobczak JM, Krenger PS, Storni F, Mohsen MO, Balke I, Resevica G, Heath MD, Velazquez TCL, Kramer MF, Scott CJW, Skinner MA, Zeltins A, Kündig TM, Vogel M, Bachmann MF. The next generation virus-like particle platform for the treatment of peanut allergy. 2023. *ALLERGY*. **IF 12.4**
- Sosic L, Paolucci M, Flory S, Jebbawi F, Kündig TM, Johansen P. Allergen immunotherapy: progress and future outlook. 2023. *EXPERT REVIEW OF CLINICAL IMMUNOLOGY*. **IF 4.4**
- Soyka MB, Ryser FS, Brühlmann C, Fehr D, Dülgeroglu J, Schmid-Grendelmeier P, Brügggen MC, Steiner UC. Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. *Allergy*. 2023;78(4):1036-1046. **IF 12.4**
- Steinmann S, Guillet C, Cheng P, Levesque M, Dummer R, Kolm I, Maul J. Identifying the potential origin of mucin in primary cutaneous mucinosis – A retrospective study and analysis using histopathology and multiplex fluorescence staining. 2023;00:1-9. **IF 9.228**
- Stücker M, Protz K, Eder S, Lächli S, Traber J, Dissemmond J. Diagnostik von Beinödemen. *Die Dermatologie*. 2023;74:182-189. **IF 0.8**
- Stratigos AJ, Garbe C, Dessinioti C, Lebbe C, van Akkooi A, Bataille V, Bastholt L, Dreno B, Dummer R, Fargnoli MC, Forsea AM, Harwood CA, Hauschild A, Hoeller C, Kandolf-Sekulovic L, Kaufmann R, Kellers-Smeets NW, Lallas A, Leiter U, Malvehy J, Del Marmol V, Moreno-Ramirez D, Pellacani G, Peris K, Saiag P, Tagliaferri L, Trakatelli M, Ioannides D, Vieira R, Zalaudek I, Arenberger P, Eggermont AMM, Röcken M, Grob JJ, Lorigan P. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023. *Eur J Cancer*. 2023;28;193:113251. **IF 10.002**
- Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahnkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma. *Annals of surgical oncology*. 2023;30(7):4359-4360. **IF 32.976**
- Thyssen JP, Nyman LK, Maul JT, Schmid-Grendelmeier P, Wu JJ, Frøstrup AG, Gren ST, Thomsen SF, Egeberg A. The Association Between Fatigue and Adult Atopic Dermatitis: A Cross-Sectional Study. *Dermatitis*. 2023;34(5):432-439. **IF 5.2**
- Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, Garzaroli M, Meier F, Meier E, Richly H, Gromke T, Siveke J, Franklin C, Klespe K, Mauch C, Kilian T, Seegräber M, Schilling B, French L, Berking C, Heinzerling L. Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real Life Retrospective Multicenter Study. *Cancers*. 2023. **IF 6.639**
- Tran T, Cyr PR, Verdieck A, Lu MD, Ahrens HT, Berry EG, Bowen W, Braun RP, Cusick-Lewis JM, Doan HQ, Donohue VL, Erlich DR, Ferris LK, Harkeman E, Hartmann RI, Holt J, Jaimes N, Joslin TA, Kebaeva Z, Liebman TN, Ludzik J, Marghoob AA, Simpson I, Stein JA, Stulberg DL, Tromme I, Trunquist MJ, Usatine RP, Walker AM, Walker BL, West RF, Wilson ML, Witkowski A, Wu DJ, Seiverling EV, Nelson KC. Expert Consensus Statement on Proficiency Standards for Dermoscopy Education in Primary Care. *J Am Board Fam Med*. 2023;8;36(1):25-38. **IF 2.395**
- Troesch A, Hoellwerth M, Forchhammer S, Del Regno L, Lodde G, Turko P, Cheng P, Levesque M, Hadaschik E, Livingstone E, Peris K, Flatz L, Koelblinger P, Dummer R, Dimitriou F. The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas: A retrospective cohort study from five European skin cancer reference centres. *J EADV* 2023;37:922-931. **IF 9.228**
- Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. *Nat Cancer*. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Erratum in: *Nat Cancer*. 2023 Aug 14;: PMID: 37525015; PMCID: PMC10518254. **IF 22.7**
- Vittrup I, Frøstrup AG, Gren ST, Thomsen SF, Wu JJ, Schmid-Grendelmeier P, Maul JT, Egeberg A, Thyssen JP. Disease burden of moderate-severe atopic dermatitis by use of systemic treatment: Results from the Danish Skin Cohort. *J Eur Acad Dermatol Venereol*. 2023;37(5):e688-e690. **IF 9.2**
- Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. *J Am Acad Dermatol*. 2023 Dec 1:S0190-9622(23)03250-4. doi: 10.1016/j.jaad.2023.11.040. Epub ahead of print. PMID: 38043594. **IF 13.8**
- Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. *Eur J Cancer*. 2023 Nov 21;196:113425. doi: 10.1016/j.ejca.2023.113425. Epub ahead of print. PMID: 38039778. **IF 8.4**
- Wang M, Fukushima S, Sheen YS, Ramelyte E, Pacheco NC, Shi C, Liu S, Banik I, Aquino JD, Acosta MS, Levesque M, Dummer R, Liau JY, Chu CY, Shain AH, Yeh I, Bastian BC. The genetic evolution of acral melanoma. *bioRxiv*. 2023:2023.10.18.562802
- Wietecha M, Lauenstein D, Cangkrana M, Seiler S, Jin J, Goppelt A, Claassen M, Levesque M, Dummer R, Werner S. Phase-specific signatures of wound fibroblasts and matrix patterns define cancer-associated fibroblast subtypes. 2023. **IF 10.447**
- Xander C, Wolfensperger M, Bosshard PP. Multidrug-resistant *Trichophyton rubrum* in a 67-year-old female patient with tinea corporis. *J Eur Acad Dermatol Venereol*. 2023. **IF 9.228**

Reviews 2023

Bossi P, Ascierto PA, Basset-Seguín N, Dreno B, Dummer R, Hauschild A, Mohr P, Kaufmann R, Pellacani G, Puig S, Moreno-Ramírez D, Robert C, Stratigos A, Gutzmer R, Queirolo P, Quaglino P, Peris K. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. *Crit Rev Oncol Hematol*. 2023;11:104066. **IF 23.168**

Dramburg S, Hilger C, Santos AF, de Las Vecillas L, Aalberse RC, Acevedo N, Aglas L, Altmann F, Arruda KL, Asero R, Ballmer-Weber B, Barber D, Beyrer K, Biedermann T, Bilo MB, Blank S, Bosshard PP, Breiteneder H, Brough HA, Bublin M, Campbell D, Caraballo L, Caubet JC, Celi G, Chapman MD, Chruszcz M, Custovic A, Czolk R, Davies J, Douladiris N, Eberlein B, Ebisawa M, Ehlers A, Eigenmann P, Gadermaier G, Giovannini M, Gomez F, Grohman R, Guillet C, Hafner C, Hamilton RG, Hauser M, Hawranek T, Hoffmann HJ, Holzhauser T, Iizuka T, Jacquet A, Jakob T, Janssen-Weets B, Jappe U, Jutel M, Kalic T, Kamath S, Kespohl S, Kleine-Tebbe J, Knol E, Knulst A, Konradsen JR, Korošec P, Kuehn A, Lack G, Le TM, Lopata A, Luengo O, Mäkelä M, Marra AM, Mills C, Morisset M, Muraro A, Nowak-Węgrzyn A, Nugraha R, Ollert M, Palosuo K, Pastorello EA, Patil SU, Platts-Mills T, Pomés A, Poncet P, Potapova E, Poulsen LK, Radauer C, Radulovic S, Raulf M, Rougé P, Sastre J, Sato S, Scala E, Schmid JM, Schmid-Grendelmeier P, Schrama D, Sénéchal H, Traidl-Hoffmann C, Valverde-Monge M, van Hage M, van Ree R, Verhoeckx K, Vieths S, Wickman M, Zakzuk J, Matricardi PM, Hoffmann-Sommergruber K. EAACI Molecular Allergy User's Guide 2.0. *Pediatr Allergy Immunol*. 2023;34 Suppl 28:e13854. **IF 5.464**

Faye O, Flohr C, Kabashima K, Ma L, Paller AS, Rapelanoro FR, Steinhoff M, Su JC, Takaoka R, Wollenberg A, Yew YW, Postigo JAR, Schmid-Grendelmeier P, Taïeb A. Atopic dermatitis: A global health perspective. *J Eur Acad Dermatol Venereol*. 2023. **IF 9.2**

Fehr D, Lang C, Masenga J, Mavura D, Schmid-Grendelmeier P, Brügggen MC. Atopic dermatitis: The importance of future research in Africa. *Allergy*. 2023;78(1):327-328. **IF 12.4**

Hellings PW, Lau S, Scadding GK, Bjermer L, Backer V, Chaker AM, Conti DM, De Corso E, Diamant Z, Djukanovic R, Fokkens W, Gevaert P, Gray CL, Han JK, Heaney LG, Hoffmann HJ, Jesenak M, Johansen P, Kumaran MS, McDonald M, Melén E, Mullol J, Reitsma S, Ryan D, Scadding G, Schmid-Grendelmeier P, Teeling T, Odemyr M, Wahn U. EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care. *Front Allergy*. 2023;4:1236977. **IF 2.4**

Henning MAS, Hay R, Rodriguez-Cerdeira C, Szepietowski JC, Piraccini BM, Ferreirós MP, Arabatzis M, Sergeev A, Nenoff P, Kotrekova L, Nowicki RJ, Faergemann J, Padovese V, Prohic A, Skerlev M, Schmid-Grendelmeier P, Sigurgeirsson B, Gaitanis G, Lecerf P, Saunte DML. Position statement: Recommendations on the diagnosis and treatment of *Malassezia* folliculitis. *J Eur Acad Dermatol Venereol*. 2023;37(7):1268-1275. **IF 9.2**

Morgenroth S, Roggo A, Pawlik L, Dummer R, Ramelyte E. What Is New in Cutaneous T Cell Lymphoma? *Curr Oncol Rep*. 2023;25(11):1397-1408. **IF 5.945**

Nenoff P, Reinel D, Mayser P, Abeck D, Bezold G, Bosshard PP, Brasch J, Daeschlein G, Effendy I, Ginter-Hanselmayer G, Gräser Y, Hamm G, Hengge U, Hipler UC, Höger P, Kargl A, Kolb-Mäurer A, Krüger C, Malisiewicz B, Mayer J, Ott H, Paasch U, Schaller M, Uhrlaß S, Zidane M. S1 Guideline onychomycosis. *J Dtsch Dermatol Ges*. 2023. **IF 5.231**

Pascolo S. Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history. *Eur J Immunol*. 2023;7:e2249941. **IF 6.668**

Ramelyte E, Nägeli MC, Hunger R, Merat R, Gaide O, Navarini AA, Cozzio A, Wagner NB, Maul LV, Dummer R. Swiss Recommendations for Cutaneous Basal Cell Carcinoma. *Dermatology*. 2023;239(1):122-131. **IF 5.197**

Schmid-Grendelmeier P, Rapelanoro Rabenja F, Beshah AM, Ball MD, Dlova N, Faye O, Flohr C, Hsu C, Mavura D, Manuel RC, Ramaroz-atovo LS, Sendrasoa F, Wollenberg A, Ruiz Postigo JA, Taïeb A. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in Sub-Saharan Africa? *J Eur Acad Dermatol Venereol*. 2023. **IF 9.2**

Šošić L, Paolucci M, Flory S, Jebbawi F, Kündig TM, Johansen P. Allergen immunotherapy: progress and future outlook. *Expert Rev Clin Immunol*. 2023;19(7):745-769. **IF 5.124**

Thyssen JP, Schmid-Grendelmeier P. Long-term disease control in atopic dermatitis using biologics. *Lancet*. 2023;401(10372):172-173. **IF 168.9**

Thyssen JP, Halling AS, Schmid-Grendelmeier P, Guttman-Yassky E, Silverberg JI. Comorbidities of atopic dermatitis-what does the evidence say? *J Allergy Clin Immunol*. 2023;151(5):1155-1162. **IF 14.2**

Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M, Berardi A, Bedbrook A, Bindslev-Jensen C, Bousquet J, de Bruin-Weller M, Bruscky D, Buyuktiryaki B, Canonica GW, Castro C, Chanturidze N, Chong-Neto HJ, Chu CY, Chularojanamontri L, Cork M, Criado RFJ, Barredo LC, Custovic A, Darsow U, Emurlai A, de Pablo A, Del Giacco S, Girolomoni G, Deleva Jovanova T, Deleuran M, Douladiris N, Duarte B, Dubakiene R, Eller E, Engel-Yeger B, Ensina LF, Filho NR, Flohr C, Fomina D, Francuzik W, Galimberti ML, Giménez-Arnau AM, Godse K, Mortz CG, Gotua M, Hide M, Hoetzenecker W, Hunzelmann N, Irvine A, Jack C, Kanavarou I, Katoh N, Kinaciyan T, Kocatürk E, Kulthanan K, Lapeere H, Lau S, Machado Forti Natri M, Makris M, Mansour E, Marsland A, Morelo Rocha Felix M, Moschione Castro AP, Nettis E, Nicolas JF, Nosbaum A, Odemyr M, Papapostolou N, Parisi CAS, Paudel S, Peter J, Pokharel P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid-Grendelmeier P, Serra-Baldrich E, Siemens K, Smith C, Staubach P, Stevanovic K, Su-Kücü Ö, Sussman G, Tavecchio S, Teovska Mitrevska N, Thaci D, Toubi E, Traidl-Hoffmann C, Treudler R, Vadasz Z, van Hofman I, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Yew Y, Zhao Z, Zwiener R, Worm M. A concept for integrated care pathways for atopic dermatitis-A GA2 LEN ADCARE initiative. *Clin Transl Allergy*. 2023;13(9):e12299. **IF 4.4**

Book Chapters 2023

Greis C. (2023) Plattformen und Ökosysteme in der Dermatologie. In: Matusiewicz (Hrsg.) Plattformen und Tech-Giganten im Gesundheitswesen. ISBN: 978-3-95466-760-4. MWV, Berlin (Book Chapter)

2024

Original Papers 2024

Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. *Eur J Cancer*. 2024;1;202:113976. **IF: 10.002**

- Andersson AM, Ingham AC, Edslev SM, Sølberg J, Skov L, Koch A, Ghauharali-van der Vlugt K, Stet FS, Brügger CM, Jakasa I, Kezic S, Thyssen JP. Ethnic endotypes in paediatric atopic dermatitis depend on immunotype, lipid composition and microbiota of the skin. *J Eur Acad Dermatol Venereol*. 2024;38(2):365-374. **IF: 9.2**
- Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. *Nat Commun*. 2024;2;15(1):146. **IF: 17.694**
- Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Quaglino P, Lebbé C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzalez-Cao M, Minisini AM, De Placido S, Sanmamed MF, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Palmieri G, Dummer R, Sileni VC. Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma. *NEJM Evid*. 2024;3(10):EVID0a2400087. **IF: 96.2**
- Ballmer-Weber BK, Wangorsch A, Bures P, Hanschmann KM, Gadermaier G, Mattsson L, Mills CEN, van Ree R, Lidholm J, Vieths S. New light on an old syndrome: Role of Api g 7 in mugwort pollen-related celery allergy. *J Allergy Clin Immunol*. 2024;154(3):679-689. **IF: 11.4**
- Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, Benedetti F, Crespo I, Grimm AJ, Morotti M, Zimmermann S, Duran R, Imbimbo M, de Olza MO, Navarro B, Homicsko K, Bobisse S, Labes D, Tsourti Z, Andriakopoulou C, Herrera F, Pétremand R, Dummer R, Berthod G, Kraemer AI, Huber F, Thevenet J, Bassani-Sternberg M, Schaefer N, Prior JO, Matter M, Aedo V, Dromain C, Corria-Osorio J, Tissot S, Kandalaf LE, Gottardo R, Pittet M, Sempoux C, Michielin O, Dafni U, Trueb L, Harari A, Laniti DD, Coukos G. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with pre-existing CD8+ T-myeloid cell networks in melanoma. *Science Immunology*. 2024;2;9(92):eadg7995. **IF: 30.63**
- Birkenmaier I, Maul LV, Oyanguren I, Sorbe C, Fröhlich F, Schlapbach C, Heidemeyer K, Yawalkar N, Boehncke WH, Ring HC, Thyssen JP, Egeberg A, Micheroli R, Thomsen SF, Mainetti C, Cozzio A, Kündig TM, Levesque MP, Navarini A, Maul JT. *Arch Dermatol Res*. 2024;1;316(9):654. **IF: 2.4**
- Birkmann K, Jebbawi F, Waldern N, Hug S, Inversini V, Keller G, Holm A, Grest P, Canonica F, Schmid-Grendelmeier P, Fettelschoss-Gabriel A. Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses. *Vaccines* 2024;12(6), 562. **IF: 7.8**
- Boaitey YA, Owusu-Ofori A, Anyogu A, Aghakhanian F, Arora N, Parr JB, Bosshard PP, Raheem S, Gerbault P. Prevalence of yaws and syphilis in the Ashanti region of Ghana and occurrence of H. ducreyi, herpes simplex virus 1 and herpes simplex virus 2 in skin lesions associated with treponematoses. *PLoS One*. 2024;19(5):e0295088. **IF: 3.7**
- Bruch-Gerharz D, Stephan B, Maul JT. Skin and pregnancy. *Dermatologie (Heidelb)*. 2024;75(11):835-836. **IF: 3.5**
- Brüggen MC, Ingen-Housz-Oro S. Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms-Reply. *JAMA Dermatol*. 2024;1;160(6):687-688. **IF: 11.5**
- Brüggen MC, Traidl S, Mitamura Y, Walsh S, French LE, Gulati N, Phillips E, Maverakis E, Ingen-Housz-Oro S. Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients. *Allergy*. 2024;79(10):2876-2880. **IF 12.6**
- Brüggen MC, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S; DRESS Delphi consensus group; Abe R, Ardern-Jones M, Assier H, Barbaud A, Bensaid B, Bernal W, Bernier C, Brassard A, Brezinová E, Cabañas R, Cardones A, Chu CY, Chua SL, Descamps V, Didona B, Divito SJ, Dodiuk-Gad R, Elman S, Gaspar K, Mortz CG, Hama N, Lee HY, Horváth B, Jörg L, Kaffenberger BH, Kucinskiene V, Lebrun-Vignes B, Lehloenyá RJ, Meyersburg D, Micheletti R, Milpied B, Miyagawa F, Mostaghimi A, Nägeli M, Naldi L, Opiel E, Phillips EJ, Pirani T, Ranki A, Mälkönen T, Rosenbach M, Salavastru C, Staumont-Salle D, Sandberg H, Setterfield J, Shinkai K, Shiohara T, Soria A, Tartar D, Tiplica GS, Traidl S, Vorobyev A, von Wächter C, Worswick S, Cho YT. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. *JAMA Dermatol*. 2024;1;160(1):37-44. **IF 11.5**
- Burri E, Mangana J, Cheng PF, Schneider A, Weber A, Dummer R, Ramelyte E. Influximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids. *J Immunother Cancer*. 2024;5;12(7):e008074. **IF: 10.3**
- Caron AGM, van Huizen AM, Musters AAH, Gerbens LAA, Middelkamp Hup MA, Flohr C, Irvine AD, Vestergaard C, Peris K, Brandling-Bennett HA, Drucker AM, Spuls PI; MTX Consensus for AD Survey Study Group. International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study. *J Eur Acad Dermatol Venereol*. 2024;1. **IF: 8.4**
- Carminara SE, Cvijetic I, Huber S, Müller S, Kostner L, Goessinger EV, Narainsing J, Dutilh G, Heidemeyer K, Yawalkar N, Conrad C, Plaza T, Maul JT, Cozzio A, Navarini AA. ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis. *J Eur Acad Dermatol Venereol*. 2024;24. **IF: 8.4**
- Chanda T, Hauser K, Hobelsberger S, Bucher TC, Garcia CN, Wies C, Kittler H, Tschandl P, Navarrete-Dechent C, Podlipnik S, Chousakos E, Cmaric I, Majstorovic J, Alhajwan L, Foreman T, Peternel S, Sarap S, Özdemir İ, Barnhill RL, Llamas-Velasco M, Poch G, Korsing S, Sondermann W, Gellrich FF, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Goebeler M, Schilling B, Utikal JS, Ghoreschi K, Fröhling S, Krieghoff-Henning E; Reader Study Consortium; Brinker TJ. Dermatologist-like explainable AI enhances trust and confidence in diagnosing melanoma. *Nat Commun*. 2024;15;15(1):524. **IF 14.7**
- Chang YT, Prompsy P, Kimeswenger S, Tsai YC, Ignatova D, Pavlova O, Iselin C, French LE, Levesque MP, Kuonen F, Bobrowicz M, Brunner PM, Pascolo S, Hoetzenecker W, Guenova E. MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. *Nat Commun*. 2024;25;15(1):752. **IF: 16.6**
- Conde-Montero E, Moreau A, Schlager JG, Pastor D, Hafner J. Protocols in wound healing: Evidence-based or mere rituals? *Int Wound J*. 2024;21(10):e70062. **IF: 2.6**
- Colla N, Maul JT, Vallejo-Yagüe E, Burden AM, Möller B, Nissen MJ, Yawalkar N, Papagiannoulis E, Distler O, Ciurea A, Micheroli R. Impact of blue-collar vs. white-collar occupations on disease burden in psoriatic arthritis patients: A Swiss clinical quality management in rheumatic diseases cohort study. *Clin Rheumatol*. 2024;7. **IF: 2.9**

- Dana IN, Kurtansky NR, Pastore LM, Xu JR, Nazir ZH, Dusza SW, Chousakos E, Reiter O, Navarrete-Dechent C, Braun RP, Rabinovitz HS, Marghoob AA. Differentiating seborrheic keratosis from melanoma among lesions exhibiting blue-white veil: A retrospective study. *J Am Acad Dermatol*. 2024;9:S0190-9622(24)03118-9. **IF 13.8**
- Darbellay B, Huber M, Bisschoff IJ, Guillod C, Hügel R, Pirkhammer D, Sator PG, Taskesen T, Lang CCV. Real-world burden of atopic dermatitis: Austrian and Swiss data from the MEASURE-AD study. *J Dermatolog Treat*. 2024;35(1):2415407. **IF: 2.9**
- Diaz-Calvillo P, Munoz-Barba D, Urena-Paniego C, Maul LV, Cerninara S, Kostner L, Lopez AM, Arias-Santiago S. Effects of COVID-19 Pandemic on the Diagnosis of Melanoma and Keratinocyte Carcinomas: a Systematic Review and Meta-analysis. *Acta Derm Venereol*. 2024;14:104:adv19460. **IF: 0.6**
- Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerding V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Matter CM, Michielin O, Gutzmer R, Long GV, Becher B, Levesque MP, Dummer R. A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma. *Nat Cancer*. 2024;29. **IF: 23.5**
- de Joode K, Mora AR, van Schaik RHN, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin O, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex SL, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. *J Immunother*. 2024;1;47(5):190-194. **IF: 3.9**
- Di Gangi S, Guillet C, Anzengruber F, Zechmann S, Meier TO. Deep vein thrombosis after sclerotherapy and endovenous laser ablation of varicose veins – an observational study. *Vasa*. 2024;53(4):275-285. **IF: 2.1**
- Doerfler P, Schoefmann N, Cabral G, Bauer W, Berli MC, Binder B, Borst C, Botter S, French LE, Goerge T, Hafner J, Hartmann D, Høgh A, Hoetzenecker W, Holzer-Geissler JCJ, Kamolz LP, Kofler K, Luger T, Nischwitz SP, Popovits M, Rappersberger K, Restivo G, Schlager JG, Schmuth M, Stingl G, Stockinger T, Stroelin A, Stuetz A, Umlauf J, Weninger WP, Wolff-Winiski B. Development of a cellular assay as a personalized model for testing chronic wound therapeutics. *J Invest Dermatol*. 2024;1:S0022-202X(24)01866-9. **IF: 5.7**
- Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, von Bergwelt-Baildon M, Subklewe M, Tomsitz D, Ascierto P, Dummer R, Gogas H, Lebbé C, Long G, McArthur G, Neilan T, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler K, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness A, Blank C, Wolchok J, French L, Hauschild A, Heinzerling L. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects. *European Journal of Cancer*. 2024 **IF 10.002**
- Esposito M, Yerly L, Shukla P, Hermes V, Sella F, Balazs Z, Lattmann E, Tastanova A, Turko P, Lang R, Kolm I, Staeger R, Kuonen F, Krauthammer M, Hafner J, Levesque MP, Restivo G. COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma. *Br J Dermatol*. 2024;25:ljae258. **IF 9.4**
- Fabi A, Milosavljevic S, Lang C, Guillet C, Schmid-Grendelmeier P. Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria. *Allergo J Int* 33, 32–40 (2024). **IF: 1.1**
- Fehr D, Rentschler M, Sendrasoa F, Li N, White A, Distler M, Lang C, Masenga G, Mosha N, Seemango G, Clemens C, Rasamoelina T, Soankasina A, Rabenja F, Mavura D, Masenga J, Schmid-Grendelmeier P, Brügggen C. Sensitizations to pollen differ between Central European and Sub-Saharan African atopic dermatitis patients. *Allergo J Int* (2024). **IF: 1.3**
- Flory S, Hviid-Vyff B, Šošić L, Schmid JM, Ahlbeck L, Widmer ECJ, Lang CCV, Ikenberg K, Kündig TM, Hoffmann HJ, Johansen P. How to hit the allergy target: a critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound-guided injections. *Allergy*. 2024;7. **IF 12.6**
- Fischer A, Martínez-Gómez JM, Mangana J, Dummer R, Erlic Z, Nöbling S, Beuschlein F, Maurer A, Messerli M, Huellner MW, Skawran S. 18 F-FDG PET/CT for Detection of Immunotherapy-Induced Hypophysitis—A Case-Control Study. *Clin Nucl Med*. 2024;1;49(12):e656-e663. **IF 10**
- Frei J, Jarzebska NT, Mellett M, Kündig TM, Pascolo S, Reichmuth AM. Design and Synthesis of Circular RNA Expression Vectors. *Methods Mol Biol*. 2024;2786:205-215. **IF 1.829**
- Gantenbein L, Cerninara SE, Maul JT, Navarini AA, Maul LV. Artificial intelligence-driven skin aging simulation as a novel skin cancer prevention. *Dermatology*. 2024;14:1-20. **IF 3.2**
- Gaudy-Marqueste C, Grob JJ, Garbe C, Ascierto PA, Arron S, Basset-Seguín N, Bohne AS, Lenoir C, Dummer R, Fargnoli MC, Guminski A, Hauschild A, Kaufmann R, Lallas A, Del Marmol V, Migden M, Penicaud M, Rembielak A, Stratigos A, Tagliaferri L, Zalaudek I, Arance A, Badinand D, Bossi P, Challapalli A, Clementi M, Di Stefani A, Ferrándiz-Pulido C, Giuffrida R, Gravina GL, Ha P, Heinzerling L, Mallet S, Paradisi A, Mohr P, Piccerillo A, Rutkowski D, Saiag P, Sollena P, Trakatelli M, Wojcieszek P, Yom SS, Zelin E, Peris K, Malvey J. Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts. *J Eur Acad Dermatol Venereol*. 2024. **IF: 8.4**
- Geisshüsler S, Nilsson F, Ziak N, Kotkowska Z, Paolucci M, Buzhor MG, Zoratto N, Johansen P, Leroux JC. Cyclodextrin microneedles for the delivery of a nanoparticle-based peptide antigen vaccine. *Eur J Pharm Biopharm*. 2024;9:114249. **IF 4.4**
- Goessinger EV, Dittrich PG, Nöcker P, Notni G, Weber S, Cerninara S, Mühleisen B, Navarini AA, Maul LV. Classification of melanocytic lesions using direct illumination multispectral imaging. *Sci Rep*. 2024;16;14(1):19036. **IF 3.8**
- Goessinger EV, Niederfeilner JC, Cerninara S, Maul JT, Kostner L, Kunz M, Huber S, Koral E, Habermacher L, Sabato G, Tadic A, Zimmermann C, Navarini A, Maul LV. Patient and dermatologists perspectives on augmented intelligence for melanoma screening: A prospective study. *J Eur Acad Dermatol Venereol*. 2024;27. **IF 8.4**
- Guillet C, Stillhard A, Welti M, Hauser X, Kempf W, Riera C, Grimm F, Schmid-Grendelmeier P, & Kolm I. Problems when diagnosing cutaneous leishmaniasis: a retrospective study analyzing clinical, histopathological and immunohistochemical features. *J Dtsch Dermatol Ges*. 2024. **IF: 5.5**
- Guillet C, Hauser X, Stillhard A, Schmid-Grendelmeier P, Kolm I. Nodular Vasculitis: Retrospective Study of an Uncommon Disease in a Non-Tuberculosis Endemic Country with Focus on Treatment Modalities and Efficacy. *Dermatology*. 2024;18:1-8. **IF 3.0**
- Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, Abdullah SE, Benlahrech A, Orloff M, Nathan P, Piperno-Neumann S, Staeger R, Dummer R, Meier-Schiessner B. Tebentafusp induces a T cell driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. *J Invest Dermatol*. 2024;15:S0022-202X(24)01886-4. **IF 5.7**

- Hassel JC, Stanhope S, Greenshields-Watson A, Machiraju D, Enk A, Holland C, Abdullah SE, Benlahrech A, Orloff M, Nathan P, Piperno-Neumann S, Staeger R, Dummer R, Meier-Schiesser B. Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action. *J Invest Dermatol*. 2025 Mar;145(3):559-572.e9. doi: 10.1016/j.jid.2024.03.048. Epub 2024 Jul 15. PMID: 39019150. **IF 5.9**
- Haurig MB, Andersson AM, Maul JT, Xu J, Lwin SM, Flohr C, Hove LS, Agner T, Koch A, Griffiths CEM, Zachariae C, Thyssen JP. Skin diseases among adults in Tasiilaq, East Greenland. *Int J Circumpolar Health*. 2024;83(1):2412378. **IF 1.3**
- Hepner A, Versluis JM, Wallace R, Allayous C, Brown LJ, Trojaniello C, Gerard CL, Jansen YJ, Bhave P, Neyns B, Haydon A, Michielin O, Mangana J, Klein O, Shoushtari AN, Warner AB, Ascierto PA, McQuade JL, Carlino MS, Zimmer L, Lebbe C, Johnson DB, Sandhu S, Atkinson V, Blank CU, Lo SN, Long GV, Menzies AM. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. *Eur J Cancer*. 2024;196:11344. **IF: 8.4**
- Hess J, Barysch-Bonderer MJ, Seeli C, Laube J, Ghosh A, Deinsberger J, Weber B, Hafner J, Meier-Schiesser B. Identifying Key Drivers in the Pathogenesis of Martorell Hypertensive Ischaemic Leg Ulcer: A Comparative Analysis with Chronic Venous Leg Ulcer. *Acta Derm Venereol*. 2024 May 30;104:adv40090. doi: 10.2340/actadv.v104.40090. PMID: 38813744; PMCID: PMC11161809. **IF 4.437**
- Hjálmsdóttir Á, Hasler F, Waeckerle-Men Y, Duda A, López-Deber MP, Pihlgren M, Vukicevic M, Kündig TM, Johansen P. T cell independent antibody responses with class switch and memory using peptides anchored on liposomes. *NPJ Vaccines*. 2024;22:9(1):115. **IF 6.9**
- Holgersen N, Nielsen VW, Rosenø NAL, Ring HC, Holm Nielsen S, Maul JT, Thyssen JP, Egeberg A, Thomsen SF. The Copenhagen Hidradenitis Suppurativa Cohort: Insights from the First 8 Years. *Dermatology*. 2024;240(5-6):917-921. **IF 3.2**
- Holzinger T, Frei J, Jarzebska NT, Beer HD, Kündig TM, Pascolo S, Läuchli S, Mellett M. Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy. *Anti-Cancer Drugs*. 2024;1;35(10):912-921. **IF 2.389**
- Jabet A, Bérot V, Chiarabini T, Dellière S, Bosshard PP, Siguier M, Tubiana R, Favier M, Canestri A, Makhloufi S, Nouchi A, de Risi-Pugliese T, Boquel F, Crémer G, Khoury R, Sidali O, Hamane S, Benderdouche M, Palous M, Chasset F, Gräser Y, Hubka V, Fekkar A, Hennequin C, Piarroux R, Normand AC, Monsel G. Trichophyton mentagrophytes ITS genotype VII infections among men who have sex with men in France: An ongoing phenomenon. *J Eur Acad Dermatol Venereol*. 2024. **IF 9.3**
- Jacques SK, McKeown J, Grover P, Johnson DB, Zaremba A, Dimitriou F, Weiser R, Farid M, Namikawa K, Sullivan RJ, Rutkowski P, Lebbe C, Hamid O, Zager JS, Michielin O, Neyns B, Nakamura Y, Robert C, Mehnert J, Ascierto PA, Bhave P, Park B, Zimmer L, Mangana J, Mooradian M, Placzke J, Allayous C, Glitza Oliva IC, Mehmi I, Depalo D, Wicky A, Schwarze JK, Roy S, Boatwright C, Vanella V, Long GV, Menzies AM, Lo SN, Carlino MS. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. *Eur J Cancer*. 2024;199:113563. **IF: 8.4**
- Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buiques A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. First-in-human study of naprafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. *Eur J Cancer*. 2024;196:113458. **IF 8.4**
- Jarzebska NT, Frei J, Mellett M, Kündig TM, Pascolo S, Reichmuth AM. A Basic Method for formulating mRNA-Lipid Nanoparticle Vaccines in the Lab. *Methods Mol Biol*. 2024;2786:237-254. **IF 1.829**
- Kähler KC, Gutzmer R, Angela Y, Livingstone E, Lodde G, Meiss F, Rafei-Shamsabadi DA, Weyer-Fahlbusch SS, Nashan D, Loquai C, Hassel JC, Sachse MMM, Maul LV, Heinzerling L, Heppt MV, Colapietro C, Rusch J, Blome C. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective. *J Cancer Res Clin Oncol*. 2024;14;150(5):252. **IF 2.7**
- Karakaya T, Slaufova M, Di Filippo M, Hennig P, Kündig T, Beer HD. CARD8: A Novel Inflammasome Sensor with Well-Known Anti-Inflammatory and Anti-Apoptotic Activity. *Cells*. 2024;13;13(12):1032. **IF 6**
- Keller J, O' Siorain JR, Kündig TM, Mellett M. Molecular aspects of Interleukin-36 cytokine activation and regulation. *Biochem Soc Trans*. 2024;28:BST20230548. **IF 3.8**
- Knoch C, Baghin V, Turko P, Winkelbeiner N, Staeger R, Wei K, Banzola I, Mellett M, Levesque MP, Kuendig T, French LE, Heinzerling L, Meier-Schiesser B. Distinct Variations in Gene Expression and Cell Composition across Lichen Planus Subtypes. *Int J Mol Sci*. 2024 Sep 8;25(17):9720. doi: 10.3390/ijms25179720. PMID: 39273670; PMCID: PMC11396712. **IF 5.6**
- Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Agüero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. *Life (Basel)*. 2024;13;14(10):1297. **IF 3.2**
- Kristensen SIP, Frithioff A, Ternov NK, Guitera P, Braun RP, Malvey J, Navarrete-Dechent C, Hölmich LR, Frøndø M. Gamification and serious games in dermatology education: A systematic review and quality assessment. *J Eur Acad Dermatol Venereol*. 2024;38(7):e562-e567. **IF 8.4**
- Kurtansky NR, D'Alessandro BM, Gillis MC, Betz-Stablein B, Cermignano SE, Garcia R, Girundi MA, Goessinger EV, Gottfroid P, Guitera P, Halperin AC, Jakrot V, Kittler H, Kose K, Liopyris K, Malvey J, Mar VJ, Martin LK, Mathew T, Maul LV, Mothershaw A, Mueller AM, Mueller C, Navarini AA, Rajeswaran T, Rajeswaran V, Saha A, Sashindranath M, Serra-García L, Soyer HP, Theocharis G, Vos A, Weber J, Rotemberg V. The SLICE-3D dataset: 400,000 skin lesion image crops extracted from 3D TBP for skin cancer detection. *Sci Data*. 2024;14;11(1):884. **IF 5.8**
- Lacouture, M. E., E. Goleva, N. Shah, V. Rotemberg, L. Kraehenbuehl, K. F. Ketosugbo, T. Merghoub, T. Maier, A. Bang, S. Gu, T. Salvador, A. P. Moy, T. Lyubchenko, O. Xiao, C. F. Hall, E. Berdyshev, J. Crooks, R. Weight, J. A. Kern and D. Y. M. Leung. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. *Clinical Cancer Research*. 2024;1;30(13):2822-2834. **IF 11.5**
- Le Rhun E, Weller M, Anders C, Larkin J, Li J, Moss NS, Tawbi H, Dummer R. «Symptomatic» melanoma brain metastases: A call for clear definitions and adoption of standardized tools. *Eur J Cancer*. 2024;6;208:114202. **IF: 7.7**
- Lin C, Canonica F, Wüthrich S, Fettelschoss-Gabriel A, Schlapbach R, Nanni P. m-nitrobenzyl alcohol supercharging reagent enhances the chromatographic separation and the charging of disulfide bond linked and His-tag peptides. *J Chromatogr A*. 2024;10:1722:464828. **IF 4.759**

Linnemann E, Nielsen ML, Maul LV, Richter C, Dommann I, Zink A, Schlapbach C, Yawalkar N, Conrad C, Cozzio A, Kündig T, Navarini A, Egeberg A, Maul JT. Predictors of initiating biologics in the treatment of psoriasis. *Int J Dermatol*. 2024;63(10):e231-e239. **IF 3.5**

Liopyris K, Navarrete-Dechent C, Marchetti MA, Rotemberg V, Apalla Z, Argenziano G, Blum A, Braun RP, Carrera C, Codella NCF, Combalia M, Dusza SW, Gutman DA, Helba B, Hofmann-Wellenhof R, Jaimes N, Kittler H, Kose K, Lallas A, Longo C, Malvehy J, Menzies S, Nelson KC, Paoli J, Puig S, Rabinovitz HS, Rishpon A, Russo T, Scope A, Soyer HP, Stein JA, Stolz W, Sgouros D, Stratigos AJ, Swanson DL, Thomas L, Tschandl P, Zalaudek I, Weber J, Halpern AC, Marghoob AA. Expert Agreement on the Presence and Spatial Localization of Melanocytic Features in Dermoscopy. *J Invest Dermatol*. 2024;144(3):531-539.e13. **IF 5.7**

Long G, Hauschild A, Santinami M, Kirkwood J.M., Atkinson V, Mandala M, Merelli B, Sileni V.C., Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnani S.B., Burgess P, Jandoo T, Dummer R. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. *NEJM*. 2024;7:391(18):1709-1720. **IF 158.5**

Loos B, Salas-Bastos A, Nordin A, Debbache J, Stierli S, Cheng PF, Ruffi S, Wyss C, Levesque MP, Dummer R, Wong WW, Pascolo S, Cantù C, Sommer L. TGF β signaling sensitizes MEK1-resistant human melanoma to targeted therapy-induced apoptosis. *Cell Death Dis*. 2024;21;15(12):925. **IF 8.1**

Mamaghani S, Penna RR, Frei J, Wyss C, Mellett M, Look T, Weiss T, Guenova E, Kündig TM, Lauchli S, Pascolo S. Synthetic mRNAs Containing Minimalistic Untranslated Regions Are Highly Functional In Vitro and In Vivo. *Cells*. 2024;24;13(15):1242. **IF 5.1**

Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, Mengozzi A, Wang YJ, Kündig TM, Räber L, Suschitzky F, Matter CM. Inflammation in acute myocardial infarction: the good, the bad and the ugly. *Eur Heart J*. 2024;7;45(2):89-103. **IF 37.6**

Maul JT, Ak M, Cerminara SE, Steinmann S, Goessinger EV, Darzina A, Oyanguren Monferrer I, Micheroli R, Kokolakis G, Roeder E, Oestereich F, Mateu E, Burlando M, Navarini AA, Kündig T, Maul LV. Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT). *Acta Derm Venereol*. 2024;27;104:adv40946. **IF 3.5**

Maul JT, Kolios A, Thomsen SF, Ring H-C. Secukinumab treatment of hidradenitis suppurativa: questions remain. *Lancet*. 2024;17;403(10427):616-617. **IF 98.4**

Maul JT, Maul L, Didaskalu J, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon H, Zheng M, Wu J, Thyssen J, Egeberg A, Armstrong A, Nielsen M. Correlation between DLQI and PASI in patients with psoriasis - a cross-sectional Global Healthcare Study on Psoriasis (GHSP). *Acta Derm Venereol*. 2024;12;104:adv20329. **IF 4.437**

Maul LV, Jamiolkowski D, Lapidus RA, Mueller AM, Hauschild A, Garbe C, Lorigan P, Gershenwald JE, Ascierto PA, Long GV, Wang-Evers M, Scolyer RA, Saravi B, Augustin M, Navarini AA, Legge S, Németh IB, Jánosi ÁJ, Mocellin S, Feller A, Manstein D, Zink A, Maul JT, Buja A, Adhikari K, Roeder E. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. *JAMA Netw Open*. 2024;5;7(2):e2356479. **IF 10.5**

Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martín-Liberal J, Joerger M, Alonso G, Goebeler ME, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz ME, Calvo E, Esteban-Villarubia J, Oberoi A, Sabat P, Soto-Castillo JJ, Koster KL, Saavedra O, Sayehli C, Gromke T, Lüubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt AM, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle PR, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll FJ, Wild P, Chun FKH, Reis H, Lloyd P, Machacek M, Gajewski TF, Fridman WH, Eggermont AMM, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, da Silva A, Lichtenegger FS, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. *Nature*. 2024;637(8048):1218-1227. **IF 58.7**

Meienberger N, Maul JT, Fröhlich F, Maul LV, Kündig T, Nordmann T, Anzengruber F. Atypical and Typical Presentation of Erythema Nodosum: Clinical Differences in Treatment and Outcome. *Dermatology*. 2024;240(2):226-232. **IF 3.5**

Meier-Schiesser B, Zecha C, Zierold S, Kolm I, Röckel M, Fröhlich W, Mittag N, Schmitt C, Kumbrink J, Hassel J, Berking C, Nashan D, French L, Vera-González J, Dummer R, Kerl-French K, Heinzlerling L. Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level. 2024;13;15:157-164. **IF 13.8**

Meier-Schiesser B, Zecha C, Zierold S, Kolm I, Röckel M, Fröhlich W, Mittag N, Schmitt C, Kumbrink J, Hassel JC, Berking C, Nashan D, French LE, Vera-González J, Dummer R, Kerl-French K, Heinzlerling L. Checkpoint inhibitor-induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level. *JAAD Int*. 2024 Jan 13;15:157-164. doi: 10.1016/j.jdin.2023.11.013. PMID: 38882039; PMCID: PMC11180371

Mendelson K, Martin TC, Nguyen CB, Hsu M, Xu J, Lang C, Dummer R, Saenger Y, Messina JL, Sondak VK, Desman G, Hasson D, Bernstein E, Parsons RE, Celebi JT. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation. *JCI Insight*. 2024;6;9(6):e166611. **IF 6.3**

Mick A, Wecker H, Ziehfrennd S, Maul JT, Biedermann T, Zink A. Cracking the code: unveiling the nexus between atopic dermatitis and addictive behavior: a cross-sectional exploration of risk factors. *Arch Dermatol Res*. 2024;14;316(4):102. **IF 1.8**

Näf L, Miescher I, Pfuderer L et al. Näf L, Miescher I, Pfuderer L, Schweizer TA, Brunner D, Dürig J, Gröniger O, Rieber J, Meier-Buegler G, Spanaus K, Calcagni M, Bosshard PP, Achermann Y, Stark WJ, Buschmann J. Pro-angiogenic and antibacterial copper-containing nanoparticles in PLGA/amorphous calcium phosphate bone nanocomposites. *Heliyon*. 2024;10(5):e27267. **IF 4.0**

Neisinger S, Sousa Pinto B, Ramanauskaitė A, Bousquet J, Weller K, Metz M, Magerl M, Kocatürk E, Cherrez-Ojeda I, Gimenez-Arnau AM, Parisi CAS, Altrichter S, Ensina LF, Bouillet L, Asero R, Gonçalves M, Guillet C, Rutkowski K, Bernstein JA, Hardin H, Godse K, Brzoza Z, Sousa JIL, Thomsen SF, van Doorn M, Hide M, Ye YM, Vandersee S, Lapiņa L, Peter J, Zhao Z, Han L, Nasr I, Rockmann-Helmbach H, Sørensen JA, Kara RÖ, Kurjane N, Kurchenko AI, Kaidashev I, Tsaryk V, Stepanenko R, Maurer M. CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria. *Clin Transl Allergy*. 2024;14(1):e12328. **IF 4.6**

Nielsen ML, Petersen TC, Maul LV, Thyssen JP, Thomsen SF, Wu JJ, Navarini AA, Kündig T, Yawalkar N, Schlapbach C, Boehncke WH, Conrad C, Cozzio A, Micheroli R, Erik Kristensen L, Egeberg A, Maul JT. Predicting Psoriatic Arthritis in Psoriasis Patients - A Swiss Registry Study. *J Psoriasis Psoriatic Arthritis*. 2024;9(2):41-50. **IF 8.6**

Nolting A, Hasler S, Probst-Mueller E, Schmid-Grendelmeier P, Lanz J, Guillet C. Hen's egg white allergy in adults leading to strong impairment of quality of life. *Sci Rep.* 2024;26;14(1):29401.

IF 3.8

Nusbaum KB, Boettler M, Korman AM, Alavi A, Alloo A, Dissemond J, French LE, Huang WW, Kolios AGA, Marzano AV, Micheletti RG, Most-aghimi A, Ortega-Loayza AG, Rosenbach M, Schreml S, Tolkachjov SN, Kaffenberger BH. Subjective assessments in pyoderma gangrenosum diagnostic frameworks undermine framework agreement. *Int J Dermatol.* 2024;63(2):e67–e69. **IF 3.5**

Paolucci M, Antz N, Homère V, Kolm I, Kündig TM, Johansen P. A murine model of peanut-allergic asthma. *Front Allergy.* 2024;25;5:1378877. **IF 3.3**

Pinter A, Eyerich K, Costanzo A, Garrelts A, Schuster C, Mert C, Lampropoulou A, Fotiou K, Maul JT, Papp KA. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO). *J Dermatolog Treat.* 2024;35(1):2350227. **IF 2.8**

Piontek K, Radonjic-Hoesli S, Grabbe J, Drewitz KP, Apfelbacher C, Wöhrl S, Simon D, Lang C, Schubert S. Comparison of patch testing Brazilian (Green) propolis and Chinese (poplar-type) propolis: Clinical epidemiological study using data from the Information Network of Departments of Dermatology (IVDK). *Contact Dermatitis.* 2024;5. **IF 4.8**

Ramelyte E, Welti M, Gardin F, Maul JT, Dummer R, Imhof L. Post-Excision Soft X-Ray Radiotherapy for Keloids: Experience in a Tertiary Referral Center. *Dermatology.* 2024;19:1–9. **IF: 3.5**

Ramirez-Fort MK, Gilman CK, Alexander JS, Meier-Schiesser B, Gower A, Olyae M, Vaidya N, Vahidi K, Li Y, Lange CS, Fort M, Deurdulian C. Gender and disease-inclusive nomenclature consolidation of therapeutic target, prostate-specific membrane antigen (PSMA) to folate hydrolase-1 (FOLH1). *Front Med (Lausanne).* 2024 Feb 9;10:1304718. doi: 10.3389/fmed.2023.1304718. PMID: 38444631; PMCID: PMC10913592. **IF 3.1**

Reich K, Bianchi L, Khemis A, Maul JT, Tsianakas A, Schempp CM, Petersen K, Noergaard MM, Puig L. Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA). *Dermatol Ther (Heidelb).* 2024;14(2):453–468. **IF 3.5**

Ring HC, Thorsen J, Kirby B, Ingram JR, Rosenø NAL, Holgersen N, Nielsen VW, Nikolai Thein Agaard D, Maul JT, Wu JJ, Thyssen JP, Egeberg A, Thomsen SF. Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study. *Br J Dermatol.* 2024;2:ljae042. **IF 11.0**

Rocuzzo G, Roggo A, Ramelyte E, Marchisio S, Astrua C, Ribero S, Scarisbrick J, Fava P, Quaglini P. Advances in the pharmacological management of cutaneous T-cell lymphoma. *Expert Opin Pharmacother.* 2024;25(7):885–894. **IF 2.5**

Roshardt Prieto NM, Turko P, Zellweger C, Nguyen-Kim TDL, Staeger R, Bellini E, Levesque MP, Dummer R, Ramelyte E. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma. *Melanoma Res.* 2024;1;34(2):166–174. **IF 2.2**

Sachs D, Jakob R, Restivo G, Hafner J, Lindenblatt N, Ehret AE, Mazza E. A quadriphasic mechanical model of the human dermis. *Biomech Model Mechanobiol.* 2024;23(4):1121–1136. **IF 3.0**

Sampson HA, Arasi S, Bahnson HT, Ballmer-Weber B, Beyer K, Bindslev-Jensen C, Bird JA, Blumchen K, Davis C, Ebisawa M, Nowak-Wegrzyn A, Patel N, Peters RL, Sicherer S, Spergel J, Turner PJ, Yanagida N, Eigenmann PA. AAAAI-EAACI PRACTALL: Standardizing oral food challenges–2024 Update. *Pediatr Allergy Immunol.* 2024;35(11):e14276. **IF 4.3**

Santos AF, Riggioni C, Agache I, Akdis CA, Akdis M, Alvarez-Perea A, Alvaro-Lozano M, Ballmer-Weber B, Barni S, Beyer K, Bindslev-Jensen C, Brough HA, Buyuktiryaki B, Chu D, Del Giacco S, Dunn-Galvin A, Eberlein B, Ebisawa M, Eigenmann P, Eiwegger T, Feeney M, Fernandez-Rivas M, Fiocchi A, Fisher HR, Fleischer DM, Giovannini M, Gray C, Hoffmann-Sommergruber K, Halken S, O'B Hourihane J, Jones CJ, Jutel M, Knol EF, Konstantinou GN, Lack G, Lau S, Mejias AM, Marchisotto MJ, Meyer R, Mortz CG, Moya B, Muraro A, Nilsson C, de Oliveira LCL, O'Mahony L, Papadopoulos NG, Perrett KP, Peters R, Podesta M, Poulsen LK, Roberts G, Sampson H, Schwarze J, Smith P, Tham E, Untersmayr E, Van Ree R, Venter C, Vickery B, Vlieg-Boerstra B, Werfel T, Worm M, Du Toit G, Skypala I. EAACI guidelines on the management of IgE-mediated food allergy. *Allergy.* 2024;30. **IF 12.4**

Sasaki M, Sundberg M, Frei R, Ferstl R, Heye KN, Willems EP, Akdis CA, Lauener R; CK-CARE Study Group; Roduit C. Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis. *Allergy.* 2024;79(1):142–152. **IF 12.6**

Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liskay G, Loquai C, Mandalà M, Yamazaki N, Queirolo P, Guenzel C, Polli A, Thakur M, di Pietro A, Ascierto PA. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. *Eur J Cancer.* 2024;204:114073. **IF 8.4**

Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggemont A, Scolyer RA. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. *J Immunother Cancer.* 2024;13;12(3):e007501. **IF 10.9**

Schlenker R, Schwalie PC, Dettling S, Huesser T, Irmisch A, Mariani M, Martínez Gómez JM, Ribeiro A, Limani F, Herter S, Yángüez E, Hoves S, Somandín J, Siebourg-Polster J, Kam-Thong T, de Matos IG, Umana P, Dummer R, Levesque MP, Bacac M. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma. *Med.* 2024;4:S2666–6340(24)00127-2. **IF: 12.8**

Schmauch E, Severin Y, Xing X, Mangold A, Conrad C, Johansen P, Kahlenberg JM, Mellett M, Navarini A, Nobbe S, Sarkar MK, Satyam A, Tsoi LC, French LE, Nilsson J, Linna-Kuosmanen S, Kaikkonen MU, Snijder B, Kellis M, Gudjonsson JE, Tsokos GC, Contassot E, Kolios AGA. Targeting IL-1 controls refractory pityriasis rubra pilaris. *Sci Adv.* 2024;5;10(27):eado2365. **IF 11.7**

Schmid F, Kerl-French K, Meier-Schiesser B, Lehmborg K, Hoeger PH. Ustekinumab for pyoderma gangrenosum-like skin ulcerations in late-onset leukocyte adhesion deficiency. *J Allergy Clin Immunol Glob.* 2024 Feb 29;3(2):100233. doi: 10.1016/j.jacig.2024.100233. PMID: 38560722; PMCID: PMC10981098

Seiler A, Amann M, Hertler C, Christ SM, Schettle M, Kaeppli BM, Jung-Armstutz J, Nigg C, Pestalozzi BC, Imesch P, Dummer R, Blum D, Jenewein J. Effects of dignity therapy on psychological distress and wellbeing of palliative care patients and family caregivers – a randomized controlled study. *BMC Palliat Care.* 2024;14;23(1):73. **IF 7.25**

- Sousa-Pinto B, Ramanauskaitė A, Neisinger S, Witte-Händel E, Gimenez-Arnau AM, Guillet C, Parisi CAS, Katelaris CH, Fomina D, Larenas-Linnemann D, Garcia E, Kocaturk E, Siebenhaar F, Lima H, Kaidashev I, Nasr I, Canales IO, Ojeda IC, Hébert J, Bousquet J, Bernstein JA, Peter J, Sanchez J, Sousa JIL, Kulthanan K, Weller K, Godse K, Rutkowski K, Lapina L, Bouillet L, Han LL, Ensina LF, Gonçalves M, Magerl M, van Doorn M, Metz M, Khoshkhui M, Hide M, Türk M, Kurjane N, Conlon N, Salameh P, Kolkhir P, Asero R, Stepanenko R, Altrichter S, Gil-Mata S, Thomsen SF, Zuberbier T, Tsaryk V, Ye YM, Brzoza Z, Zhao Z, Maurer M. Validity, reliability and responsiveness of digital visual analogue scales for chronic spontaneous urticaria monitoring: A CRUSE® mobile health study. *Allergy*. 2024;24. **IF: 12.6**
- Sonkoly E, Maul JT, Megna M, Gorecki P, Crombag E, Buyze J, Savage L. Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial. *Acta Derm Venereol*. 2024;4;104:adv18672. **IF 3.2**
- Spreafico A, Munoz Couselo E, Irmisch A, Bessa J, Au-Yeung G, Bechter O, Svane I, Sanmamed M, Gambardella V, McKean M, Callahan M, Dummer R, Klein Ch, Umama P, Jusites N, Heil F, Fahrni L, Opolka-Hoffmann E, Waldhauer I, Bleul C, Staack R, Karanikas V, Fowler S. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure. *Front. Oncol*. 2024;21;14:1346502. **IF 5.2**
- Staeger R, Martínez-Gómez J, Turko P, Ramelyte E, Kraehenbuehl L, Del Prete V, Hasan Ali O, Levesque M, Dummer R, Nägeli M, Mangana J. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. *Cancer*. 2024, 16(5). **IF 5.2**
- Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, Basset-Seguín N, Chang ALS, Dalle S, Fernández Orland A, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Yoo SY, Okoye E, Bassukas I, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Inocencio TJ, Chen CI, LaFontaine PR, Seebach F, Lowy I, Fuy MG. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up. *J Am Acad Dermatol*. 2024;90(2):414-418. **IF 7.102**
- Staeger R, Martínez-Gómez JM, Turko P, Ramelyte E, Kraehenbuehl L, Del Prete V, Hasan Ali O, Levesque MP, Dummer R, Nägeli MC, Mangana J. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. *Cancers (Basel)*. 2024;20;16(5):854. **IF: 4.5**
- Storz L, Schmid B, Bosshard PP, Schmid-Grendelmeier P, Brügglen MC, Lang C. Decreased skin colonization with *Malassezia* spp. and increased skin colonization with *Candida* spp. in patients with severe atopic dermatitis. *Front Med*. 2024;11:1353784. **IF 3.0**
- Taylor AM, McKeown J, Dimitriou F, Jacques SK, Zimmer L, Allayous C, Yeoh HL, Haydon A, Ressler JM, Galea C, Woodford R, Kahler K, Hauschild A, Festino L, Hoeller C, Schwarze JK, Neyns B, Wicky A, Michielin O, Placzke J, Rutkowski P, Johnson DB, Lebbeck C, Dummer R, Ascierto PA, Lo S, Long GV, Carlino MS, Menzies AM. Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy. *Eur J Cancer*. 2024;199:113561. **IF 8.4**
- Tetart F, Walsh S, Milpied B, Gaspar K, Vorobyev A, Tiplica GS, Didona B, Welfringer-Morin A, Kucinskiene V, Bensaid B, Marvanova E, Salavastru C, Brezinova E, Chua SL, Lovgren ML, Hammers CM, Barbaud A, Mortz CG, Horvath B, Meyersburg D, Lebrun-Vignes B, Bodemer C, Brügglen MC, French LE, Ingen-Housz-Oro S. Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management. *J Eur Acad Dermatol Venereol*. 2024;38(11):2073-2081. **IF 8.4**
- Theiler M, Luchsinger I, Rast AC, Schwiieger-Briel A, Weibel L, Boss-hard PP. Precision diagnostics in paediatric dermatology: Advancing management of tinea capitis through dermatophyte PCR. *J Eur Acad Dermatol Venereol*. 2024. **IF 9.3**
- Thein D, Maul JT, Schmid-Grendelmeier P, Thyssen JP, Egeberg A. Prevalence of ichthyoses in Denmark – a nationwide registry-based study. *Br J Dermatol*. 2024;2;ljae177. **IF 11.0**
- Thein D, Nielsen ML, Maul JT, Thomsen SF, Thyssen JP, Egeberg A. Impact of the pre-biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study. *J Eur Acad Dermatol Venereol*. 2024;25. **IF 9.3**
- Thevan J, Schmauch E, Nilsson J, Guillet CF, Boesch A, Krähenbühl L, Meier-Schiesser B, Schmid-Grendelmeier P, Kündig T, Kolios AGA. Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. *Dermatology*. 2024;240(5-6):694-701. **IF 3.0**
- Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Bärenfaller K, Behrendt H, Bieber T, Bigliardi P, Bigliardi-Qi M, Bonefeld CM, Bösch S, Brügglen MC, Diemert S, Duchna HW, Fähndrich M, Fehr D, Fellmann M, Frei R, Garvey LH, Gharbo R, Gökkaya M, Grando K, Guillet C, Guler E, Gutermuth J, Herrmann N, Hijnen DJ, Hülpüsch C, Irvine AD, Jensen-Jarolim E, Kong HH, Koren H, Lang CCV, Lauener R, Maintz L, Mantel PY, Maverakis E, Möhrenschrager M, Müller S, Nadeau K, Neumann AU, O'Mahony L, Rabenja FR, Renz H, Rhyner C, Rietschel E, Ring J, Roduit C, Sasaki M, Schenk M, Schröder J, Simon D, Simon HU, Sokolowska M, Ständer S, Steinhoff M, Piccirillo DS, Täubel A, Takaoka R, Tapparo M, Teixeira H, Thyssen JP, Traidl S, Uhlmann M, van de Veen W, van Hage M, Virchow C, Wollenberg A, Yasutaka M, Zink A, Schmid-Grendelmeier P. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. *Allergy*. 2024;79(10):2605-2624. **IF: 12.6**
- Useini V, Tanadini-Lang S, Lohmeyer Q, Meboldt M, Andratschke N, Braun RP, Barranco García J. Automated self-supervised learning for skin lesion screening. *Sci Rep*. 2024;3;14(1):12697. **IF 3.8**
- Vasilevska J, Cheng PF, Lehmann J, Ramelyte E, Gómez JM, Dimitriou F, Sella F; TuPro Consortium; Ferretti D, Salas-Bastos A, Jordaan WS, Levesque MP, Dummer R, Sommer L. Monitoring melanoma patients on treatment reveals a distinct macrophage population driving targeted therapy resistance. *Cell Rep Med*. 2024;26:101611. **IF: 11.7**
- Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forscher N, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. *Eur J Cancer*. 2024;196:113425. **IF: 8.4**
- Wallimann A, Achermann Y, Ferris C, Morgenstern M, Clauss M, Stadelmann V, Rüdiger HA, O'Mahony L, Moriarty TF. Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection. *J Bone Jt Infect*. 2024;24;9(4):191-196. **IF 1.8**
- Wang M, Fukushima S, Sheen YS, Ramelyte E, Cruz-Pacheco N, Shi C, Liu S, Banik I, Aquino JD, Sanguaza Acosta M, Levesque M, Dummer R, Liao JY, Chu CY, Shain AH, Yeh I, Bastian BC. The genetic evolution of acral melanoma. *Nat Commun*. 2024;21;15(1):6146. **IF 14.7**
- Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, Anz D, Piseddu I, Pesch G, Vera J, Froehlich W, Weckbach L, Tomsitz D, Loquai C, Zimmer L, Mangana J, Dummer R, Gutzmer R, Klespe KC, Stege H, Meiss F, Thoms KM, Terheyden P, Bröckelmann PJ, Johnson DB, French LE, Heinzerling L. Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity. *Front Cardiovasc Med*. 2024;10;11:1408586. **IF: 3.8**

Weber V, Weimann K, Kolm I, Meier-Schiesser B. Erythema nodosum [Erythema nodosum]. *Z Rheumatol*. 2024 Oct;83(8):641–649. German. doi: 10.1007/s00393-024-01529-4. Epub 2024 Jun 17. PMID: 38884811; PMCID: PMC11485184. **IF 0.9**

Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, Chiarion-Sileni V, Mohr P, Karanikolova TS, Teterycz P, Espinosa E, Schnecko P, Cheng P, Bender M, Jiang S, Burke T, Ascierto P, Gogas H, Rodas I, Rutkowski P, Schadendorf D, Dummer R. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. *Cancers*. 2024;16(21):3558. **IF 4.5**

Winkler JK, Kommos KS, Toberer F, Enk A, Maul LV, Navarini AA, Hudson J, Salerni G, Rosenberger A, Haenssle HA. Performance of an automated total body mapping algorithm to detect melanocytic lesions of clinical relevance. *Eur J Cancer*. 2024;202:114026. **IF 7.7**

Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA, Gaudy-Marqueste C, Medina T, Lao CD, Walker J, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Sandhu S, Lebbé C, Ascierto PA, Long GV, Ritchings C, Nassar A, Askelson M, Benito MP, Wang W, Hodi FS, Larkin J; CheckMate 067 Investigators. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. *N Engl J Med*. 2024;15. **IF 158.5**

Wolf P, Ceovic R, Conrad C, Falkensteiner K, Graier T, Kołt-Kamińska M, Marovt M, Mateeva V, Maul JT, Navarini AA, Nicolescu AC, Ratzinger G, Pavlovsky L, Sanzharovskaya M, Szegeđi A, Reich A. Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network. *J Eur Acad Dermatol Venereol*. 2024;27. **IF 8.4**

Wolk K, Schielein M, Maul JT, Widmayer F, Wanke K, Fischmann W, Nathan P, Sabat R. Patient-reported assessment of medical care for chronic inflammatory skin diseases: an enterprise-based survey. *Front Med (Lausanne)*. 2024;18;11:1384055. **IF 3.1**

Woodford R, McKeown J, Hoeijmakers LL, Mangana J, Dimitriou F, Allayous C, Zaman F, Aya F, Marsiglio J, Goodman R, Rayson V, Placzke J, Kessels J, Ramalyte E, Haque W, Wilson I, Trojaniello C, Benannoune N, Roberts-Thomson R, Robert C, Blank CU, Dummer R, Lebbe C, Haydon A, Arance A, Hu-Lieskovan S, Johnson DB, McCart-hur GA, Rutkowski P, Neyns B, Sullivan RJ, Weber J, Carlino MS, Ascierto PA, Lo S, Long GV, Menzies AM. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy. *Eur J Cancer*. 2024;29;212:115055. **IF 7.7**

Zahn D, Arp HPH, Fenner K, Georgi A, Hafner J, Hale SE, Hollender J, Letzel T, Schymanski EL, Sigmund G, Reemtsma T. Should Transformation Products Change the Way We Manage Chemicals? *Environ Sci Technol*. 2024;7;58(18):7710–7718. **IF: 5.0**

Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheeler M, Ottensmeier CH. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. *Ann Surg Oncol*. 2024 May 4. **IF 3.7**

Ziadlou R, Pandian GN, Hafner J, Akdis CA, Stingl G, Maverakis E, Brüggen MC. Subcutaneous adipose tissue: Implications in dermatological diseases and beyond. *Allergy*. 2024;79(12):3310–3325. **IF: 12.6**

Zila N, Eichhoff OM, Steiner I, Mohr T, Bileck A, Cheng PF, Leitner A, Gillet L, Sajic T, Goetze S, Friedrich B, Bortel P, Strobl J, Reitermaier R, Hogan SA, Martínez Gómez JM, Staeger R, Tuchmann F, Peters S, Sary G, Kuttke M, Elbe-Bürger A, Hoeller C, Kunstfeld R, Weninger

W, Wollscheid B, Dummer R, French LE, Gerner C, Aebbersold R, Levesque MP, Paulitschke V. Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy. *Clin Cancer Res*. 2024;30(1):159–175. **IF 11.5**

Zuberbier T, Muraro A, Nurmatov U, Arasi S, Stevanovic K, Anagnostou A, Bonaguro R, Chinthrajah S, Lack G, Fiocchi A, Le TM, Turner P, Lozano MA, Angier E, Barni S, Bégin P, Ballmer-Weber B, Cardona V, Bindslev-Jensen C, Cianferoni A, de Jong N, de Silva D, Deschildre A, Galvin AD, Ebisawa M, Fleischer DM, Gerdtts J, Giovannini M, Gradman J, Halken S, Arshad SH, Khaleva E, Lau S, Loh R, Mäkelä MJ, Marchisotto MJ, Morandini L, Mortz CG, Nilsson C, Nowak-Węgrzyn A, Podestà M, Poulsen LK, Roberts G, Rodríguez Del Río P, Sampson HA, Sánchez A, Schnadt S, Smith PK, Szajewska H, Mitrevska NT, Toniolo A, Venter C, Warner A, Wong GWK, Wood R, Worm M. GA2LEN ANA-CARE consensus statement: Potential of omalizumab in food allergy management. *Clin Transl Allergy*. 2024;14(11):e70002. **IF 4.6**

Reviews 2024

Kraehenbuehl, L., J. D. Wolchok, T. Merghoub and D. Hirschhorn. Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects. *Cancer Cell*. 2024;42(5): 738–741. **IF 50.3**

Mendelson K, Martin TC, Nguyen CB, Hsu M, Xu J, Lang CC, Dummer R, Saenger Y, Messina JL, Sondak VK, Desman G, Hasson D, Bernstein E, Parsons RE, Celebi JT. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation. *JCI Insight*. 2024;6:e166611. **IF 9.484**

Rocuzzo G, Roggo A, Ramelyte E, Marchisio S, Astrua C, Ribero S, Scarisbrick J, Fava P, Quaglino P. Advances in the pharmacological management of cutaneous T-cell lymphoma. *Expert Opin Pharmacother*. 2024;25(7):885–894. **IF: 3.2**

Sangers TE, Kittler H, Blum A, Braun RP, Barata C, Cartocci A, Combalia M, Esdaile B, Guitera P, Haenssle HA, Kvorning N, Lallas A, Navarrete-Dechent C, Navarini AA, Podlipnik S, Rotemberg V, Soyer HP, Tognetti L, Tschandl P, Malvey J; EADV AI Task Force. Position statement of the EADV Artificial Intelligence (AI) Task Force on AI-assisted smartphone apps and web-based services for skin disease. *J Eur Acad Dermatol Venereol*. 2024;38(1):22–30. **IF 8.4**

Sun N, Ogulur I, Mitamura Y, Yazici D, Pat Y, Bu X, Li M, Zhu X, Babayev H, Ardicli S, Ardicli O, D'Avino P, Kiykim A, Sokolowska M, van de Veen W, Weidmann L, Akdis D, Ozdemir BG, Brüggen MC, Biedermann L, Straumann A, Kreienbühl A, Guttman-Yassky E, Santos AF, Del Giacco S, Traidl-Hoffmann C, Jackson DJ, Wang DY, Lauerma A, Breiteneder H, Zhang L, O'Mahony L, Pfaar O, O'Hehir R, Eiwegger T, Fokkens WJ, Cabanillas B, Ozdemir C, Kistler W, Bayik M, Nadeau KC, Torres MJ, Akdis M, Jutel M, Agache I, Akdis CA. The epithelial barrier theory and its associated diseases. *Allergy*. 2024;79(12):3192–3237. **IF: 12.6**

Traidl-Hoffmann C, Afghani J, Akdis CA, Akdis M, Aydin H, Bärenfaller K, Behrendt H, Bieber T, Bigliardi P, Bigliardi-Qi M, Bonfeld CM, Bösch S, Brüggen MC, Diemert S, Duchna HW, Fähndrich M, Fehr D, Fellmann M, Frei R, Garvey LH, Gharbo R, Gökkaya M, Grando K, Guillet C, Guler E, Gutermuth J, Herrmann N, Hijnen DJ, Hülpüsch C, Irvine AD, Jensen-Jarolim E, Kong HH, Koren H, Lang CCV, Lauener R, Mantz L, Mantel PY, Maverakis E, Möhrenschrager M, Müller S, Nadeau K, Neumann AU, O'Mahony L, Rabenja FR, Renz H, Rhyner C, Rietschel E, Ring J, Roduit C, Sasaki M, Schenk M, Schröder J, Simon D, Simon HU, Sokolowska M, Ständer S, Steinhoff M, Piccirillo DS, Taieb A, Takaoka R, Tapparo M, Teixeira H, Thyssen JP, Traidl S, Uhlmann M, van de Veen W, van Hage M, Virchow C, Wollenberg A, Yasutaka M, Zink A, Schmid-Grendelmeier P. Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration. *Allergy*. 2024;79(10):2605–2624. **IF: 12.6**

Wahl P, Drennan P, Schläppi M, Achermann Y, Leunig M, Gautier E, Benninger E. Systemic antibiotic prophylaxis in arthroplasty - a narrative review of how many doses are optimal. *EFORT Open Rev.* 2024;2;9(12):1106-1119. **IF 4.3**

Ziadlou R, Pandian GN, Hafner J, Akdis CA, Stingl G, Maverakis E, Brüggen MC. Subcutaneous adipose tissue: Implications in dermatological diseases and beyond. *Allergy.* 2024;79(12):3310-3325. **IF 12.6**

Book Chapters 2024

Geiges, Michael L.: Auf den Spuren historischer Patientenversuche im Moulagenmuseum Zürich. Medizinische Wachsmoulagen als medizinhistorische Quellen. In: Baur, I., Gächter T, et al: *Entwicklungen im Medizinrecht – Vom klassischen Arztrecht zu One Health.* Stämpfli Verlag, Bern, 2024, S. 601–617

Karakaya T, Slafova M, Di Filippo M, Hennig P, Fenini G, Kündig T, Beer HD. Efficient Generation of CRISPR/Cas9-Mediated Knockout Human Primary Keratinocytes by Electroporation. *Methods Mol Biol.* 2024;27. **IF 1.8**

Ludwig R, Lang C, Dummer R. Kapitel 397 Histiozytosen. Referenz Dermatologie 1. Auflage 2024. **IF: 0.1**

Dissertations 2024

Verardi F, Maul LV, Borsky K, Steinmann S, Rosset N, Pons HO, Sorbe C, Yawalkar N, Micheroli R, Egeberg A, Thyssen JP, Heidemeyer K, Boehncke WH, Conrad C, Cozzio A, Pinter A, Kündig T, Navarini AA, Maul JT. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT). *J Eur Acad Dermatol Venereol.* 2024;38(4):719-731. **IF 9.2**

Hess J, Barysch-Bonderer MJ, Seeli C, Laube J, Ghosh A, Deinsberger J, Weber B, Hafner J, Meier-Schiesser B. Identifying Key Drivers in the Pathogenesis of Martorell Hypertensive Ischaemic Leg Ulcer: A Comparative Analysis with Chronic Venous Leg Ulcer. *Acta Derm Venereol.* 2024;30;104:adv40090. **IF 3.5**

Flory S, Hviid-Vyff B, Šošić L, Schmid JM, Ahlbeck L, Widmer ECJ, Lang CCV, Ikenberg K, Kündig TM, Hoffmann HJ, Johansen P. How to hit the allergy target: A critical appraisal of intralymphatic immunotherapy with practical recommendations on ultrasound-guided injections. *Allergy.* 2024 Aug;79(8):2222-2234.

Von Wächter-Gniadek Paul: Safety of Tumescent Liposuction Under Local Anesthesia in 9,002 Consecutive Patients.



“It is inspiring to see how progress in research contributes to meaningful improvements in patient care and our everyday clinical practice.”

Meier-Schiesser Barbara, Dr. med. Dr. sc. nat.



“Skin cancer research has played a pioneering role in advancing immunotherapy, opening new doors of hope across countless cancer types.”

Mangana Joanna, PD Dr. med.





17 Key Figures Department of Dermatology, University Hospital Zurich

Financial Data




Research



Staff

- Budget University Hospital Zurich
- Third-party funds



Teaching

Congresses/Symposia 2023/2024

- International**
 - International Dermatoscopy Course, Juni 2024
- National**
 - ZDFT Zürcher Dermatologische Fortbildungstage, June 2023/2024
 - 4 Grosse Semesterfortbildungen (March/April and November 2023/2024)
 - 2 Interdisciplinary Dermooncoloy Symposia (May 2023 and 2024)
 - Allergology: Welfare-Symposium for Prof. P. Schmid-Grendelmeier, February 29, 2024
 - 2 Fortbildungen for General Practitionars (October 2023 and 2024)
 - 3 Dermatosurgery Courses (July and January 2023/2024)

University Hospital Zurich

Department of Dermatology

Rämistrasse 100

8091 Zurich

c.frey-blanc@usz.ch

www.usz.ch/dermatologie

Follow USZ on

